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This thesis is composed of six themed chapters. Chapter-1 (Introduction) lays out the 
theoretical dimensions of the research, focusing on the three key themes of cuprizone (CPZ), 
oligodendrocytosis and gliosis (astrocytes and microglial activation). Chapter-2 provides the 
detailed Materials and Methods used for this thesis. Chapter-3, presents the investigation 
of whether disruption of blood brain barrier following short (5-week) and long (12-week) 
term CPZ-feeding results in associated with infiltrates T-cells into the brain (Paper I). 
Chapter-4 is a systematic review of literature on the behavioural phenotypes associated with 
CPZ (Paper II). In Chapter-5, tests whether CPZ induces sensorimotor deficits and 
histological changes (oligodendrocytosis, gliosis and neuronal loss) in pathways associated 
with sensorimotor function (Paper III). Chapter-6 is an overall discussion, recommendation 
for further research and conclusion. 
These papers are published in the following peer-reviewed journals  
Paper I: Sen MK, Almuslehi MSM, Gyengesi E, Myers SJ, Shortland PJ, Mahns DA and 
Coorssen JR (2019). Suppression of the peripheral immune system limits the central immune 
response following cuprizone-feeding: Relevance to modelling multiple sclerosis. Cells, 
8(11), 1314; https://doi.org/10.3390/cells8111314. 
 
Paper II: Sen MK, Mahns DA, Coorssen JR and Shortland PJ (2019).  
Behavioural phenotypes in the cuprizone model of central nervous system demyelination. 
Neuroscience and Biobehavioral Reviews, 107:23-46. doi: 10.1016/j.neubiorev.2019.08.008. 
 
Paper III: Sen MK, Almuslehi MSM, Coorssen JR, Mahns DA, and Shortland PJ (2020).  










Feeding cuprizone (CPZ) to animals has been long known to lead to regional degeneration of 
oligodendrocytes (OLG) and has been used to model the demyelinating aspect of human 
conditions like multiple sclerosis (MS). The MS aetiology is unknown and no single animal 
model faithfully replicates the myriad of symptoms. Currently, there are two competing 
hypotheses regarding the pathophysiology underlying the initiation of MS: ‘outside-in’ and 
‘inside-out’. In this thesis, the broad objective was to develop an animal model of progressive 
demyelination reminiscent to MS. CPZ was used to induce OLG degeneration (termed 
oligodendrocytosis) and pertussis toxin (PT) was used to breach blood brain barrier (BBB) in 
order to test whether demyelination within the brain when combined with a breach of the 
BBB could trigger an adaptive immune response in the brain and thereby provide new 
evidence for an ‘inside-out’ hypothesis. The second broad aim was to investigate 
sensorimotor behavioural deficits and associated regulating pathways to find a link between 
CPZ-induced behavioural deficits and MS clinical symptoms. The results of the present thesis 
are presented in the following published manuscripts.   
 
In paper I, I investigated whether oligodendrocytosis can trigger an adaptive immune 
response while the BBB was compromised. In this study, I combined the standard (0.2%) or 
half dose (0.1%) of CPZ-feeding for 5 weeks (or 12 weeks) with disruption of the BBB using 
PT. I found a concurrent marked loss of OLG (and consequent demyelination) and an 
increased innate immune response involving microglia and astrocytes at both time points. 5 
weeks of 0.1% and 0.2% CPZ-feeding produced comparable oligodendrocytosis but a dose-
dependent demyelination and gliosis, suggesting a slower onset and/or clearance of myelin 
debris following 0.1% CPZ.  Even when the BBB was disrupted during CPZ-feeding, a 
detectable CD4/8 signal was not found in the brain. However, dose-dependent reductions in 
the splenic CD4/8 signals were observed following CPZ-feeding suggesting that peripheral 
immune function was compromised by CPZ-feeding. Having observed that a low dose of 
CPZ produced comparable oligodendrocytosis but had smaller effects on the peripheral 
immune system, the duration of low dose CPZ-feeding was extended to 12 weeks, with and 
without PT injection, to test whether a slower, progressive demyelination (i.e. more 
reminiscent of MS) could trigger an adaptive immune response in the CNS. Prolonged 0.1% 
CPZ-feeding produced comparable oligodendrocytosis, demyelination and suppression of 
splenic CD4/8 signal, but, once again, detectable CD4/8 signal was not found in the brain 
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suggesting that the peripheral action of CPZ is a major impediment to studying the role of the 
peripheral immune system following demyelination and disruption of the BBB. CPZ-feeding 
evoked changes in the whole brain proteome that mainly related to immune function, 
metabolism, cellular structure and synaptic function were observed. Notably, many of the 
CPZ-induced changes involved mitochondrial and endoplasmic reticulum functions 
indicating that internal biochemical/metabolic dysregulation is a potential key step in CPZ-
mediated oligodendrocytosis.  
 
In paper II, I reviewed the behavioural phenotypes observed in CPZ model and compared 
these to the clinical prevalence in MS patients. In this review, I identified a potential miss-
match between the behavioural investigation using the CPZ model and the clinical prevalence 
of MS. Current behavioural tests in the CPZ model are focused mainly on motor, anxiety and 
cognition, but did not include all of the common MS clinical symptoms (e.g. pain and 
fatigue). Only a few studies have investigated other key symptoms such as pain, visual 
disturbances, fatigue and depression and none have examined symptoms such as sleep 
disturbances. I also found inappropriate use of behavioural instruments measuring deficits 
and suggested the appropriate application of instruments. In addition, I found that most of the 
histological correlations associated with behavioural deficits have focused on corpus 
callosum demyelination, which is inappropriate, rather than the functional relevant regions of 
the central nervous system (CNS). I suggest regionally relevant histological and biochemical 
analysis in order to validate the appropriate interpretation of behavioural deficits.  
 
In paper III, whether CPZ changes in sensorimotor function are associated with changes 
(oligodendrocytosis, demyelination and gliosis) in functionally relevant structures of the 
sensorimotor pathways in the CNS were investigated. Within 2-3 weeks of CPZ-feeding, 
mice showed hyperactivity using the grooming and rearing tests and crossed the ladder more 
quickly compared to control mice. On both the ladder and beam tests, CPZ mice exhibited 
more foot slips compared to controls. In contrast, no changes in nociceptive thresholds to 
thermal or mechanical stimuli were seen between groups. Histological analysis showed a 
significant concurrent oligodendrocytosis, demyelination and gliosis in the cerebrum, 
cerebellum and brain stem. No loss of specific subpopulations of neurons or motoneurons 
staining was found but a significant increase in astrocyte staining was seen throughout the 
white matter tracts of all levels of the spinal cord. Importantly, components of the descending 
motor pathways in and around the cerebellar nuclei involved in motor function displayed 
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marked demyelination and gliosis, whereas these changes did not exist (except gliosis) in the 
regions associated with sensory pathways, such as the spinothalamic tract. The results suggest 
that CPZ induces subtle motor changes such as ataxia and that this is associated with deficits 
in CNS regions associated with motor and balance functions such as the cerebellum and 
brainstem. 
 
In summary, the results of this thesis provide evidence for the first time that:  
 Peripheral immune system suppression limits the migration of T-cells into the CNS in 
CPZ-fed mice even when the BBB is compromised.  
 CPZ-induced mitochondrial stress is associated with the oligodendrocytes 
degeneration.  
 Increasing the complexity of the locomotor tasks can detect early subtle motor 
behavioural deficits consistent with ataxia. 
 Profound demyelination and gliosis in the deep cerebellar nuclei and brain stem 
regions were associated with motor and balance functions.  
 Gliosis (but not demyelination) was observed in spinal cord white and grey matter 
regions but no changes were observed in nociceptive response using thermal and 
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APC Adenomatous polyposis coli LPL Lipoprotein lipase 
APO Apolipoprotein LRP Lipoprotein receptor-related 
protein 
ATP Adenosine triphosphate LYZ Lysozyme 
AMSC Adipose mesenchymal stem cell MAG Myelin associated glycoprotein 
PDGFR-α Anti-platelet-derived growth 
factor alpha 
MHC Major histocompatibility 
complex 
B6 C57BL/6  MMP Matrix metalloproteinase 
BBB Blood brain barrier MS Multiple sclerosis 
BDNF Brain derived neurotrophic 
factor  
MBP Myelin basic protein 
Calr Calreticulin MOG Myelin oligodendrocyte 
glycoprotein 
CD Cluster of differentiation  NeuN Neuronal nuclei 
CNS Central nervous system NG-2 Chondroitin sulfate proteoglycan 
CNPase  2′,3′-cyclic nucleotide-3′-
phosphodiesterase 
NGF Nerve growth factor 
CPZ Cuprizone NOGO 
A 
Neurite outgrowth inhibitor A 
DNA Deoxyribonucleic acid NOR Node of Ranvier 
EAE Experimental autoimmune 
encephalomyelitis 
NF-κB Nuclear factor-kappa B 
GFAP Glial fibrillary acidic protein OLG Oligodendrocyte 
GSTP 1 Glutathione S-transferase pi 
isoform 
OPC Oligodendrocyte progenitor cell 
HMGCS Hydroxymethylglutaryl-CoA 
synthase  
Oligo Oligodendrocyte transcription 
factor 
IBA 1 Ionized calcium binding adaptor 
molecule 1 
PLP Proteolipid protein 
IHC Immunohistochemistry PDGF Platelet-derived growth factor 
IgG Immunoglobulin G RCA-1 Ricinus communis agglutinin-1 
IFN-γ Interferon gamma ROS Reactive oxygen species 
IGF Insulin-like growth factor RNS Reactive nitrogen species 
IL Interleukin TGF-β Transforming growth factor beta 
IP-10 Interferon gamma-induced 
protein 10  
TLR Toll-like receptor 
ITG-β Integrin beta  TNF-α Tumour necrosis factor alpha 
LGALS Galactose-specific lectin  TSPO Translocator protein 






1.1 Cuprizone (CPZ) model 
1.1.1 Chemical constituent and a brief history of CPZ animal model  
Cuprizone (CPZ) is a chemical compound derived from a biochemical reaction of cyclohexanone 
and oxaldihydrazone [1, 2]. Its empirical formula and molecular weight are C14H22N4O2 and 
278.36 respectively [3].  
 
Chemical structure of CPZ (adopted from [1]) 
The first observations of the demyelinating properties of CPZ were reported in the early 1960s by 
W. Carlton in a series of studies [2, 4, 5]. In these studies it was found that CPZ-feeding caused 
growth retardation and demyelination in the cerebrum and cerebellum [2, 4, 5]. Later, it was 
identified that preferential loss of oligodendrocytes (OLG) resulted in demyelination and glial 
activation [6]. Three decades later, a detailed study from Hiremath et al. [7] showed the 
effective/optimum dose, duration and strain-dependent effects of CPZ on demyelination and glial 
activation [7]. Follow up investigations revealed that CPZ was preferentially toxic to mature 
OLG with regeneration of new OLG as the result of the proliferation of oligodendrocyte 
progenitor cells (OPC) when CPZ-feeding was stopped [8]. The gender equality of demyelination 
and glial reactivity in C57BL/6 (B6) mice strain was shown by Taylor and co-workers [9]. 
Despite the marked OLG degeneration, demyelination and innate immune involvement, only the 
inactive adaptive immune cells in the brain was observed [10]. Furthermore, CPZ appears to 
produce an atrophy of the peripheral immune organs [e.g. spleen and thymus, 11, 12, 13]. The 












Table 1: Milestones in the progression of CPZ model 
Chronology Milestone Reference 
1 Mice showed growth retardation, weakness and myelin loss in the cerebrum and cerebellum. [4] 
2 Astrocytes activation in the brain and cerebellum. [2] 
3 CPZ-feeding involved in the formation of mega/giant mitochondria in liver.  [14] 
4 CPZ-induced OLG death resulting in secondary demyelination. [6] 
5 Astrocytes and microglia involved in the removal of vacuolated myelin. [6] 
6 CPZ-feeding depleted (e.g. monoamine oxidase and cytochrome oxidase) or elevated (e.g. 
succinate dehydrogenase) liver and brain mitochondrial enzymes. 
[15] 
7 Initiation of remyelination after removal of CPZ from chow. [16] 
8 0.2% CPZ-feeding for 4-5 weeks in B6 mice showed reproducible demyelination and glial 
activation. 
[7] 
9 Degeneration of mature OLG and regeneration of OPC in the corpus callosum once CPZ-
feeding stopped. 
[8] 
10 CPZ-feeding was associated with the changes of lipid profile in brain (e.g. 30% reduction of 
brain cerebroside). 
[17] 
11 Microglia promoted OPC proliferation through the secretion of insulin-like growth factor (IGF-
1/2). 
[8, 18] 
12 First quantitative assessment of behavioural (e.g. motor) changes using modern instrument (e.g. 
complex wheel).  
[19] 
13 Presence of inactive T-cell and absence of B-cell.  [10] 
14 Chemically synthesized agent (e.g.  IGF-1) increased OPC in the corpus callosum in CPZ-fed 
mice. 
[20] 
15 Marked loss of mature OLG, demyelination and glial activation in hippocampus. [21] 
16 Regional variability of glial response in the cerebrum.  [22] 
17 ‘Bottom-up’ proteomics approach showed majority of the altered proteins were involved in 
mitochondrial function. 
[23] 
18 Similar OLG degeneration, demyelination and glial response in both male and female B6 mouse 
strain. 
[9] 
19 A detail report on loss of mature OLG, demyelination and glial activation in cerebellum. [24] 
20 Lack of mature OLG loss, demyelination and glial activation in spinal cord. [25] 
21 No formation of glial scar in the acute and chronic phases of astrogliosis. [26] 
22 Astrocytes regulate microglial recruitment and lack of astrocytes (/knock-out) impairs 
phagocytic process. 
[27] 
23 Preferential toxicity to mature OLG whereas OPC, microglial and astroglial cells were protected 
in vitro. 
[28] 
24 Peripheral immune organs (e.g. spleen and thymus) atrophy.  [11-13] 
25 ‘Top-down’ proteomics approach showed changes in protein profiles in cortex, peripheral blood 
mononuclear cell and spleen. 
[29] 
26 Suppression of T-cell function implicated by reduction in protein disulphide isomerase (that 
participates in the assembly of major histocompatibility complex, MHC-I molecule). 
[29] 
27 Blood brain barrier (BBB) disruption using stereotactic application of lysolecithin or ethidium 
bromide did not infiltrate B or T-lymphocytes in the demyelinating areas (e.g. corpus callosum) 
after 5 week of CPZ-feeding. 
[30] 
28 Recruitment of peripheral immune cells (e.g.  cluster of differentiation, CD3 T-cells) in the 
corpus callosum and secondary disease progressions (e.g. demyelination and inflammation) in 2 
weeks CPZ-feeding once BBB was disrupted using pertussis toxin and immune system was 
boosted using complete Freund's adjuvant. 
[31] 
29 CPZ-induced changes in lipid distribution in corpus callosum did not recover entirely after 




1.2 Oligodendrocytes degeneration in CPZ model 
1.2.1 Oligodendrocytes (OLG) 
Oligodendrocytes (OLG) represent ~70% of all glial cells in the central nervous system  
[CNS, 33]. OLG form a lipid-rich myelin sheath around axons with periodic gaps called 
nodes of Ranvier [NOR, 34, 35, 36]. The insulated axon allows rapid, saltatory conduction of 
electrical impulses between the NOR [34, 37-39]. The loss of OLG results in the 
demyelination of axons which compromises the speed of saltatory conduction. Moreover, the 
loss of myelin impedes the transfer of essential substrates (e.g. lactate) from OLG to axons 
(via monocarboxylate transporters) resulting in energy deprivation and axonal/neuronal 
degeneration [40-42].  
OLG are mainly categorized into two types based on their proliferation, regeneration and 
myelinating properties (Figure 1). The first category is oligodendrocyte progenitor cells 
(OPC) that represent ~5-8% of the total numbers of cells in the CNS [43]. They originate 
during the embryonic development from neuro-epithelial cells in the sub-ventricular zone of 
the cerebrum [44, 45] and the dorsal portion of the spinal cord [34, 46, 47]. OPC are mitotic 
(similar to stem cells), highly proliferative leading to the generation of mature OLG [48]. 
Consequently OPC are the largest dividing cell population among glial cells [49, 50]. They 
are found throughout the CNS with numbers in the white matter that are 1.5 times higher than 
those found in the grey matter [49]. During demyelination OLG are lost/degenerate and OPC 
rapidly migrate to the injury sites and proliferate. These events are regulated by the 
expression of several transcription factors such as OLG transcription factors 1-2, myelin 
transcription factor 1 and SRY-box containing gene 10 [48]. The second category of OLG is 
the mature OLG, which is non-mitotic. They mature from OPC in a stepwise process [51, 52] 
that is regulated by many factors including, growth factors, neurotransmitters and 


























Mature OLG are sub-categorized into four types (I-IV) based on their size, number of 
processes and function as summarized in Table 2. Both types I and II have small somata with 
type I generating 15-30 myelin segments in multiple adjacent axons and are found throughout 
the CNS [38, 53, 54]. Type II produces thin myelin and support medium diameter (60-70 μm) 
axons located mainly in the cerebrum and cerebellum [36, 53, 54]. Type III OLG have larger 
cell bodies, and ensheath a small number of larger diameter axons mainly in the cerebellum 
and spinal cord. Type IV OLG are mainly found in the brain stem and spinal cord, and are 
similar to Schwann cells of the peripheral nervous system in that they myelinate a single axon 
despite being of different embryonic developmental paths [36, 38, 53, 54] 
 
Table 2: Categories of mature OLG   
Type General characteristics Schematic 
images   
Main abundance Reference 
I Small round cell body 
  
Throughout the 




[36, 53, 54]  
Large number of thin cellular 
process 
Produce thin myelin and support 
15-30 short diameter axon 
II Small cuboidal  cell bodies and 
few  thin cellular process 
 
 




[36, 53, 54]  
Produce thin myelin and support 
medium (60-70 μm) axon 
Similarities 
between 
I and II 
Support myelin volumes of 




Intermodal length typically  
50-150 μm  
 
III Larger cell bodies than I and II 
 
 
Mainly restricted in 
cerebellum and 
spinal cord 
 [36, 53, 54]  
One or two long cellular process 
Support medium axons thin 
myelin with longer intermodal 
length generally 200-500 μm 
IV Elongated cell bodies and longer 
process 
 
White matter of 
brain stem and 
spinal cord 
 [36, 53, 54]  
Generate thick myelin to support 
1-3 large axon with very long 




Support myelin volumes of 
approximately  
30,000 μm3 







1.2.2 Mechanisms of CPZ-induced OLG injury and cell death (oligodendrocytosis)  
The mechanism of CPZ-induced OLG apoptosis remains ill-defined. A few lines of evidence 
have shown that CPZ is preferentially toxic to OLG both in vitro and in vivo [28, 55, 56]. As 
summarized in Table 3, CPZ ingestion causes an imbalance of essential ions such as copper, 
iron, zinc, sodium and manganese in the different parts of the body including brain and liver 
[3, 15, 57-59]. Ions imbalance leads to the perturbation of mitochondrial [12, 23, 28, 29, 60-
62] and endoplasmic reticulum [29, 63-69] function. As a result, mega-mitochondria 
formation occurs in the liver, thymus, cerebrum and cerebellum [12, 61, 62, 70]. In addition, 
the function of mitochondrial enzymes such as superoxide dismutase, carbonic anhydrase II, 
monoamine oxidase and cytochrome C oxidase are suppressed [57, 71, 72]. These cumulative 
events decrease mitochondrial functions including adenosine triphosphate (ATP) synthesis 
and increase production of reactive oxygen (ROS) and nitrogen species (RNS) production 
[73]. Elevated concentrations of ROS and RNS enhance further the disruption of 
mitochondria and endoplasmic reticulum functions [63, 64]. Dysregulation of endoplasmic 
reticulum functions leads to a misfolded protein response and subsequently OLG stress [63, 
74, 75]. Consequently, OLG apoptosis occurs due to decreased energy supply and lower 
levels of anti-oxidant enzymes to neutralize toxic products [e.g. ROS/RNS, 76, 77, 78]. Loss 
of myelin (i.e. demyelination) and the activation of microglia and astrocytes (i.e. gliosis) are 
the main consequences of loss or degeneration of OLG is termed as oligodendrocytosis [29, 
79], which is also called oligodendrocytopathy [80, 81]. Activated innate immune cells (e.g. 
microglia) remove the myelin debris (termed phagocytosis) from the area of demyelination 
and, in the process, produce toxic substances such as ROS and RNS. Inappropriate (/failure) 
clearance of myelin debris from the sites of demyelination by microglia or the lack of 
microglial recruitment by the astrocytes further increase the production of ROS and RNS 












Table 3: Ion imbalance in CPZ-fed animal  
Ion Tissue  Condition Reference 
Iron Serum:↓, liver:↑and corpus callosum:x  B6, oral feeding,  
0.2%, 4 weeks 
[59]  
Copper Blood:↓, liver:↓, kidney:x, cerebellum:x, 
hippocampus:x, cortex:x, thalamus:x and striaturm:x 
B6, oral feeding, 0.2%, 
6 weeks 
[58] 
Manganese Blood:x, liver:↓, cerebellum:↓, striatum:↓, kidney:↓, 
cortex:x, hippocampus:x and thalamus:x 
Iron Blood:x, liver:↑, kidney:x, cerebellum:x, 
hippocampus:x, cortex:x, thalamus:x and striaturm:x 
Zinc Blood:x, liver:x, kidney:↓, cerebellum:x, 
hippocampus:x, cortex:x thalamus:x and striaturm:x 
Copper Liver:x, kidney:↑, heart:↑, stomach:x, spleen:↑, large 
intestine:x, small intestine:↑, prosencephalon-
mesencephalon:x, cerebellum:↑ and pons-medulla:↑ 
*CD mice, drinking 
water, 0.2%, 9 months 
 
[3] 
Zinc Liver:↑, kidney:↑, heart:x, stomach:x, spleen:x, large 
intestine:↑, small intestine:↑, prosencephalon-
mesencephalon:↑, cerebellum:↑ and pons-medulla:↑ 
Sodium Brain:↑ Swiss mice, 0.5%, oral 




Key: ↑, increase; ↓, decrease; and x, no change. *Only 3 months data was considered as CPZ studies 















1.2.3 Why are OLG vulnerable to CPZ? 
Oligodendrocytes (OLG) are considered to be the most CPZ-sensitive glial cells in the CNS 
[8, 28, 76, 82] due to the following reasons. Firstly, mature OLG increase their surface area 
and increase gene expression during remyelination, and support axons up to 100 times that of 
their own weight [39, 76, 77, 83] by producing around 5000-50,000 μm2 of myelin membrane 
with a volume up to 3×104 μm3 [53, 84]. To execute this job, OLG use large amounts of ATP 
and oxygen. For example, to synthesize one gram of myelin it needs ~3.24×1023 ATP 
molecules [85]. An uninterrupted supply of energy from essential metabolites, such as 
glucose and lactate [86, 87], and a constant supply of oxygen is needed to avoid 
hypoglycaemia- or hypoxia-related damage to OLG [88]. Unfortunately, in both conditions, 
increased ROS and RNS are produced which increase the exposure of OLG to oxidative 
injury [76, 89]. Secondly, insufficient production of de-toxicant substances increases the 
vulnerability to oxidative injury. For example, glutathione has protective effects against 
oxidative stress [90, 91]. Compared with astrocytes or macrophages, OLG have three times 
less glutathione, thereby increasing their susceptibility to oxidative injury [89, 92] whereas 
astrocytes or macrophages remain viable [89, 93]. Moreover, OLG have low levels of 
metallothionein [94] and lower abundance of manganese superoxide dismutase [95] which 
also contribute to their vulnerability to oxidative stress. Thirdly, increased iron content in 
OLG increases iron-induced susceptibility to oxidative injury [96, 97]. OLG have 20 times 
more iron compared with astrocytes [92]. Moreover, OLG carry a large amount of iron 
storage protein ferritin [97]. Iron is essential for glycolysis, oxidative phosphorylation and the 
ATP production that is required to support myelin synthesis [97-99]. Increased intracellular 
iron concentrations in OLG lead to free radical production by the conversion of hydrogen 
peroxide to free-radical ions (via Fenton’s reaction) and consequent damage to cellular 
membranes, proteins, DNA and lipid peroxidation [74, 100-103]. Finally, during myelination 
the normal process of protein assembly/folding in the endoplasmic reticulum is impaired [74] 
due to the increased iron and free-radical production that trigger an unfolded protein response 
[63, 104, 105]. Together, these events trigger the reduction of OLG function and exacerbation 








1.2.4 CPZ is preferentially toxic to mature OLG over OPC and neurons  
Both in vitro and in vivo studies have argued that mature OLG are more susceptible than OPC 
and neurons to CPZ-induced injury [28, 108-111]. CPZ concentrations from 20-500 µM did 
not have any effect on viability of neuronal cell lines (e.g. SH-SY5Y and GN11) and primary 
mixed glial cells (microglia and astrocytes) in vitro [28, 111]. In addition, primary cultures of 
cortical neurons from newborn Wistar rats were unaffected when bathed in buffer containing 
200 µM of CPZ [111]. These results indicate that CPZ has no effect at these concentrations 
on neuronal cells in vitro. Likewise, in vivo studies showed that following 0.2% CPZ-feeding 
for 5-10 weeks, no loss of neuron was found in cortex, optic nerve and hippocampus [108-
110] suggesting that neurons are resistant to CPZ-induced toxicity. One study, using fluoro-
jade (a fluorescent marker of neuronal degeneration) found that following prolonged CPZ-
feeding (0.2% for 12 weeks) leads to an ongoing neural degeneration when animals were 
examined at 17 weeks (5 weeks after the cessation of CPZ-feeding) in the hilus neurons of 
the hippocampus suggesting that neurons were primarily unaffected at early stages, whereas 
prolonged CPZ-feeding triggered a state of  progressive neuronal degeneration [112]. 
Whether CPZ affects other neurons such as Purkinje neurons in the cerebellum and motor 
neurons in the spinal cord remains untested. In contrast, when mature OLG were incubated 
with as little as 50 µM CPZ, loss of OLG was evident and increased in a dose dependent 
manner whereas OPC were unaffected in the same CPZ dosing [28]; this sensitivity profile 
persisted when OLG/OPC were co-cultured with glial cells [55]. This relative toxicity of CPZ 
on OLG, vis-a-vis the relative insensitivity of OPC/neurones/glia was confirmed using 
mitochondrial staining. In mitochondria of mature OLG showed the reduction of 
mitochondrial transmembrane potential which is an indication of loss of mitochondrial 
function whereas intact mitochondria were present in OPC [28, 55]. Likewise, in vivo studies 
showed dose- and time-dependent CPZ-induced degeneration (and subsequent regeneration) 
of OLG [8, 82, 113]. In the ‘acute’ phase, following 0.2% CPZ-feeding for 5-6 weeks in B6 
mice, loss of mature OLG starts in the first week of feeding with an increased number of 
OPC becoming evident, indicating that the latter are either unaffected by CPZ-feeding or that 
oligodendrocytosis  is a strong stimulus for OPC proliferation and migration to the site of 
demyelination [8]. The reason for OPC insensitivity to CPZ is not clear, but may be related to 
the proliferative ability of OPC (similar to stem cell) compared to the post-mitotic and non-
migratory status of mature OLG [51, 114]. In addition, “unknown internal protecting 
machinery” has been proposed for OPC to limit CPZ-induced mitochondrial injury [28, 60]. 
What happens in the longer feeding paradigm? In the ‘chronic’ phase when mice are fed with 
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0.2% CPZ for 12-14 weeks, an increased loss of mature OLG but OPC depletion was 
reported possibly due to toxicity induced by secretion of the inflammatory mediators 
(cytokines and chemokines) including tumor necrosis factor, interleukin-1β, interferon- γ, and 
nitric oxide resulting in longer lasting demyelination and irreversible remyelination [82].  
 
In CPZ model, the detection and quantification of different stages of OLG development (e.g. 
mature or immature) are mainly accomplished immunohistochemically (IHC; Table 4) and 
with conventional myelin staining procedures such as Luxol Fast Blue (a copper 
phthalocyanine dye that binds to the lipoprotein components of the myelin sheath). For IHC, 
molecular marker/antibody based detection is used as each marker is expressed only in a 
particular stage of OLG development [74]. For example, the proliferating OPC can be 
recognised by the expression of anti-platelet-derived growth factor alpha (PDGFR-α) or the 
chondroitin sulphate proteoglycan (NG-2) markers [115] whereas differentiating OPC and 
mature OLG can be detected by the expression of transcription factor Olig-2 [115-117]. 
However, commonly used antibodies for mature OLG are adenomatous polyposis coli (APC), 
glutathione S-transferase pi isoform (GSTP1), 2′,3′-cyclic nucleotide-3′-phosphodiesterase 
(CNPase) or neurite outgrowth inhibitor A [NOGO A, 118, 119, 120]. Fully developed (i.e. 
differentiated) OLG are detected based on the expression of myelin proteins such as myelin 
basic  [MBP, 27, 121], myelin oligodendrocyte glycoprotein  [MOG, 122], myelin associated 
protein  [MAG, 121] or proteolipid protein  [PLP, 21] using their corresponding antibodies. 
In addition, conventional histology staining such as Luxol Fast Blue [23, 123, 124], Sudan 
Black [29] or Black Gold II [125, 126] are commonly used to measure myelin status (e.g. loss 
or subsequent regeneration) in the CNS. However, it has been shown that the Gallyas silver 
staining method is the preferred method used for myelin staining due to a higher signal-to-
noise ratio of this technique compared to other staining methods. In this method, colloidal 
silver ions bind to the negatively charged side chains of the proteins such as myelin protein 
[127, 128]. What happens in the peripheral nervous system in CPZ-fed mice? Schwann cell 
(also called as neurilemma cell) plays similar role to wrap up the peripheral axon like OLG in 
the CNS. Whether CPZ degenerate schwann cell in the periphery is not investigated. 
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Table 4: Frequently used OLG markers in CPZ studies  
Protein marker  Stage Status in CPZ Reference 
  Acute Chronic  
 PDGFR-α Proliferating/resting 
OPC 
↑ ↓ [115, 123]  
 NG-2 Proliferating/resting 
OPC 
↑ ↓ [22, 115]  
 Olig-2 Differentiating 
OPC and mature 
OLG 
↓ ↓ [115, 116] 
 APC Mature OLG ↓ ↓ [115, 123]  
 NOGO A Mature OLG ↓ ↓ [24, 129]  
 GSTP1 Mature OLG ↓ ↓ [119] 
 CNPase Mature OLG ↓ ↓ [120]  
MBP, PLP, MOG and 
MAG 
Developed OLG ↓ ↓ [27, 121, 122] 























1.2.5 Variability of OLG degeneration in CPZ 
Whether or not CPZ causes homogenous OLG loss throughout the CNS has not been 
systematically investigated. The existing literature suggests that a higher level of OLG 
degeneration is seen in the cerebrum and cerebellum. In cerebrum, the magnitude of CPZ-
induced oligodendrocytosis is duration, dose of CPZ, and region-dependent. For example, 
there is significant loss of mature OLG in the corpus callosum by 2 weeks of CPZ-feeding [8] 
whereas, in the hippocampus it takes 3-4 weeks [21] suggesting regional variability. 
Following OLG loss, near complete demyelination (histologically detectable and statistically 
significantly different) in the hippocampus was seen after 5-6 weeks [21, 130] compared to 
4.5 weeks in the corpus callosum [22]. Likewise, OPC recruitment to the demyelinating areas 
is greater by 4 weeks in the corpus callosum whereas in cerebral cortex it takes 4.5 weeks 
[22]. Interestingly, within the corpus callosum itself, there is a regional variation in OLG loss 
and demyelination. For example, 0.2% CPZ-feeding for 5 weeks shows limited changes in 
the rostral region whereas the caudal area of the corpus callosum was highly demyelinated 
[131]. In the cerebellum, loss of mature OLG is observed in CPZ-fed animals in both white 
and grey matter areas [24, 132, 133]. During the remyelination, the rostral regions such as the 
lingual cerebelli, and lobulus simplex recover faster than caudal regions such as the 
comissura cerebelli lobulus and lobulus paramedianus, reflecting regional variabilities in 
CPZ-induced pathological change [24]. In brain stem, reports have so far been inconsistent 
and unclear. For example, a decreased number of carbonic anhydrase II positive OLG [57], 
decreased myelin lipid content [17], reduced oligodendroglia [134], and vacuolation of the 
OLG cytoplasm [6] have been reported in the brain stem but no clear description of the status 
of mature or immature OLG in different areas of brain stem have been reported. In the spinal 
cord, the only two studies conducted reported no OLG loss [25, 60] suggesting that more 
detailed investigation is needed both in white and grey matter regions of the CNS to 
determine the regional distribution of CPZ-induced OLG loss. 
 
The age of an animal has a great impact on CPZ-induced OLG degeneration. In juvenile (3-4 
weeks old) B6 mice, CPZ-feeding resulted in a reduction of mature OLG and an increased 
number of proliferating OPC in the corpus callosum after one week of feeding and reached a 
peak within 2 weeks of CPZ-feeding. In contrast, late initiation of OPC proliferation is 
observed in young adult mice [i.e. 6-7 weeks old, 129]. In older mice (i.e. 8 months old) no 
changes of mature OLG are observed [135] after 6 weeks of 0.2% CPZ-feeding. In another 
study, reduced regeneration of mature OLG from proliferating OPC was found when animals 
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were 12-16 months old [136]. The causes of age-related vulnerability of OLG de- and 
regeneration in the CPZ model are unknown. However, it can be inferred that the reduction of 
age-dependent immune regulation [137], decreased length of internodes [138] and decreased 
epigenetic modulation in older animals [139, 140] may regulate OLG loss and regeneration. 
The degree of OLG loss also differs between different strains of animal in different parts of 
the CNS regions. In cerebrum, greater OLG loss is found in the lateral corpus callosum than 
the midline corpus callosum in SJL mice [141]. Likewise, the cerebral cortex of CPZ-fed 
BALB/cJ mice showed less change compared to B6 mice whereas similar pathological 
changes are observed in the corpus callosum [142]. Moreover, both CD1 and B6 mice 
showed depletion of mature OLG upon CPZ-feeding but the severity was greater in B6 than 
CD1 in different CNS structures [e.g. corpus callosum and dorsal fornix, 121]. However, 
when higher CPZ concentrations such as 0.6% [124, 143], 1% [144, 145] and 2% [68] were 
used in larger species like rats a comparable levels of OLG and myelin loss were observed to 
that seen in mice. However, no single study using CPZ has systematically compared the 
oligodendrocytosis between strains (mice vs rat) and their underlying genetic make-up.  
 
The variability apparent in the studies highlighted above could occur for several reasons. The 
distinct anatomical structure and variation in the density of OLG in different parts of the CNS 
structures may play a vital role in regional variability. For example, the number of NOGO A 
positive mature OLG [22] and NG-2 positive OPC are greater in the white (1.5 times) than 
the grey matter [49]. Similarly, the density of NOGO A positive OLG is lower in the cerebral 
cortex than in the white matter lobes of the cerebellum [24]. Secondly, the regional sensitivity 
may be due the operation of regionally specific, subcellular signalling pathways [38, 146]. 
For example, loss of the non-receptor tyrosine kinase Fyn (a signalling molecule of the Src 
kinase family) causes more hypo-myelination [147] in the brain than the spinal cord [148]. 
Likewise, mice haplo-insufficient for type III neuregulin-1 (a growth factor that promotes 
oligodendrocyte and Schwann cell development) showed less myelination in the corpus 
callosum but no effect on the optic nerve and spinal cord, further indicating regional 
differences in the regulation of OLG function and their susceptibility injury [149]. Whether 
the expression of Fyn or neuregulin-1 contributes to the regional heterogeneity of 
oligodendrocytosis in CPZ-fed animals remains untested. Another possibility for these effects 
could be that different regions of the CNS have different subtypes of OLGs based on 
biochemical profile and axon myelination. Most recently, RNAscope analysis showed 12 
different subtypes of mature OLGs distribute not only differentially in the brain and spinal 
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cord but also respond differentially in response to injury [150]. The distribution of different 
OLG subtypes in the CNS may also contribute to the regional variability of OLG loss. In one 
study, increased degeneration of type I OLG was detected in the cortex [6]. However, the 
effect on other subtypes, especially type III and IV OLG, which are mainly present in the 
brain stem and spinal cord, remains untested. Fourthly, regional variabilities of 
mitochondrial function may play a role in susceptibility to OLG injury [60, 151]. For 
example, following 4 weeks of 0.2% CPZ-feeding there was a loss of mature OLG in the 
cerebrum whereas spinal cord OLG were intact despite the presence of similar changes in 
mitochondria complex IV and superoxide dismutase in both regions of interest [60] 
suggesting additional factors play a role in the degeneration of OLG. Moreover, it could also 
possible that differential absorption or entrance of CPZ into the different parts of the CNS 
evokes differential response to the OLG remains untested. 
 
1.3 Immune response in the CPZ model 
1.3.1 Innate immune response 
Components of the innate immune system, such as microglia and astrocytes, rapidly respond 
to injury or infection [152, 153] with the response of these cells being used as markers of the 
effects of CPZ [82].   
 
1.3.1.1 Astrocytes 
Astrocytes, the ‘glue’ of the CNS, are characterized by the non-overlapping star shaped 
extensions from the cell body and comprise ~30% of the glial cells in the CNS [154-156]. 
They actively participate in numerous critical aspects of CNS development by regulating 
neurogenesis, synapse formation, propagation of action potential, BBB formation, 
neurotransmission, phagocytosis and developing brain circuits [155, 157, 158]. Based on cell 
morphology and anatomical locations, astrocytes are subdivided into two types: fibrous and 
protoplasmic. Fibrous astrocytes have small cell bodies, fewer processes and are mainly 
found in white matter. Grey matter dominant protoplasmic astrocytes have relatively more 
processes and larger cell bodies. In addition regional variations in morphology have been 
observed such as velate in the cerebellum and radial astrocytes in the spinal cord [159]. 
Reactive astrocytes may play either ‘bad-A1’ or ‘good-A2’ roles in the CNS as summarized 
in Figure 2. Upon activation, A1 astrocytes upregulate neurotoxic factors such as 
complement cascades. A1 astrocytes are abundant in various human neurological diseases 
including Alzheimer’s, Huntington’s, Parkinson’s, amyotrophic lateral sclerosis and multiple 
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sclerosis [160]. A1 astrocytes secrete soluble, highly neurotoxic substances such as TNF-α 
and IL-1β/6 that degrade neurons and OLG through a caspase 2/3 dependent mechanism 
[155, 160]. In contrast, neurotrophic factors such as nerve growth factor (NGF), brain derived 
neurotrophic factor (BDNF), and leukaemia inhibitory factor (LIF) secretion by A2 astrocytes 
promote neuron growth and synapse repair [160]. A1 astrocytes can be detected by the 
expression of complement component C3 whereas A2 astrocytes can be detected by the 
expression of S100 calcium-binding protein A10 (S100A10) as shown before [160]. 
 
1.3.1.2 Astrocytes and CPZ 
As a result of CPZ-feeding astrocytes become hypertrophic with enlarged somata and 
processes indicative of activation (Figure 2). In CPZ model, strong astrocytic activation 
occurs both in cerebrum and cerebellum [21, 22, 24, 161]. In relation with the degree of OLG 
loss, the highest number of astrocytes response is observed by 4.5-5 weeks of CPZ-feeding 
[22]. During the remyelination, when new mature OLG are generated (via migration and 
maturation of OPC), astrocyte activation decreases [82]. However, how astrocytes become 
reactive and the roles of A1 and A2 phenotypes have not been defined in the CPZ model. 
When astrocytes secrete growth factors including IGF-1/2 and PDGF-α which promote OPC 
proliferation [82, 162] and recruit microglia is considered an A2 function [27] whereas the 
upregulation of the inflammatory mediators (e.g.  cytokine IL-6 [163] and neuronal nitric 
oxide synthase [164]) are indications of A1 function. Measuring the expression of 
intermediate filament proteins such as glial fibrillary acidic protein (GFAP), vimentin and 
nestin, astrocytes are detected immunohistochemically [165, 166]. In the CPZ model, the 
activation of astrocytes is mainly detected using GFAP as a marker [26, 27], which is 
expressed predominantly on the processes of the astrocytes but with increasing astrocyte 
activation GFAP is readily detected in the soma [155, 165]. However, other intermediate 
filament protein markers, such as vimentin and nestin, also increase their expression in 
reactive astrocytes during CPZ-induced oligodendrocytosis [27, 167]. Detail information on 



















Figure 2: Different faces of astrocytes and microglia in CPZ model.  
Quiescent astrocytes are normally star shaped. Upon CPZ-feeding, astrocytes become 
hypertrophied. Hypertrophied astrocytes secrete mediators which can be either beneficial (i.e. 
neuroprotective) or detrimental (i.e. cytotoxic). Astrocytes termed A2 produce protective 
effects whereas A1 astrocytes evoke cytotoxic effects. A2 astrocytes facilitate OPC 
proliferation by the secretion of IGF-1/2 or PDGF-α whereas NO and IL-6 are released from 
the A1 astrocytes to damage tissues and neurons. These different phenotypes can be detected 
using the differential expression of protein markers such as C3 for A1 astrocytes or S100A10 
for A2 astrocytes. Likewise, in response to CPZ-feeding, microglia turn from a normal 
branch shape (resting stage) to amoeboid shape (activated stage). Activated microglia secrete 
both beneficial and detrimental cytokines. Like astrocytes, microglia are divided into 2 
phenotypes. M2 microglia have anti-inflammatory actions by the production of IL4, IL10 and 
IL13. They help OPCs to proliferate and facilitate remyelination. M2 microglia can be 
detected using expression of the specific protein marker arginase-1. In contrast, M1 microglia 
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damages the tissue and neurons by the release of pro-inflammatory cytokines such as TNF-α, 





Microglia are a resident population of cells in the CNS that are derived from the same 
mesodermal origin that gave rise to the peripheral immune system, including macrophages 
and monocytes [168-170]. Consequently, the presence of macrophages in the close vicinity of 
CNS lesions make it difficult to distinguish macrophages from activated microglia as both 
share a similar amoeboid shape and antigenic markers [65, 171]. Human microglia are, on 
average, 4.2 years old, and turnover at a median rate of ~28% per year with most (i.e. >96%) 
thus being renewed throughout the life span [172] by clonal expansion [173] and migration 
[174, 175]. In CNS, microglia constitute about 5-20% of the total glial cell population and 
total numbers range from 100-200 billion depending on health status [176-178]. As part of 
their homeostatic functions, microglial cell bodies remain immobile while the processes 
continuously scan the surroundings and communicate with other cells such as neurons and 
astrocytes [179]. In infection, degeneration or tissue injury, microglia can respond within one 
minute [180] and undergo morphological changes from normal ‘branched’ to active 
‘amoeboid’ shapes [179, 181]. There has been considerable debate whether the innate 
immune response is detrimental or beneficial. In unfavourable conditions (e.g. tissue injury) 
microglia become activated (e.g. increased expression or proliferation) and polarized, playing 
both neuro-destructive M1 or neuroprotective M2 roles. As shown in Figure 2 the ‘classical 
M1’ response is involved in pro-inflammatory effects to eliminate harmful intracellular 
substances such as microorganisms while the ‘alternative M2’ microglial response is to 
extracellular stimuli such as the clearance of myelin debris through phagocytosis [65, 182, 
183]. 
 
1.3.1.4 Microglia and CPZ 
Dose and time-dependent activation of microglia [7] occurs within the first week of CPZ-
feeding, well before the histological detection of demyelination (at 3-4 weeks) in the corpus 
callosum, cerebral cortex, thalamus, basal ganglia, hippocampus and cerebellum [22, 161]. 
The microglial activation can be both ‘M1’ and ‘M2’ in the CPZ model and can be detected 
using the expression of specific markers such as interferon gamma-induced protein 10 (IFNγ-
10) or iNOS for M1 and arginase-1 for M2 [65, 184-186]. M1 activation occurs mainly 
through triggering factors such as interferon (IFN)-γ, interleukin (IL)-12/23, tumour necrosis 
factor (TNF)-α, granulocyte and colony-stimulating factors, whereas the major stimulating 
factors in M2 pathways are IL-4/10, IgG and glucocorticoids [186-188]. Upregulation of toll-
like receptor-4 (TLR-4), lysozyme (LYZ)-1/2, TNF-α and matrix metalloproteinase (MMP)-
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12 are also considered as M1 responses. In addition, activated microglia in CPZ-fed mice 
secrete high amount of amino acid metabolites and reactive oxygen/nitrogen species [18, 
189]. These substances exacerbate the OLG and tissue damage [65, 190]. Moreover, the 
increased expression of phagocytosis regulating genes such as lipoprotein receptor-related 
protein (LRP)-1, calreticulin (Calr), CD14 and integrin beta (ITGB)-2 and galactose-specific 
lectin (LGALS)-3 by microglia facilitate phagocytosis and the removal of myelin debris 
[190]. Moreover, increased expression of chemokine ligands (CXCL)-10/13, IGF-1/2, IL-1ß, 
transforming growth factor beta (TGFB)-1, vascular endothelial growth factor (VEGF)-a/b 
and platelet-derived growth factor (PDGF)-α/β from microglia facilitate OPC recruitment and 
differentiation [18, 184, 190]. The source of increased microglia numbers in CPZ-fed animals 
is unclear. It has been proposed that increased number of microglia in CPZ-fed animal arise 
due to local proliferation, recruited from the other sites of the CNS, or infiltrate from the 
peripheral blood circulation [10, 191]. Immunohistochemical staining of ionized calcium-
binding adapter molecule 1 [IBA 1, a general microglial marker; 168], has been used widely 
to detect microglia in CPZ studies [116]. IBA 1 is a calcium-binding actin-cross-linking 
protein specifically expressed in microglia/macrophages, however, it does not differentiate 
between active and resting microglia [168, 192, 193]. To detect activated microglia, ricinus 
communis agglutinin-1 (RCA-1) 1 can be used [194]. Select antibodies can be used to detect 
peripheral macrophage CD68 [195] and CD45 [10] as shown in Table 5. 
 
Table 5: Commonly used astrocytes and microglia markers in CPZ study 
Cell type Protein marker Developmental stage State in CPZ Reference 
   Acute  Chronic   
Astrocytes GFAP Reactive astrocytes ↑ ↑ [26]  
 Vimentin Proliferating astrocytes ↑ ↑ 
Microglia IBA 1 General 
microglia/macrophage 
↑ ↑ [116] 
RCA-1 Activated microglia ↑ ↑ [194] 
Mac-3 Phagocytic microglia/ 
macrophage 
↑ ↑ [142] 








↑  [184]  
CD45 Macrophage    [10]  
CD11b Microglia/macrophage ↑ ↑ [196]  




receptor 2 (TLR2) 
Astrocytes/microglia ↑ ↑ [197]  
Nestin Astrocytes/microglia ↑ ↑ [22] 
Translocator protein 
(TSPO) 
Astrocytes/microglia ↑ ↑ [198] 
Key: ↑, increase and  ↓, decrease 
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1.3.1.5 Regional heterogeneity of glial activation  
Whether the magnitude of gliosis is equally distributed throughout the CNS in the CPZ 
model has not been clearly defined. To date, it has been revealed that the pattern of 
astrocytes activation depends upon OLG degeneration, duration of CPZ-feeding and the 
specific location of the analysis within the CNS. In cerebrum, highest amount of microglial 
and astrocytes activation is found in the corpus callosum compared to cerebral cortex [22]. -
Whether the magnitude of gliosis is equally distributed throughout the cortex (e.g. 
auditory, motor and somatosensory) has yet to be investigated. Likewise, in the cerebellum, 
highest activation of microglia are found at 4-6 weeks of CPZ-feeding whereas it takes ~8 
weeks to become the highest activation of astrocytes in the cerebral cortex [24, 132]. In the 
spinal cord, no gliosis has been found in cervical and thoracic regions [25] but the lumbar 
region remains to be investigated. Unfortunately, no description of the glial activation in the 
brain stem was found despite a thorough search of the literature. Known effects are 
summarised in Figure 3. The literature thus clearly indicates a regional variability in CPZ-
induced gliosis which may arise from several factors. From the existing data, it has been 
found that the glial activation depends upon OLG loss. For example, the highest number of 
OLG loss occurs in cerebrum and cerebellum resulting in increased glial activation 
suggesting first OLG loss then glial activation. In contrast, in spinal cord, no loss of OLG is 
found and no glial activation noted. Based on the limited studies in spinal cord and brain 
stem, it is not possible to draw a clear conclusion about the regional sensitivity of OLG and 
glia to CPZ, suggesting additional investigation is needed whether or not CPZ induced 

















Figure 3: Regional variability of CPZ outcome.  
CPZ causes concurrent loss of mature OLG and the activation of microglia and astrocytes in the 
cerebrum and cerebellum. Migration of OPCs to the demyelinating site leads to local increases in 
OPC number and regeneration of mature OLG. Regeneration of new OLGs facilities wrapping the 
unmyelinated axons resulting remyelination. Many publications have investigated changes in the 
conducted in cerebrum and cerebellum in the CPZ model. However, only a few studies were 
concentrated in the brain stem. Unfortunately from these studies no investigation has shown clearly 
the effect of CPZ-feeding on demyelination, OLGs de- and regeneration, or gliosis. Likewise, a very 
limited number of studies were conducted in the spinal cord. These studies showed no loss of OLG 
and glial activation in cervical and thoracic regions [25, 60]. However, lumbar spinal cord remains to 
be investigated. This differential outcome of OLGs de- and regeneration and glial activation followed 




1.3.2 Adaptive immune response 
Despite oligodendrocytosis, demyelination and glial activation, there is no apparent 
involvement of peripheral adaptive immune cells during 4-5 weeks of CPZ-feeding; notably, 
the BBB remains intact [10, 30]. Flow cytometry analysis showed the presence of inactive T-
cells, but no B-cells in the corpus callosum during CPZ-feeding and recovery phases [10]. In 
addition, IHC staining for the pan T-cell marker (termed CD3) showed few T-cells in the 
corpus callosum in CPZ-fed animal [190]. An absence of B- and T-cells at demyelinating 
sites, such as the corpus callosum and cerebral cortex, persisted even when the BBB was 
breached using stereotaxic injection of ethidium bromide or lysolecithin in mice fed with 
CPZ for 5 weeks [30]. However, combining transient CPZ-feeding (2 weeks) with breach of 
the BBB and a peripheral ‘immune booster’ (complete Fraud’s adjuvant) led to CD3 
infiltration of the brain and a secondary demyelination and inflammation process mediated by 
T-cells [31]. The  immunogenicity  of  the  myelin  fragments  appears  to  be  enhanced  by  post‐
translation modification of the parent molecules (where arginine is converted to citrulline) through 
the processes of citrullination as demonstrated in animal [199] and human studies [200]. Whether 
the failure to initiate an immune response with prolonged feeding (≥5 weeks) is due to a 
suppressive toxic effect of CPZ on the peripheral immune system is unclear. 
 
1.4 Multiple sclerosis (MS) 
The BBB separates the CNS from the peripheral immune system. In most MS patients, the 
BBB is compromised and free access of adaptive cells into the CNS is observed [201, 202]. 
Immune cells inside the CNS become reactive and create neuro-inflammation that leads to 
demyelination and axonal damage [203, 204]. Approximately 2-5 million people worldwide 
suffer from this disease [205, 206]. Unfortunately, till now, the underlying causes of MS are 
not clearly known. Environmental factors (e.g. deficiency of vitamin D, smoking and viral 
infection) and genetic susceptibility (e.g. major histocompatibility complex, MHC I-II) are 
suggested as possible initial triggers [203, 204, 207, 208]. The clinical features of MS are the 
presence of two or more episodes of demyelinating lesions (~95% patients) in the brain 
and/or spinal cord and the presence of oligoclonal immunoglobulin G (IgG, ~90% patients) in 
cerebrospinal fluid [203, 207]. The pattern of demyelination and inflammation is largely 
heterogeneous in MS [209-212]. All active lesions show profound reduction of myelin 
proteins such as MBP, MOG, PLP and MAG. In addition, infiltration of T-lymphocytes and 
macrophages into the demyelinating sites are found. These lesions are categorised into four 
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patterns (I, II, III and IV) depending upon the presence of immunoglobulin, activation of the 
complement cascade, OLG degeneration pattern, distribution of myelin protein loss and 
extent of demyelination (Table 6). Type I and II lesions are defined by the involvement of 
immunoglobulin G/complement complexes, with limited OLG dystrophy, whereas type III 
and IV lesions are defined by the marked apoptosis and depletion of mature OLG and an 
intact BBB [209-211].  
 
 Table 6: Heterogeneity of MS   
Patterns I and II:   
Similarities:  
 Disruption of BBB which is confirmed by the presence of IgG 
 Plaques are centred on small veins and showed sharply demarcated edges with peri-
venous extensions 
 Presence of remyelination shadow plaques (complete remyelinated lesions) 
 Presence of T-lymphocytes and macrophages   
 Less OLG damage  
 Similar pattern of loss of myelin proteins (MBP, PLP, MOG and MAG) 
 
Dissimilarities:  
 Pattern I is found mainly in acute MS (patients who die or are subjected to biopsy within 
the first year after disease onset) whereas pattern II occurs mostly in acute, relapsing 
remitting MS, secondary progressive MS and primary progressive MS 
 Deposition of complement complex (part of immune system promoting phagocytosis and 
inflammation) is only found in pattern II lesions  
 
Patterns III and IV: 
Similarities:  
 Absence of remyelination shadow plaque 
 Presence of T-lymphocytes and macrophages  
 Large numbers of OLG damaged  
 Demyelinating lesions are around inflamed vessels  
 Absence of IgG and complement complex  
 
Dissimilarities: 
 Preferential loss of MAG in pattern III  
 Pattern III lesions are mostly found in patients with acute MS whereas pattern IV are 










A long-standing unresolved question, however, is what initiates demyelination [213, 214]? 
Two alternative theories have been proposed: the first is termed ‘outside-in’ because of 
infiltration of autoreactive peripheral immune cells into the CNS is thought to be the 
causative factor; the second is termed ‘inside-out’ as demyelination resulting from internal 
metabolic disturbances is thought to initiate the disease cascade, leading to inflammation that 
then recruits autoimmune cells into the CNS [31, 213-215]. These alternate models of MS 
initiation are summarized in Figure 4. ‘Outside-in’ theorists propose that the dysregulated 
peripheral immune system leads to an autoimmune response against components of myelin in 
the CNS [216, 217]. This theory has been developed and tested using the experimental 
autoimmune encephalomyelitis (EAE) animal model [216, 217]. In EAE, animals (i.e. mainly 
mice) are immunised with exogenous antigens (e.g. either MBP, PLP or MOG) and also 
peripherally injected with complete Freund’s adjuvant (CFA) to activate peripheral immune 
cells, including T- and B-cells. When these procedures are combined with a breach of the 
BBB (e.g. by pertussis toxin (PT) injection), autoreactive adaptive immune cells from the 
periphery migrate into the CNS resulting in degeneration of OLG, demyelination and gliosis 
[216, 217]. It is argued that a similar process results in autoimmune cell migration into the 
CNS in MS [218-220]. However, there are several key differences between the EAE model 
and clinical MS. First, the autoimmune response in humans occurs spontaneously, whereas in 
EAE the immune response is initiated in the periphery by the administration of exogenous 
antigens (MBP/PLP/MOG) and immune activators [221, 222]. Second, CD8+ T-cells are the 
predominant immune cells in MS whereas in EAE, CD4+ T-cells predominate [223, 224]  
[225, 226]. Moreover, the spinal cord is the main demyelinating site in EAE [217, 227, 228] 
whereas MS is a disease of the human cerebral and cerebellar cortex. Although therapies 
developed in EAE improve outcomes in animals, these therapies generally have more limited 







Figure 4: Initiation of oligodendrocytosis and autoimmunity in MS.  
Two competing theories exist. In the ‘Outside-In’ theory, an unknown trigger leads to peripheral 
adaptive T- and/or B-cells entering into the CNS following a disruption of the BBB. T-cells inside the 
CNS cause OLG apoptosis resulting in destruction of the myelin sheath and production of damaged 
myelin. Innate astrocytes and microglia present myelin debris as an antigen to T-cells and exacerbate 
the process of OLG damage. In contrast, in the ‘Inside-Out’ theory, damage to OLG inside the CNS 
leads to oligodendrocytosis with the ensuing glial response (and consequent cytokines and 
chemokines released) leading to compromised BBB that allows peripheral immune cells access to the 
CNS. Once within the central CNS, T-cells (CD4 and CD8) cells interact with APC, via the MHC, 









Due to the inability of the EAE model to address questions about the initial events in the 
generation of auto-reactivity and the progression of MS, recent work has focused on the 
‘inside-out’ theory and the need to develop a new animal model. In support of the ‘inside-out’ 
theory, it has been shown that extensive OLG loss occurs without disruption of the BBB in 
MS patients with type III and IV lesions [209, 210]. Notably, only a few inflammatory 
parenchymal T- and B-cells were found in the active demyelinating sites in the brain [230, 
231]. Moreover, abnormal white matter exhibits reduced myelin density, extensive axonal 
loss and chronic fibrillary gliosis without focal inflammation [232]. Furthermore, ablation of 
MS patient’s immune system followed by replacement with autologous haematopoietic stem 
cell transplantation (e.g. T cell depleted and CD34 selected autologous peripheral blood stem 
cell transplantation) while halting the autoimmune response did not stop demyelination, 
markers of axonal damage (amyloid precursor protein) and disease progression [233]. In 
contrast to these observations that are typically seen during late stages of disease, in the initial 
stage of MS, myelin degeneration or abnormality begins at the inner sheath and may occur at 
sites where there is no evident inflammation, suggesting the operation of processes that are 
not inevitably linked to inflammation and immune autoreactivity [234]. Additionally, 
therapies that target suppression of immune function - e.g. Priliximab (cMT 412), Glatiramer 
acetate, Natalizumab (Tysabri) and Alemtuzumab (Lemtrada) - while effectively 
suppressing the autoimmune reactions (e.g. decreasing the number of relapses in the relapsing 
remitting MS), have little or no effect during the progressive phase suggesting that alternative 
mechanisms underpin disease initiation and progression in MS [229, 235]. Recent studies in 
animal models have shown that the degeneration of OLG can trigger a secondary immune 
response suggesting that the earliest events in MS may occur without autoimmune 












Hypothesis and Objectives 
The broad objective of this thesis was to develop an animal model to explore the very early 
stages of demyelination that may be associated with conditions such as multiple sclerosis 
(MS). Cuprizone (CPZ) was used to induce degeneration of OLG to model the processes of 
demyelination in the absence of adaptive immune cell infiltration. Whether breaching the 
blood brain barrier (BBB) results in infiltration of adaptive immune cells into the CNS is not 
clearly defined in the CPZ model. Therefore, to further test the ‘inside-out’ theory of MS, it 
was hypothesized that disruption of the BBB would lead to infiltration of adaptive immune 
cells into the CNS in response to CPZ-induced oligodendrocytosis.  
Objectives:  
 Quantification of OLG and myelin in the brain 
 Quantification of microglia and astrocytes in the brain 
 Quantification of CD4 and CD8 T-cell signal intensity in brain and spleen 
 Quantification of whole brain proteome changes 
 
The behavioural deficits associated with CPZ-induced demyelination and relevant CNS 
structures are not clearly defined. I hypothesized that demyelination in the sensorimotor 
network is associated with behavioural deficits and that increasing the complexity of the 
motor assessment tasks will detect subtle locomotor deficits during the early phases of CPZ-
feeding. Therefore, the second broad aim of this thesis was to measure behavioural deficits 
and identify regulating pathways associated with those deficits.  
Objectives: 
 Investigation of  motor behavioural deficits using different locomotor tasks of  
varying  complexity  
 Investigation of nociceptive behaviour using flexion withdrawal reflex threshold 
tests  
 Quantification of OLG and myelin in CNS white and grey matter regions 
 Quantification of microglia and astrocytes in CNS white and grey matter regions 
























2DE Two-dimensional gel electrophoresis LST Lateral striatum  
Ab Antibody LVN Lateral vestibular nucleus  
AFD Automated frozen disruption M1 Primary motor cortex  
AC Anterior commissure M2 Secondary motor cortex  
ANOVA Analysis of variance MBP Myelin basic protein 
APC Adenomatous polyposis coli MCC Midline corpus callosum 
AU Auditory cortex MCP Middle Cerebellar peduncle  
B6 C57Bl/6  MP Membrane protein 
BBB Blood brain barrier MST Middle striatum  
BSA Bovine serum albumin MVN Medial vestibular nucleus 
Calb Calbindin MW Molecular weight 
CCBB Colloidal coomassie brilliant blue NeuN Neuronal nuclei 
CCX Cerebellum cortex  NOGO A Neurite outgrowth inhibitor A 
CD Cluster of differentiation  OCT Optical cutting temperature 
Ctrl Control OLG Oligodendrocyte 





Protein analysis through 
evolutionary relationships 
ChAT Choline acetyltransferase PBS Phosphate buffered saline 
CPZ Cuprizone PFA Paraformaldehyde 
CNS Central nervous system pI Isoelectric point 
CV Cerebellar vermis PN Prepositor nucleus  
CVN Cerebellar vestibular nucleus  PT Pertussis toxin 
DAPI 4′,6-diamidino-2-phenylindole  PYT Pyramidal tract 
DAVID Database for annotation, visualization and 
integrated discovery 
PVDF Polyvinylidene difluoride 
DF Dorsal funiculus RN Red nucleus 
DFX Dorsal fornix RR Rotarod 
DH Dorsal horn ROI Region of interest 
DLF Dorsal lateral funiculus RPM Revolutions per min 
DN Dentate nucleus  RSD Relative standard deviation 
DPA Dynamic plantar aesthesiometer S1FL Primary somatosensory front limb 
DTT Dithiothreitol S1HL Primary somatosensory hind limb 
EAE Experimental autoimmune encephalomyelitis S2 Secondary somatosensory 
EC External capsule  SCP Superior cerebellar peduncle  
GFAP Glial fibrillary acidic protein SDS Sodium dodecyl sulphate 
GO Gene ontology SEM Standard error of the mean 
HEPES 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) 
SN Substantia nigra 
HP Hippocampus  SP Soluble protein 
HR Hargreaves SPVN Spinal vestibular nucleus  
HTH Hypothalamus STRING Search tool for retrieval of 
interacting genes/proteins 
IBA 1 Ionized calcium-binding adapter molecule 1 SUVN Superior vestibular nucleus   
IC Internal capsule TBST Tris buffered saline-tween 20 
ICN Inferior colliculus nucleus  TH Thalamus  
ICP Inferior cerebellar peduncle  TBP Tri-butyl phosphine 
IEF Isoelectric focussing VF Ventral funiculus 
IPN Interposed nucleus VH Ventral horn 
IP Intraperitoneal  VI Visual cortex  
IPG Immobilised pH gradient VLF Ventral lateral funiculus 
IS Inverted screen VP Ventral pallidum 
KEGG Kyoto encyclopaedia of genes and genomes WB Western blot 
LCC Lateral corpus callosum   





2.1 Suppliers and materials 
Suppliers Materials 
Amresco, USA Urea, Thiourea, HEPES, CHAPS, CBB, Triton X100, Sodium 
azide, Ammonium sulphate, Mineral oil, Tween 20, Tris, Tris-
glycine-SDS electrode buffer, Glycerol and BSA 
Sigma-Aldrich, USA  Polyvinylpyrrolidone, Formalin, Goat serum, PFA, CPZ, PT, 
PBS, EDTA, EGTA, Ammonium bicarbonate, Protease and 
Phosphatase inhibitors  
Bio-Rad, USA Protean IEF Cell, Electrophoretic tank, IPG strip, Ampholytes, 
PVDF, Acrylamide, TBP, Bromophenol blue, Agarose, 
Focussing tray and 2DE standard  
Merck, Germany Acetic acid, Acetic anhydride, SDS, Acetonitrile and Mounting 
medium  
Abcam, UK Goat anti-rabbit IgG H&L (HRP), Goat anti-rabbit IgG H&L 
(HRP), Rabbit anti-CD4, Rabbit anti-β-actin, Rabbit anti-CD4, 
Alexa Fluor 488 conjugated rabbit anti-ChAT and Mouse anti-
MBP 
Invitrogen, USA Rat anti-CD8, Alexa Fluor 594 conjugated goat anti-rabbit IgG 
and Alexa Fluor 488 conjugated goat anti-rat IgG 
Waters, USA Formic acid, Mass spec glass vial,  NanoAcquity ultra 
performance liquid chromatography,  Xevo QToF mass 
spectrometer, C18 Symmetry trapping column and C18 BEH 
analytical column   
Merck-Millipore, USA Alexa Fluor 488 conjugated mouse anti-GFAP, Rabbit anti-
NOGO A, 3 Kd cut-off filter column, Luminata Crescendo 
Western HRP Substrate, Rabbit anti-APC and Mouse anti-
NeuN 
Santa-Cruz Biotechnology, USA Mouse anti-CD8 and Mouse anti-mouse IgGκ BP-HRP 
Chem-Supply, Australia Silver nitrate, Gelatine, Ammonium nitrate, Sodium carbonate 
and Chromium potassium sulphate dodecahydrate 
Astrol Scientific, Australia Ethanol, Methanol and DTT 
VWR, USA Xylene, Pyridine and Vortex  
Sino Biological, USA Mouse CD4 and CD8 recombinant protein (His Tag) 
Promega Corporation, USA Trypsin 
Vector Laboratories, USA Vectasheild plus 4′,6-diamidino-2-phenylindole 
Tory laboratories, Australia Sodium pentabarbitone 
Cenvet, Australia Isoflurane  
Camlab, UK Whatman paper 
Bio-chemicals, Australia Sodium chloride 
Wako, Japan Rabbit anti-IBA 1  
Life Technologies, USA EZQ™ Protein Quantitation Kit  
BDH chemicals, UK Potassium ferricyanide  
Knittel Glass, Germany Slide and Cover slip 
Sakura, USA 6-well plate, OCT and Cryomold  
Coles, Australia Skimmed milk and Sucrose 





Gordon's specialty stockfeeds, 
Australia 
Mice chow 
Tecniplast, Italy Animal home case (GM500) 
Corning Incorporated, USA Falcon tube and Microtips  
GE Healthcare, USA FLA-9000 and LAS-4000 
Bioseb, France Dynamic plantar aesthesiometer and Hargreaves apparatus 
Peri-Star, China Perfusion pump  
Sartorius, Germany Mikro dismembrator 
Zeiss, Germany Olympus microscope 
Leica, Germany Cryostat 
UGO Basile, Italy Rotarod 
Beckman Coulter, USA Ultracentrifuge 
John Morris Scientific, Australia Speed Vac 
Logitech, China C525 HD Webcam 
Thermo Scientific, Australia -80°C freezer  
Electrical balance Adam, Australia  
NIH, USA ImageJ 
DECODON, Germany Delta 2D 
GraphPad prism, USA GraphPad Prism 
CorelDRAW, Canada  CorelDRAW 
FUJIFILM Corporation, Japan MultiGauge 






2.2.1 Animals and housekeeping  
Male C57BL/6 (B6) mice were purchased from Animal Resources Centre, Australia 
(www.arc.wa.gov.au). As B6 mouse produces reproducible demyelination and gender 
indifference [7, 29, 82, 141], this strain was used throughout (studies I-III). Mice were 
acclimatised for one week to adapt to their new environment prior to the start of a study. 
Basic enrichments including nesting material (crinkle nest) and a pipe tube (polyvinyl 
chloride) were provided. Animals were maintained on a 12 hours light/dark cycle (8am-8pm 
light; 8pm-8am dark, 50-60% humidity and 21-23°C room temperature, RT) throughout the 
entire period. Mice were housed in pairs in individual GM500 ventilated cages (Tecniplast, 
Italy) that measured 40.5x20.5x18.5 cm. Research and animal care procedures were approved 
by the Western Sydney University animal ethics committee (A10394/A11938) in accordance 
with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes 
as laid out by the National Health and Medical Research Council of Australia. Three 
independent studies were carried out and the total number of animals used is summarized in 
Table 1. 
 
Table 1: Number of animals and key focus of studies 
Study  Number of 
animals 
Age  Intervention 
(feeding) 
Main focus of analysis  
I 60 6 week 5 weeks  Behaviour, histology, western blot and 
proteomics 
II 48 6 week 12 weeks  Behaviour, histology, western blot and 
proteomics 














2.2.2 Cuprizone (CPZ)-feeding (used in studies I-III)  
Oral CPZ-feeding ([Bis(cyclohexanone)oxaldihydrazone], Sigma-Aldrich, USA) was used to 
induce oligodendrocyte (OLG) degeneration and demyelination as previously described [8, 
29, 82, 113]. Standard rodent powder chow (Gordon's Specialty Stockfeeds, Australia) with 
and without CPZ was prepared freshly each day and provided (along with water) ad libitum. 
Naïve, control (Ctrl) mice received normal food without CPZ for the entire period. Age and 
weight matched animals were used for CPZ and Ctrl groups. The dose and duration of 
feeding are summarized in Table 2. 
 
Table 2:  CPZ-feeding in different studies 
Study Intervention Feeding dose (w/w) 
I 5 weeks feeding 0.1 and 0.2% CPZ 
II 12 weeks feeding 0.1% CPZ 
III 5 weeks feeding 0.2% CPZ 
 
2.2.3 Pertussis toxin (PT) injection (used in studies I-II) 
Three doses of 400 ng of PT (Sigma-Aldrich) dissolved in 200 µl of 0.01 M phosphate 
buffered saline (PBS, Sigma-Aldrich) were injected intraperitoneally (IP) to breach the blood 
brain barrier [BBB, 236, 237-239]. This is the same dose used to breach the BBB in the 
experimental autoimmune encephalomyelitis model [EAE, 236, 237, 238]. All PT+CPZ 
groups (PT+0.1% and PT+0.2% CPZ) received CPZ and three injections of PT on day 14th, 
16th, and 23rd of CPZ-feeding. Age matched PT controls (with no CPZ) received three 
injections of PT on day 14th, 16th, and 23rd. PT injections were timed to coincided with the 
onset of CPZ-mediated oligodendrocytosis and gliosis [7, 8, 82]. The evidence of BBB 
breach using PT was assessed using horseradish peroxidase-substrate staining in the follow 
up study from our lab [240].  
 
2.2.4 General monitoring of animal health (studies I-III) 
Mice were weighed using an electrical balance (Adam, www.adamequipment.com, Australia) 
at the beginning of all studies, throughout the feeding period (at 3-7 days interval) and prior 
to culling to assess the impact of CPZ-feeding and PT injections on weight gain. Throughout 
the studies, all mouse activities daily monitoring for signs of abnormal posture, gait and body 





2.2.5 Spontaneous activities test (study III) 
The number of rears (vertical activity) and grooming events (fur licking and limb scratching) 
were measured quantitatively using cylinder (CY) test by the same trained observer. In this 
test, mice were placed in a transparent plastic CY (14 cm high and 10.5 cm diameter) 14 cm 
above the bench surface for 2 minutes. Each trial (n=3/time point, with 1 hour, h rest between 
trials) was recorded (Logitech C525 HD Webcam, China) and individual events counted 
manually.  
 
2.2.6 Behavioural assessments (studies I-III) 
Behavioural assessments of different mice groups were carried out in a blinded manner by 
same trained observed. The code linking individual animals to experimental groups was not 
released until all groups had completed their feeding and behavioural analysis had been 
completed. All tests were conducted in the first 1-5 hours of the light phase (i.e. 9am-1pm) to 
ensure constant timing of tests and to minimize sleep cycle and tiredness. All tests were 
conducted at RT in normal lighting condition of the laboratory. All conditions for the training 
(2-3 times) and test sessions were identical. After a 30 minutes habituation in the behaviour 
lab, mice were trained and tested with the accelerating rotarod (RR), inverted screen (IS), 
walking beam (WB), walking ladder (WL), dynamic plantar aesthesiometer (DPA) and 
Hargreaves (HR) apparatus. All instruments were cleaned after each trial with 70% ethanol 
(Astrol Scientific, Australia, prepared in distilled water). The number of behavioural tests 
were conducted in different studies are shown in Table 3.  
 
Table 3:  Type of behaviour tests were performed in various studies 




I Rotarod 10 6 
II Rotarod and inverted screen 12 4 
III Rotarod, walking ladder, walking beam, 











2.2.6.1 Rotarod (RR)  
Locomotor activity and balance of mice were measured using the accelerating RR apparatus 
(UGO Basile, Italy), which is equipped with a motor driven rotating rod [215, 241]. Each 
animal was placed on the accelerating (initial speed was 4 revolutions per minute (rpm) that 
accelerated up to 40 rpm) rod for 5 minutes (n=3 trails/mouse/time point, 1 hour rest between 
trials). In study I and III, RR test was carried out in week 1, 2, 3, 4 and 5 whereas in the study 
II, the RR test was alternated (i.e. every second week, 1, 3, 5, 7, 9 and 11) with inverted 
screen test (see below). Latency to fall (i.e. mice fall from the rod), first flipping time (i.e. 
mice start to flip along with the rod) and number of flips were measured.  
 
2.2.6.2 Inverted screen (IS) 
Muscle/grip strength was measured using the IS apparatus as described before [242]. Briefly, 
a customised (1 mm diameter wire, 12 mm2 mesh with total area of 42 cm2) IS apparatus was 
used. Each mouse was placed at the centre of the IS, which was inverted for 60 seconds  
above (35 cm) a soft surface and the latency to fall was recorded (n=3 trials/mouse/time 
point, 30 minute rest between trials). This test was conducted on weeks 2, 4, 6, 8, 10 and 12.  
 
2.2.6.3 Walking ladder  
The ladder test was also used to assess motor coordination [243-246]. A customized 60 cm 
long ladder was made of transparent plastic (3 mm width and 15 cm high) with 3 mm 
diameter metal rungs placed at 12 mm intervals (47 rungs in total). The ladder was placed 13 
cm above the bench surface. A desk lamp (25 W) was placed behind the starting side and the 
home cage at the distal end of the ladder to encourage the animal to move toward the safety 
of the darker home cage. The home cage containing nesting material was located at the end of 
the ladder in order to attract the mouse to walk towards their home confidently. On each test 
day, three trials were performed (30 minute rest between each trial) and all trials were 
recorded (Logitech C525 HD Webcam, China) for further analysis. Each video was analysed 
offline. The time to cross the ladder and the total number of ‘complete’ (no contact/extension 
beneath target rung) and ‘partial’ (contact with and extension beneath target rung) foot slips 
in both hind- and fore- limbs per mouse was quantified. The number of exploration events 






2.2.6.4 Walking beam  
The beam was used to assess motor coordination of mice as previously described [247, 248]. 
A customized 70 cm long wooden beam was placed horizontally 50 cm above the soft bench 
surface. The beam started at a width 11 mm at one end that progressively narrowed to 8 mm 
at the other. Mice were placed at the wide end and allowed to cross the beam towards the 
narrow end positioned in the mouse’s home case. A desk lamp (25 W) was placed behind the 
starting side of the beam to encourage mice to walk towards the home cage. The cut-off time 
of total walking was 1 minute. Each trial (n=3 trials in total and 30 minute rest between each 
trial) was recorded (Logitech C525 HD Webcam, China) and analysed offline. The number of 
foot hind limb slips (right, left and combined) as well as the time to cross the beam was 
quantified at each time point during the study. In addition, the measurement of the number of 
exploration was carried out. 
 
2.2.6.5 Paw withdrawal thresholds  
Hind paw withdrawal thresholds to mechanical (gram force) and thermal (seccond) stimuli 
were determined using dynamic plantar aesthesiometer (DPA) and Hargreaves (HR) 
apparatuses (Bioseb, France) respectively [249, 250]. Mice were placed inside a chamber (6.7 
cm long, 2.3 cm wide and 3 cm high with 5 mm2 ventilation) on a wire mesh and glass screen 
platforms for mechanical and thermal tests respectively. Mice were acclimatized for 45 
minutes (30 minute in the behaviour lab and 15 minute in the chamber) prior to the start of 
the test. The mechanical stimulus was given using DPA apparatus to either the right or left 
hind paw to measure the tactile threshold. From the point of initial contact, the force was 2 
gram forces/second and increased by time until the animals withdraw its paw or the 20 grams 
maximal force was achieved. Thermal stimuli were derived using the HR apparatus, an 
infrared heat source (power flux: 0.64 mW/cm2) was randomly delivered to the right or left 
hind paw and the paw withdrawal latency (15 second cut-off) was recorded. On each trial 
day, 5 consecutive paw withdrawal latencies were measured and the mean value for each trial 










2.2.7.1 Tissue preparation 
Mice were terminally anesthetized with LetobarbTM (250 mg/kg sodium pentabarbitone, Tory 
laboratories, Australia, studies I and II) injection or isoflurane (Cenvet, Australia, study III) 
exposure. Mouse limbs were fixed onto a polystyrene block using pins and the heart was 
exposed by lifting the superior part of the abdomen. A perfusion needle was inserted into the 
left ventricle of heart to infuse 30 ml of 0.9% saline for 5 minutes using perfusion pump 
(Peri-Star, China) and fluid exsanguinated via a small cut to the right atrium for 5 minutes. 
The saline was replaced using cold 50 ml 4% paraformaldehyde (PFA, prepared in phosphate 
buffer, Sigma-Aldrich) for ~5 minutes. Curling/stiffness of the tail and pallor of liver were 
taken as indications of an effective perfusion. Central nervous system (CNS) and spleen 
samples were collected and post fixed with 4% PFA at 4°C for one week and stored in 0.01 
M PBS solution containing 0.02% sodium azide (Amresco, USA) to prevent bacterial growth 
at 4°C ≤1 month or until sectioned.     
 
2.2.7.2 Sectioning 
Samples (CNS and spleen) were placed in a falcon tube containing 10 ml of 30% sucrose 
(Coles, Australia) solution for 48 hours at RT to cryo-protect the tissue. Complete 
submersion of sample was taken as an indication of effective cryo-protection. Samples were 
then embedded in 4% gelatine (Chem-Supply, Australia) in a cryomold (Sakura, USA) and 
set at -20°C for 20 minutes. Gelatine embedded sections were fixed to the tissue chuck holder 
using tissue-tek optimal cutting temperature (OCT, Sakura) compound. Tissue was then 
mounted in the cryostat (Leica, Germany) and 20-50 µm thick coronal sections were cut as 
mentioned in Table 4. Sections were transferred to either 6-well plates containing cold (5-
6°C) 0.01 M PBS (free floating) or mounted onto 0.5% gelatine-coated slides (Knittel Glass, 
Germany). Tissue slices were either immediately used for staining or kept in anti-freezing 
solution (glycerol, ethylene glycol and 0.01 M PBS at 1:1:2 v/v) at -20°C for ≤ 3 months or 
until use. 
 
Table 4: Tissue section thickness 





II Brain 40 µm 
III Whole CNS 40 µm 
50 
 
2.2.7.3 Slide coating 
CD4 and CD8 staining in spleen and silver staining were carried out on gelatine-coated 
slides. Gelatine (0.5%) was heated at 45°C for 10 minutes followed by addition of 0.05% 
positively charged chromium potassium sulphate dodecahydrate (Chem-Supply, Australia) to 
attach negatively charged tissue sections. The solution was cooled to RT for 30 minutes and 
then filtered using Whatman filter paper (pore size: 11 µm, UK) to remove any undissolved 
particles. Clean glass slides (Knittel Glass, Germany) were coated by dipping 5 times (at 5 
second interval) before air drying for 48 hour prior to use.  
 
2.2.7.4 Silver staining (studies I-III) 
All tissue sections (40-50 µm) from study I-III were mounted onto gelatine-coated slides and 
air dried for 48 hours before immersion in 10% natural formalin (Sigma-Aldrich) for 2 weeks 
at RT to increase the contrast of staining. All sections in a study were stained in parallel to 
maintain consistency. Slides were washed with distilled water and incubated in pyridine 
(VWR, USA): acetic anhydride (Merck, Germany) solution (ratio 2:1) for 30 minutes at RT. 
Sections were then rehydrated with serial dilutions of ethanol 80, 60, 40 and 20% for 20 
seconds in each step followed by two washes with distilled water. Washed slides were 
immersed in ammonical silver nitrate (Chem-Supply, Australia) containing developing 
solution for 45 minutes at RT. The developing solution contained an equal amount of stocks 
A and B (50-50 ml). A: 5 g sodium carbonate in 100 ml distilled water, B: mixture of 0.2 g 
ammonium nitrate and 0.2 g silver nitrate in 100 ml distilled water. Sections were then 
washed for 30 seconds with bleaching agent potassium ferricyanide (BDH chemicals, UK) to 
de-stain over developed (i.e. dark staining) sections followed by dehydration sequentially 
using 20, 40, 60 and 80% of ethanol for 20 seconds in each step. Sections were cleaned by 
immersing the slides in 200 ml xylene (VWR, USA) for 5 minutes to clean the sections by 
removing gelatine and ethanol at RT. Finally, slides were covered with glass cover slips 
(Knittel Glass, Germany) with mounting medium (Merck, USA) and air dried for 72 hours 









2.2.7.5 Immunofluorescence staining (studies I-III) 
Free floating coronal CNS tissue sections (40-50 µm) were bathed with warm (40-50°C) 0.01 
M PBS for 3x5 minutes to remove residual gelatine. Minimizing the non-specific binding of 
antibodies was carried out by immersing tissue sections into 5-10% normal goat serum 
(prepared in 0.01 M PBS) at RT for 2 hours on an orbital shaker (50 rpm). Sections were then 
transferred into primary antibodies dissolved in 0.1% Triton X-100 (TX-100, Amresco) in 
0.01 M PBS. Primary antibodies, such as neurite outgrowth inhibitor A (NOGO A), 
adenomatous polyposis coli (APC), glial fibrillary acidic protein (GFAP), ionized calcium-
binding adapter molecule 1 (IBA 1), calbindin (Calb), myelin basic protein (MBP), neuronal 
nuclei (NeuN) and choline acetyltransferase (ChAT) were used. For the detection of CD4 and 
CD8 cells, anti-cluster of differentiation (CD)4 and anti-CD8 antibodies were used (Tables 5 
and 6). For spleen immunofluorescence staining (spleen was used as a positive control of 
CD4 and CD8) with CD4 and CD8, mounted sections (20 µm) were used. All primary 
antibodies were incubated for 12 hours at RT while shaking in an orbital shaker (50 rpm). 
Sections were washed thrice in 0.01 M PBS and then incubated in secondary Alexa Fluor 
conjugated (either 488 or 555) antibodies for 2 hours at RT with agitation on a shaker. 
Following three more washes in 0.01 M PBS, sections were mounted on uncoated slides and 
cover-slipped (Knittel Glass, Germany) using 1.5 µg/ml vectasheild plus 4′,6-diamidino-2-
phenylindole (DAPI, Vector Laboratories) to counterstain nuclei. Tissue sections were dried 
for 30 minutes in RT in the dark and stored at 4°C in the dark until imaged (≤15 days). The 




Table 5. Antibodies used for immunofluorescence staining 
  Primary Secondary 
Study Target protein/ 
antigen 
Antibody Species Dilution Company/Catalogue  
 
Antibody Dilution Company/Catalogue 




1:1000 Merck-Millipore, USA 
/MAB3402X 
- - - 
Microglia IBA 1 Rabbit 1:1000 Wako, Japan 
/019-19741 








I-II Mature OLG NOGO A Rabbit 1:500 Merck-Millipore 
/AB5664P 
CD4 CD4 Rabbit 1:200 Abcam, UK 
/AB183685 
CD8 CD8 Rat 1:100 Invitrogen 
/MA1-70041 





III Mature OLG APC Rabbit 1:500 Merck-Millipore 
/AB5664P 







NeuN Mouse 1:500 Merck-Millipore 
/MAB377 













- - - 
Purkinje 
neurons 
Calb Rabbit 1:1000 Merck-Millipore 
/AB1778 













2.2.7.6 Antibody optimization 
The specificity of primary and secondary antibodies was optimized using a primary control 
(without primary antibody), secondary control (without secondary antibody), combination of 
primary and secondary antibodies, and blank (no primary or secondary antibody) as discussed 
previously [252, 253]. The specificity of the antibodies was confirmed by the signal obtained 
from the combination of primary and secondary antibodies whereas no signal was observed 
when primary antibody and secondary antibody were used alone. Dilutions of antibodies 
were started from low to high (for both primary and secondary antibodies) for short to long 
duration of incubation. For example, for IBA 1 primary antibody, dilutions were ranged from 
1:500, 1:1000 and 1:2000 (dilution in 0.01 M PBS and 0.1% Triton X-100) with incubation 
times of 8-20 hours at RT. Similarly, for secondary antibody dilutions ranged from 1:250 to 
1:500 with incubation times of 2-5 hours. The most intense signal (e.g. fluorescence 
intensity) was detected when 1:1000 dilution of primary antibody was incubated for 10-12 
hours with 1:250 secondary antibody dilutions for 2 hours. The same strategy was applied to 
other antibodies. Due to the direct conjugation of Alexa Fluor to GFAP and ChAT primary 
antibodies, no secondary antibody was used. Fluorescent signals were confirmed by 
comparing with previously published literature [26] and sections without using antibody. 
Non-specific binding was minimised using goat serum (study I: 5% and studies II-III: 10%) 
for 2-5 hours at RT. The optimum blocking of non-specific binding was found when 2 hours 
incubation using 5-10% serum was used.  
 
2.2.7.7 Quantification  
2.2.7.7.1 Silver myelin intensity 
All images were captured using Carl Zeiss Brightfield microscope using the same parameter 
settings for exposure time (e.g. 1 ms at 20x magnification) and illumination intensity. Images 
were opened in ImageJ (www.imagej.nih.gov) software and the region of interest (ROI) was 
contoured and the mean optical density quantified (measured as mean grey value: sum of all 
the pixels in the ROI divided by the number of pixels; range black (0) to white (256)). In 
order to quantify the extent of myelin present (which stains black), data were analysed as the 
reciprocal of the light intensity (i.e. the smaller the value, the lower the myelin content) and 
normalised to the Ctrl group in studies I and II. In study III, optical intensity inversely 
corresponds to myelin (more intensity less myelin) and data was presented as fold change 




2.2.7.7.2 Immunofluorescence intensity measurement 
Images were captured using fluorescent microscope set-up using same exposure (e.g. 100 
msec at 20x magnification) and magnification. Images were opened in ImageJ and 
fluorescence intensity was measured from each ROI as discussed before (see silver staining 
quantification) and data was presented according to their intensity (bigger the number, more 
the fluorescence intensity) in studies I and III. In study III, data were presented as fold change 
relative to Ctrl. The number of sections and animals quantified are stated in Table 6.  
 
2.2.7.7.3 Unbiased stereological counting 
To quantify the number of positively stained NOGO A, APC, GFAP, IBA 1 or NeuN cells, 
Unbiased Sterioinvestigator Workflow (www.mbfbioscience.com/stereology) was used. The 
use of this software allowed visualizing three dimensional structure of the cell and estimating 
total population of cells in a region of interest. At low magnification (e.g. 10x or 20x 
objective), the ROI was contoured and nucleated cells (DAPI positive) were counted at high 
magnification (63x). To obtain the cell density, total cell number was divided by total 
measured volume and the data is expressed as 104 cells/mm3. In study III, cell density was 
presented as fold change relative to Ctrl. For study I every 6th section (300 µm), for study II 
every 7th section (280 µm) and for study III every 9th section (360 µm) were quantified. The 
number of sections and animals quantified are stated in Table 6. Due to the small number of 
cells such as in NOGO A or APC positive OLG cells in CPZ-fed animal in areas such as 
corpus callosum, the minimum requirement of number of 3-5 cells/marker per counting frame 
as previously described [254, 255] was not achieved, thus the coefficient error (CE) increased 
above 10% whereas Ctrl group containing large number of cells and showed lower CE (>10) 
value. The detail parameters of the counting are given in the corresponding manuscripts. 
 
2.2.7.7.4 Manual counting 
Due to the small area or low number of cells, ChAT positive neurons in spinal cord, Calb-
positive Purkinje neurons in the cerebellum were counted manually and expressed as fold 
change relative to Ctrl. The number of sections and animals quantified are stated in Table 6. 
 
2.2.7.8 Anatomical structures 
The different CNS regions were identified according to the mouse brain atlas and spinal cord 
















CNS regions Silver APC NOGO A MBP GFAP IBA 1 NeuN ChAT Calb 
I Corpus callosum (CC, midline and lateral)  5/5 - 7/5 - 7/3 7/3 - - - 
II
 










Cortex (AU, VI, M1, M2, S1FL, S1HL and S2) 3/5 - - - 3/5 3/5 - - - 
Cingulum (CG) 3/5 - - - 3/5 3/5 - - - 
CC 8/5 5/5 - - 8/5 8/5 - - - 
Anterior commissure (AC)          
Dorsal fornix (DFX) 4/5 - - - 4/5 4/5 - - - 
Hippocampus (HP) 5/5 3/4 - - 3/5 3/5 - - - 
Striatum (lateral, LST and middle, MST) 3/5 - - - 3/5 3/5 - - - 
Ventral palladium (VP)          
Optic tract (OPT) 3/5 - - - 3/5 3/5 - - - 
Thalamus (TH) 3/5 - - - 3/5 3/5 - - - 
Hypothalamus (HTH) 3/5 - - - 3/5 3/5 - - - 








Cerebellar peduncle (superior, SCP; middle, MCP 




- - 3/5 3/5 - - - 
Cerebellar vestibular nucleus (CVN) 3/5 3/5 - - 3/5 3/5 - - - 
Interposed nucleus (IPN) 3/5 3/5 - - 3/5 3/5 - - - 
Dentate nucleus (DN) 3/5 3/5 - - 3/5 3/5 - - - 
Cerebellum cortex (CCX) 2/5 3/5 - - 3/5 3/5 - - - 







 Substantia nigra (SN) 3/5 - - - 3/5 3/5 - - - 
Red nucleus (RN) 3/5 - - - 3/5 3/5 - - - 
Inferior colliculus nucleus (ICN) 3/5 3/5 - - 3/5 3/5 - - - 
Vestibular nucleus (superior, SUVN; spinal, SPVN 3/5 3/5 - - 3/5 3/5 - - - 
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and lateral, LVN 
Medial vestibular nucleus (MVN) 3/5 3/5 - - 3/5 3/5 - - - 
Prepositor nucleus (PN) 3/5 3/5 - - 3/5 3/5 - - - 









Cervical (DF, DLF, VLF and VF) 5/5 3/5 - 5/5 5/5 5/5 - - - 
Thoracic (DF, DLF, VLF and VF) 5/5 3/5 - 5/5 5/5 5/5 - - - 
Lumbar (DF, DLF, VLF and VF) (DF) 5/5 3/5 - 5/5 5/5 5/5 - - - 
Cervical (DH) 5/5 - - 5/5 5/5 5/5 - - - 
Cervical (VH) 5/5 - - 5/5 5/5 5/5 5/5 5/5 - 
Thoracic (DH) 5/5 - - 5/5 5/5 5/5 5/5 - - 
Thoracic (VH) 5/5 - - 5/5 5/5 5/5 - 5/5 - 
Lumbar (DH) 5/5 - - 5/5 5/5 5/5 - - - 
Lumbar (VH) 5/5 - - 5/5 5/5 5/5 5/5 5/5 - 
Key: AU, auditory cortex; DF, dorsal funiculus; DH, dorsal horn; DLF, dorsal lateral funiculus; LCC, lateral corpus callosum; MCC, midline corpus callosum; 
M1, primary motor cortex; S1FL, primary somatosensory front limb cortex, S1HL; primary somatosensory hind limb cortex; S2, secondary motor cortex; S2,  










2.2.8 Two dimensional gel electrophoresis (2DE) and identification of proteins (studies I-II) 
2.2.8.1 Sample collection 
Mice were euthanized by overdose of isoflurane (Cenvet, Australia) exposure. Whole brains 
were collected following decapitation and immediately rinsed with ice cold 0.01 M PBS 
containing protease and phosphatase inhibitors to remove any trace amount of blood. 
Immediately brains were snap frozen in liquid nitrogen and stored at -80°C (Thermo 
Scientific, Australia) until homogenisation.  
 
2.2.8.2 Homogenisation 
Tissue homogenization was accomplished using an automated frozen disruption (AFD) 
procedure using Mikro-Dismembrator (Sartorius, Germany). Polytetrafluoroethylene (Teflon) 
tissue chambers (approximately 3 ml capacity) along with a grinding ball made of chromium 
steel were assembled and pre-cooled by immersing in liquid nitrogen bath for 5 minutes. 
Frozen tissues were transferred to above pre-cooled Teflon chambers and homogenized using 
Mikro-Dismembrator (a frequency of 40 Hz for 1 minute). The resulting pulverised frozen 
tissue was collected in to a fresh microfuge tubes and left in liquid nitrogen to prevent further 
thawing and transferred to -80°C until use as discussed previously [259-261].  
 
2.2.8.3 Proteome fractionation 
One gram of above pulverised tissue samples were transferred into fresh 15 ml falcon tubes 
(Corning Incorporated, USA) and added 1 ml of cold 20 mM HEPES (Amresco, USA) lysis 
buffer (0.104 g of HEPES salt was dissolved in 20 ml of distilled water supplemented with  
protease 1µl/ml protease and phosphatase inhibitors, Sigma-Aldrich). The sample was 
vortexed (VWR, USA) for 90 seconds followed by resuspension in HEPES buffer, the 
isotonicity was restored by the addition of an equivalent volume of ice cold two times 
concentrated 0.02 M PBS and incubated for further 5 minutes on ice. The samples were 
ultracentrifuged (Beckman Coulter, USA) at 125,000 x g using a SW 55 Ti rotor at 4°C for 2 
hours. The resulting supernatant (SP1) was collected as total cytosolic soluble protein (SP). 
The membrane pellet was washed with ice cold 0.01 M PBS to extract cytosolic proteins 
(SP2) again and ultracentrifuged for 8 hours at 125,000 x g. After the centrifugation, the 
supernatant (SP2), was collected and pooled with SP1 fraction. The combined soluble protein 
fraction (SP1 plus SP2) was concentrated using an Amicon Ultra-4 centrifugal 3 Kd cut-off 
filter column (Centrifugal filter column Millipore, USA). In order to prevent PBS and 
HEPES salts interference during 1st dimension isoelectric focussing step, the resulting SP 
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samples were washed three times using cold 4 M urea (Amresco) buffer containing protease 
and phosphatase inhibitors. The final volume of the SP fraction was maintained below 500 
µl. The above washed membrane pellet (MP) was resuspended with 500 µl of cold 
solubilisation buffer (9.616 g (8 M) urea, 3.045 g (2 M) thiourea and 0.8 g (4%) CHAPS 
were dissolved in distilled water to make a final volume to 20 ml, aliquoted 1 ml/tube and 
stored at -20°C) containing protease and phosphatase inhibitors. Both SP and MP fractions 
were aliquoted in small volumes (50 µl/tube) and stored at -80°C prior to protein estimation 
[259, 261].  
 
2.2.8.4 Protein estimation 
Protein concentrations for SP and MP fractions were quantified using EZQ™ Protein 
Quantitation Kit (Life Technologies, USA) using bovine serum albumin (BSA, Amresco) as 
standard protein. Standard protein BSA stock solution was prepared (12 mg/ml) in 2% 
sodium dodecyl sulphate (SDS, Merck, Germany) solution. From this stock BSA solution, 
different working concentrations ranging from 0.5 µg to 0.025 µg were prepared to generate a 
standard protein curve. Two microliters of each working standards with triplicate were 
spotted on Whatman filter paper (10x7 cm) along with SP and MP samples. After spotting, 
filter paper was air dried for 5 minutes on the bench surface and transferred to a plastic 
container. Carefully 50 ml of 100% methanol (Astral Scientific, Australia) was added and 
incubated for 5 minutes on an orbital shaker at 50 rpm. After incubation methanol solution 
was removed and air dried the filter paper for 5 minutes followed by 30 minute incubation 
with fresh fluorescent EZQ dye solution under dark. Immediately after the incubation, the 
filter paper was quickly rinsed with a buffer containing 10% methanol and 7% acetic acid for 
20 seconds for 3 times and scanned on FUJI LAS-4000 biomolecular imager (GE Healthcare, 
USA) for 2 seconds. Using Multi Gause software (Fujifilm, Japan) intensity of protein spots 
was measured. Protein concentrations from unknown samples (SP and MP) were measured 
against standard curve [262].  
 
2.2.8.5 Sample reduction and alkylation 
Reduction and alkylation steps were carried out to maintain all proteins in a denaturation state 
before subjecting to isoelectric focussing. One hundred micrograms of proteins from both 
soluble and membrane fractions were (n=3) taken into a clean low protein binding 
microcentrifuge tubes and were mixed with 58.8 µl of 2DE solubilisation buffer. Then equal 
volume of rehydration buffer (2% broad range pH 3-10 carrier ampholytes, Bio-Rad) was 
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added to the protein solution. The above protein solution was mixed with two mild reduction 
buffers containing 2.3 µl of tri-butyl phosphine (TBP, Bio-Rad) and dithiothreitol (DTT, 
Astral Scientific). Reduction buffer was prepared using 0.3702 g (2 M) DTT salt mixed with 
600 µl of TBP (0.2 M) and the final volume was made to 1.2 ml with distilled water. The 
combination of two agents at lower concentrations increases the capacity to cleave disulphide 
bond crosslinks to linearize proteins after alkalization. This reducing buffer was aliquoted in 
25 µl/tube and stored at -20°C. The tube was vortexed and incubated for 1 hour at 25°C on a 
heating block. After incubation, 5.1 µl of 5.6 M acrylamide solution was added to all tubes 
vortexed and incubated for further 1 hour at 25°C. After the incubation, the SP and MP were 
protein samples ready for first dimension run on immobilised pH gradient (IPG strips, Bio-
Rad) strip rehydration.  
 
2.2.8.6 IPG strip rehydration 
Non-linear pH 3-10 range 7 cm IPG strips were hydrated by loading 100 µg proteins (125 µl 
sample volume). At first, 125 µl of protein samples were dispensed into 
rehydration/equilibration tray. Peeled the plastic cover sheet from the IPG strip (7 cm, pH 3-
10 non-linear) using forceps and gently placed the strip following gel side down and 
emergence of air bubbles beneath the IPG strip were avoided. After loading all IPG strips, 
tray was covered with plastic lid and left for 16 hours on a level bench to rehydrate the strips 
and load the protein sample.  
 
2.2.8.7 Isoelectric focussing (IEF) on IPG strip 
Next day, isoelectric focusing (IEF) was carried out using above rehydrated IPG strip to 
separate proteins based on the charge of protein. Rehydrated IPG strips were placed in the 
Protean IEF focussing tray using forceps. Paper wicks (2.5 cm long and 4 mm width 
Whatman filter) at each positive and negative end of the electrode were placed connecting 
IPG strips with the platinum electrodes. All the IPG strips were overlayed with 2-3 ml of 
mineral oil (Amresco) to prevent evaporation during the focusing period. Focussing tray was 
transferred into the Protean IEF cell. Initially 250 V was applied for 15 minutes and increased 
linearly to 4000 V at 50 µA/gel for 2 hours, with multiple electrode wick changes during 
voltage ramping to facilitate desalting. The following parameters were used during the 
focusing: focus temperature: 17°C, desalting: 15 minute, linear gradient: 2 hour, Vh: 37500 
and holding voltage: 500 V. When focusing completed IPG strips were either stored at -20°C 
or immediately used for second dimension [259, 263-265].  
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2.2.8.8 Second dimension on 12.5% SDS-PAGE 
Second dimension was carried out using 1 mm thick 8.4x7 cm SDS-polyacrylamide gel 
(PAGE) gels with 12.5% acrylamide (Bio-Rad) concentration. Gels were casted the day 
before the actual run using Mini-protean Bio-Rad casting apparatus and stored at 4°C 
overnight for homogenous polymerization. Before subjecting to 2nd dimension focused IPG 
strips were incubated for 10 minutes each with 130 mM DTT in equilibration buffer followed 
by 10 minute alkylation with in equilibration buffer containing 350 mM acrylamide. This 
additional equilibration ensures that the cysteines were reduced and alkylated. Moreover, it 
helps to minimize vertical streaking and maximize separation of proteins in the second 
dimension gels. SDS-PAGE gel was placed to the casting stand. Using a paster pipet overlay 
warm agarose solution (0.5% low melting agarose, Bio-Rad) containing 2% bromophenol 
blue (Bio-Rad). Immediately, using a forceps carefully placed the IPG strips into the stacking 
gel while taking care not to trap any air bubbles beneath the IPF strip. The agarose was 
allowed to solidify for 2 minutes before mounting the gel into electrophoretic tank (Mini 
protein cell, Bio-Rad) containing tris-glycine-SDS electrode buffer (Amresco). 
Electrophoresis was carried out at 4°C/cold room by applying 150 v for 5 minutes followed 
by 90 v for 3 hours. When the tracking bromophenol dye reached to the bottom of the glass 
plate, electrophoresis was stopped and gels were removed from tank and immediately fixed 
[259, 260, 263, 265]. 
  
2.2.8.9 Protein fixation and staining 
Proteins were fixed in 10% (v/v) methanol and 7% (v/v) acetic acid solution for 1 hour at RT 
under constant shaking (50 rpm). Gels were rinsed with distilled water for 3x20 minutes to 
remove methanol and acetic acid followed by staining with high sensitive 50 ml colloidal 
Coomassie Brilliant Blue (CBB, G-250, Amresco). For 100 ml of cCBB was prepared by 
mixing 5 ml (2%) cCBB, 5 ml (30%) phosphoric acid, 25 ml (20%) ammonium sulphate and 
20 ml (100%) methanol. The final volume 100 ml was prepared by adding distilled water and 
used fresh in the day of preparation. Gels were incubated along with the dye solution for 20 
hours at RT on an orbital shaker (50 rpm). After 20 hour, carefully gel solution was discarded 
and stained gels were washed using 0.5 M sodium chloride (Bio-chemicals, Australia) 
solution for 3x15 minutes interval to remove excess dye and imaged immediately using 
TyphoonTM FLA-9000 gel imager (GE Healthcare, USA). Gels were preserved in 20% 





2.2.8.10 Gel imaging and protein spot analysis 
Quantitative analysis of gels was carried out using Delta 2D image analysis software 
(www.decodon.com/delta2d version 4.0.8, DECODON, Germany) as described previously 
[260, 266, 270-272]. Total spot numbers were calculated from the raw images using the Delta 
2D automated spot detection system while gel edges and the protein ladder were excluded 
[260, 271]. Gel images were warped and fused to generate a master image ensuring consistent 
spot matching. The fluorescent volumes of individual spots (i.e. protein abundance) as a 
function of all spot volumes detected were measured using Delta 2D to assess changes across 
the different experimental groups. Four spot inclusion criteria were applied: 1) any changes in 
spot volumes were detectable in all biological replicates (n=5 animals/group) and their 
associated technical replicate gels (n=3 gels/fraction/animal; i.e. 15 gels/experimental group); 
2) the relative standard deviation (RSD) for technical replicates did not exceed 30% within 
individual animals; 3) values had to differ significantly (p<0.05, t-test) between the naïve Ctrl 
group and at least one test group; and 4) have a fold change of ≥1.5 (increased/decreased 
fluorescence), were considered genuine changes, and thus candidates for analysis by 
LC/MS/MS. These criteria allowed for reliable and reproducible identification of CPZ, 
CPZ+PT or PT associated proteoform changes. The fold change (p<0.05, one-way ANOVA) 
of differentially abundant protein spots was calculated by dividing the average grey value 
(i.e. fluorescence intensity of the protein spot of each experimental group compared to the 
naïve Ctrl group) and presented in log2 scale as fold change relative to Ctrl 
 
2.2.8.11 Experimental molecular weight (MW) and isoelectric point (pI) calculation 
Precision Plus Protein Kaleidoscope MW and 2DE pI standard (Bio-Rad, USA) calibration 
gels (n=3) were used to calculate the experimental pI and MW of resolved proteoforms. IEF, 
second dimension and imaging of using standard proteins gels were carried out using 7 cm 
(pH 3-10, non-linear) IPG strips as discussed above. Experimental MW and pI of biological 
samples were then measured comparing the average migration of the protein standards and 
expressed as ‘experimental MW and pI’ [29, 260, 266]. The coefficient of variation (standard 
deviation/mean) for the MW and pI migration was 2.6% and 1.4% for 2DE standards 
respectively (n=3) and 4% for MW ladders for experimental gels (n=20). To quantify the gel 
shifting or likely post-translational modification (PTM) of proteins, experimental MW and pI 
values were plotted relative to theoretical values; significant changes were indicated when the 
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experimental measure fell above or below the 95% confidence intervals of the MW and pI 
calibration curves. The results are plotted as the average for both 5 and 12 weeks combined. 
 
2.2.8.12 In-gel protein spot digestion  
Protein spots of interest were cut using micro tip (Corning Incorporated) and stored at -20°C 
or subjected to trypsin digestion immediately. Excised protein gel pieces were transferred in 
0.5 ml DNase and RNase free microfuge tubes (Corning Incorporated) and de-stained with 
200 µl of 50 mM ammonium bicarbonate (Sigma-Aldrich) solution containing 50% 
acetonitrile (Merck, Germany) twice at 15 minute interval. After complete distaining, gel 
pieces were dehydrated using 100% acetonitrile. In-gel digestion was carried out by adding 
20 μl of freshly prepared trypsin (Promega Corporation, USA) solution (final concentration 
12.5 ng/µl) in 50 mM ammonium bicarbonate for 8 hours at 4°C. Digested peptides were 
removed from the gel following ultrasonic agitation in a sonicator (Soniclean, Australia) for 
30 minutes. The solution was then acidified by the addition of 2 µl (2%) formic acid (Waters, 
USA). The resulting peptide solution was concentrated to 10 µl using a Speed Vac vacuum 
concentrator machine (1400 rpm for 10-15 minutes, John Morris Scientific, Australia) and 
then transferred into recovery glass vials (Waters, USA). These were either stored at -80°C 
for future use or immediately subjected to mass spectrometry [260]. 
 
2.2.8.13 Liquid chromatography mass spectrometry (LC/MS/MS) 
The concentrated peptide solutions were analysed by LC/MS/MS using a nanoAcquity ultra 
performance liquid chromatography system (UPLC) linked to a Xevo QToF mass 
spectrometer  as previously described [29, 260, 266, 273, 274]. Peptide sample solutions (3 
µl) were loaded onto a C18 Symmetry trapping column (20 mm x 180 µm), and desalted for 
3 minutes at 5 μl/minute flow rate using 1% solvent B (LC/MS grade 1% acetonitrile and 
0.1% formic acid) in solvent A (Milli-Q water+0.1% formic acid). The peptides were washed 
off the trapping column at 400 nl/minute onto a C18 BEH analytical column (75 μm x 100 
mm), packed with 1.7 μm particles of pore size 130 Å using a 60 minute ramped LC 
protocol. The initial solvent composition was held at 1% B for 1 minute followed by linear 
ramping to 50% B over 30 minute. A further linear ramp to 85% B commenced at 31 minute 
and held until 37 minute before the solvent composition was returned to 1% B. Separated 
peptides were analysed using tandem mass spectrometry with a constant cone voltage of 25 V 
and source temperature of 100°C implementing an emitter tip that tapered to 10 µm at 2.3 
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KV. A data directed acquisition (DDA) approach was performed which continuously scanned 
across the m/z range 350-1500 for peptides of charge state 2+-4+ with an intensity of more 
than 50 counts/second, with a maximum of three ions in any given 3 second scan. Selected 
peptides were de-isotoped, fragmented and the masses measured. The ramped collision 
energy profile was set to 15-35 V at low mass and 30-40 V at high mass. The mass of the 
precursor peptide was then excluded for 30 seconds. The DDA data were acquired using 
Masslynx software (version 4.1, Micromass, UK). The raw data from Masslynx were 
converted to a peak list (PKL) file format using ProteinLynx Global Server (Waters, USA) 
and analysed using Mascot Daemon (www.matrixscience.com) and queried against the 
SwissProt and MSPnr100 databases (see www.wehi.edu.au) using delimited and species-
specific searches to identity the protein species using the following parameter settings: the 
enzyme trypsin and taxonomy Mus musculus (mouse) were fixed. No fixed modification was 
selected whereas variable modifications were carbamidomethyl, deamidated, oxidation and 
propipnamide. Only two missed cleavages of lysine or arginine residues were allowed; mass 
tolerance was set to 0.5 Da and peptide charge state was 2+-4+. When multiple proteins were 
detected from the same spot, the following criteria were applied to identify the most abundant 
and thus the most likely to have contributed to the originally detected change in spot volume: 
1) a MASCOT score >100 and sequence coverage ≥5%; 2) the highest MASCOT score of the 
proteins identified; and 3) ≥4 unique matched peptides.  
 
2.2.9 Literature mining and bioinformatics (studies I-II) 
2.2.9.1 Literature mining  
A PubMed (www.ncbi.nlm.nih.gov/pubmed/) literature search was carried out for papers 
published in the English language using the identified canonical protein name with either 
CPZ, experimental autoimmune encephalomyelitis (EAE) or multiple sclerosis (MS) to find 
literature relevant to molecular/cellular functions. 
 
2.2.9.2 Genes and UniProt accession identification 
Gene name, UniProt accession identification (UniProt ID) and subcellular location of the 
identified proteins were derived from the UniProt (www.uniprot.org) database [275]. The 
protein name obtained from LC/MS/MS was searched in UniProt against mouse (Mus 






Proteins were classified and molecular functions were revealed using protein analysis through 
evolutionary relationships (PANTHER, www.pantherdb.org) database. A mapping of genes 




Cellular components, biological processes and physiological pathways of identified proteins 
were categorised using database for annotation, visualization and integrated discovery 
(DAVID, version 6.8, david.ncifcrf.gov) database. Uniprot accessions IDs were used in 
DAVID database and categorized proteins according to their (GO, gene ontology, 
www.geneontology.org) GO cellular components and biological processes. DAVID was also 
characterized protein’s physiological pathways according to Kyoto encyclopaedia of genes 
and genomes (KEGG, www.genome.jp/kegg) category [277]. 
 
2.2.9.6 STRING 
Protein species were further characterised and grouped using the search tool for retrieval of 
interacting genes/proteins (STRING; version 10.5, string-db.org/) to identify the protein-
protein interaction [278]. In STRING database, protein IDs was used against Mus masculus. 
Protein-protein interaction map was generated based on their experimental evidence where 
each node represents a protein and connecting line represents the evidences of association 
such as text mining, co-expression, co-occurrence, databases, experiments, neighbourhood 














2.2.10 Western blot (studies I-II) 
2.2.10.1 Procedure 
Proteins (brain, spinal cord, spleen and recombinant proteins) were separated on 10% SDS-
PAGE gel (100 V for 2 hours at 4°C) and transferred (100 V for 2 hours at 4°C) onto a 
polyvinylidene difluoride (pore size: 0.22 µm, PVDF, Bio-Rad) membrane. The blotted 
membranes were incubated in blocking buffer containing skim milk (5% w/v, Coles, 
Australia) and polyvinylpyrrolidone (1% w/v, Sigma-Aldrich), in 0.05% tris buffered saline-
tween 20 (TBST) for 1 hour at RT on shaker (50 rpm). Table 7 shows the detail chemical 
constituents of buffer used in WB. Primary antibodies for CD4 and CD8 were incubated for 1 
hour at RT. All antibodies and final optimised dilutions are listed in Table 8. Blots were then 
washed thrice with 0.05% TBST at 10 minute intervals and incubated for a further 2 hours at 
RT using horseradish peroxidase-conjugated (HRP) compatible secondary antibody. Blots 
were washed thrice using TBST and incubated in the dark using 2 ml of chemiluminescence 
detection reagent (500 μl/cm2 membrane, Luminata Crescendo Western HRP Substrate, 
Merck-Millipore) for 2 minutes. Blots were scanned for 2 seconds on FUJI LAS-4000 
biomolecular imager.  
 
Table 7: Buffers related to WB 
Buffers Chemicals Quantity (for 4 litre, make final 
volume using distilled water) 
Transfer 25 mM Tris 12.12 g 
192  mM Glycine 57.6 g 
20% Methanol 800 ml 
pH 8.3 
Tris buffered saline with Tween-
20 (TBST) 
10 mM Tris 4.85 g 
150 mM Sodium chloride 36 g 
0.1% Tween 20 4 ml 
 




Antibody Species Dilution Company/ 
Catalogue 
Antibody Dilution Company/ 
Catalogue 
CD4 Anti-CD4 Rabbit  1:500 Abcam/ 
AB183685 
Goat anti-rabbit 
IgG H&L-HRP  
1:2000 Abcam/ 
AB6721 













2.2.10.2 Sample preparation 
Mice were euthanized using isoflurane exposure and samples (brain, spinal cord and spleen) 
were collected and washed to remove blood using 0.01 M PBS containing protease inhibitors, 
snap frozen in liquid nitrogen and stored in -80°C until protein extraction. Samples were 
powdered using AFD procedure (see homogenisation section). Equal ratios (~1 µl/1 µg 
tissue) of sample and pre-chilled solubilisation buffer was used to solubilize proteins, gently 
vortexed to mix properly and ultracentrifuged using 125,000 x g at 4°C for 1 hour. Resulting 
supernatant was collected as a total protein extract. Protein quantification was carried out as 
previously described using EZQ protein quantitation kit (see protein estimation section).  
 
2.2.10.3 Positive control 
To measure the CD4 and CD8 antibody specificity, biological (B6 mice) spleen samples and 
commercial CD4 and CD8 recombinant proteins (Sino Biological, USA) were used as 
positive control. Spinal cord homogenates of EAE from parallel experiment were also used as 
a positive control for CD4 signal detection in WB analysis in studies I and II. EAE was 
induced using an established method [281].  
 
2.2.10.4 Optimization of antibodies 
For optimization of CD4 and CD8 antibodies, different concentrations of primary and 
secondary antibodies, incubation and blocking time were used. CD4 primary antibody was 
used from 1:100-1:1000 dilutions (e.g. 1 µl antibody in 100 µl TBST). Dilutions of rabbit 
anti-CD4 antibody over 1:500 showed faint (or undetectable) signal/protein band whereas no 
bands were observed when 1:1000 and 2000 dilutions were used when 30 μg of spleen 
homogenate was used as a positive control. On the other hand, dilutions of secondary 
antibody goat anti-rabbit were 1:500, 1:1000 and 1:2000. Use of 1:2000 dilution showed 
sharp signal when primary antibody dilution 1:500 was used. In contrast, using goat anti-
rabbit secondary antibody at 1:500 or 1:1000 dilutions resulted in an increased background 
(dark staining, high noise to signal) when 1:500 rabbit anti-CD4 primary antibody was used. 
Likewise, incubation time was also optimised. The highest signal to noise was observed when 
1 h rabbit anti-CD4 primary antibody incubation at RT was used whereas in shorter 
incubation signal was indictable. Extended period of incubation (8-10 hour at RT or 4°C) 
generated background in the blot. Nonspecific binding of antibodies was minimised using a 
solution of 5% w/v skimmed milk (Coles, Australia) and 1% w/v polyvinylpyrrolidone 
(Sigma-Aldrich) in 0.05% TBST for 1 hour at RT. Increasing the duration of blocking time 
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up to overnight (8-10 hours) in RT or at 4°C increased the background. Taken together, 1 
hour incubation with 1:500 rabbit anti-CD4 primary antibody followed by another 1 hour 
incubation with 1:2000 goat anti-rabbit secondary antibody when 1 hour blocking was used, 
optimal signal was detected. CD8 antibody was optimized the same way as discussed in CD4. 
For CD8, 1:75 dilution of mouse primary antibody and 1:500 dilution of mouse anti-mouse 
secondary antibody for 1 hour incubation each while1 hour blocking was used; a sharp signal 
was obtained.  
 
2.2.10.5 Band quantification 
The WB image was opened in the ImageJ. A band of interest in WB was contoured using a 
rectangular box and intensity was measured (bigger the band higher the number). This band 
intensity was expressed as a raw value (n=3 bands/animal, n=3 animals/group). 
 
2.2.10.6 T-cell detection limits in peripheral and CNS tissues  
To measure the detection limit of CD4 and CD8 antibody signals in WBs, spleen samples 
from naïve mice and commercial CD4/8 recombinant proteins were used. Initially, 20, 10 and 
5 µg of homogenized spleen protein per lane were assessed by WB. For CD4, the lowest 
detectable signal was with 5 µg spleen protein, whereas 10 µg spleen proteins was needed to 
detect CD8; the minimal detectable concentrations of the commercial standards were 5 ng 
and 5 µg for CD4 and CD8, respectively. These lowest detected concentrations of both 
groups (spleen & commercial samples) were used as positive (spike) controls to confirm the 
expected minimal detection of CD4 and CD8 in WBs of total brain protein from the different 
experimental groups. Briefly, the lowest detectable amount of either CD4 or CD8 protein 
(spleen or the commercial standards) were resolved in parallel lanes of the same 1D gel along 
with 60 µg of brain protein and 60 µg of brain protein spiked with the lowest detectable 
amount of either CD4 or CD8 protein. Proteins were resolved, transferred, stained and 
imaged as before (see WB procedure).  
 
2.2.10.7 Transfer efficiency 
SDS-PAGE 1D gel prior to, and after, transfer onto PVDF membranes were fixed and stained 
with cCBB for 20 hours (see protein fixation and staining section) to determine the transfer 
efficiency of proteins. Imaging was carried out using a FLA-9000 gel imager. The density of 
the bands (n=3 bands/gel) with the molecular weights corresponding to the known molecular 
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weights of CD4/8 (37 & 50 KD, respectively) were quantified using Multigauge software 
(FUJIFILM Corporation, Japan).    
 
2.2.11 Statistical analysis 
Data were analysed using unpaired two-tailed t-test, one or two way analysis of variance 
(ANOVA) and are described in the each figure legend. For all studies appropriate Newman-
Keuls or Tukey post hoc analyses were followed to determine specific differences between 
groups. Data were presented as Mean ± Standard Error of the Mean (SEM), unless indicated 
in the text. Statistically significant was considered when p<0.05. Statistical analyses were 
performed using GraphPad Prism 7.03 (GraphPad Software, USA) software.  
 
2.2.12 Graphing 
GraphPad Prism was used to generate graphs. Figures were constructed using CorelDRAW 
(version-2018, www.coreldraw.com, Canada) and Photoshop CS6 (64 Bit, Adobe, USA) 
software. Images were adjusted en masse for colour composition if necessary and are 
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Abstract: Cuprizone (CPZ) preferentially affects oligodendrocytes (OLG), resulting in demyelination.
To investigate whether central oligodendrocytosis and gliosis triggered an adaptive immune response,
the impact of combining a standard (0.2%) or low (0.1%) dose of ingested CPZ with disruption of
the blood brain barrier (BBB), using pertussis toxin (PT), was assessed in mice. 0.2% CPZ(±PT) for
5 weeks produced oligodendrocytosis, demyelination and gliosis plus marked splenic atrophy (37%)
and reduced levels of CD4 (44%) and CD8 (61%). Conversely, 0.1% CPZ(±PT) produced a similar
oligodendrocytosis, demyelination and gliosis but a smaller reduction in splenic CD4 (11%) and CD8
(14%) levels and no splenic atrophy. Long-term feeding of 0.1% CPZ(±PT) for 12 weeks produced
similar reductions in CD4 (27%) and CD8 (43%), as well as splenic atrophy (33%), as seen with 0.2%
CPZ(±PT) for 5 weeks. Collectively, these results suggest that 0.1% CPZ for 5 weeks may be a more
promising model to study the ‘inside-out’ theory of Multiple Sclerosis (MS). However, neither CD4
nor CD8 were detected in the brain in CPZ±PT groups, indicating that CPZ-mediated suppression of
peripheral immune organs is a major impediment to studying the ‘inside-out’ role of the adaptive
immune system in this model over long time periods. Notably, CPZ(±PT)-feeding induced changes
in the brain proteome related to the suppression of immune function, cellular metabolism, synaptic
function and cellular structure/organization, indicating that demyelinating conditions, such as MS,
can be initiated in the absence of adaptive immune system involvement.
Keywords: inside-out; outside-in; oligodendrocytosis; demyelination; gliosis; histology; top-down
proteomics; bioinformatics; mitochondria
1. Introduction
Currently, there are two competing theories regarding the pathophysiology underlying the initiation
of Multiple Sclerosis (MS): ’outside-in‘ and ‘inside-out’ [1–4]. The former proposes that a dysregulated
peripheral immune system leads to an autoimmune response against myelin components of the central
nervous system (CNS). The central concept of this theory has been built mainly on the basis of studies
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using the experimental autoimmune encephalomyelitis (EAE) animal model [5–7] and correlation of the
end stage of treatment (e.g., paralysis and demyelination) with clinical tests and post-mortem samples
from MS patients. In EAE, animals are injected with exogenous antigens such as myelin basic protein
(MBP), proteolipid protein (PLP) or myelin oligodendrocyte glycoprotein (MOG) and complete Freund’s
adjuvant (CFA), activating peripheral immune cells, including T- and B-cells. When this immune
response is combined with breach of the blood brain barrier (BBB) by injection of pertussis toxin (PT),
autoreactive adaptive immune cells from the periphery migrate into the CNS leading to degeneration of
oligodendrocytes (OLG), demyelination and gliosis [5,6,8–11]. It is argued that a similar process results in
autoimmune cell migration into the CNS of MS patients [7,12–15]. The EAE animal model is thus the
favourite choice of many researchers investigating the autoimmune aspects of MS [16].
There are, however, key differences between the EAE model and clinical MS. First, EAE relies
on the use of exogenous antigens (MBP/PLP/MOG), whereas the autoimmune response in humans
occurs spontaneously and is only detected following repeated episodes of clinical symptoms [17,18].
Second, the immune reaction in EAE is driven mainly by CD4+ T-cells [19,20], whereas in MS,
CD8+ T-cells predominate [21–23]. Moreover, MS is a disease of the human cerebral and cerebellar
cortices, whereas the effects of EAE are generally localized to the spinal cord [6,10,24–27], with largely
non-overlapping changes in the brain proteomes being reported in EAE and MS patients [28,29].
Although therapies developed in EAE improve outcomes in animals, these therapies generally have
more limited success in clinical MS in terms of halting disease initiation and progression [17,30].
In contrast to this ‘outside-in’ theory, the ‘inside-out’ hypothesis suggests that MS is initiated by
an underlying degeneration of OLG and consequent demyelination that leads to the production of
endogenous myelin antigens (e.g., peptidyl arginine deiminase, MBP, MOG and PLP) that then trigger
an immune response in the CNS [3,4,31]. Histological evidence indicates that the loss of OLG and glial
activation can occur in the absence of, or with only a limited number of, peripheral immune cells [32–35]
and myelin injury [36]. The possibility of OLG triggering a secondary adaptive immune response has
been reported following long-term diphtheria toxin exposure [37] or following a peripheral immune
challenge after short-term CPZ-feeding (termed ‘cuprizone autoimmune encephalitis’ [31]). Cuprizone
(CPZ) is synthesised by combining cyclohexanone and oxaldihydrazone [38]. While the mechanism of
its toxic actions remain ill-defined, copper chelation [39] and dis-homeostasis of iron, zinc, sodium and
manganese have been reported [40–44]. Such ion imbalance leads to endoplasmic reticulum stress,
reduced mitochondrial ATP synthesis, and increased production of reactive oxygen and nitrogen
species (reviewed in [2]). OLG appear to be preferentially susceptible to CPZ toxicity and likely
degenerate due to their high energy demands and lower levels of anti-oxidant enzymes [45–47].
Intriguingly, longer-term CPZ-feeding did not evoke a peripheral immune response in the
CNS [31,37,48]. Whether the failure of numerous CPZ studies [31,37,48] to observe an immune
response associated with long duration feeding (>5 weeks) is due to a toxic effect of CPZ on the
peripheral immune system remains unclear [31,37], but CPZ has been shown to have deleterious effects
on immune organs like the spleen [49] and thymus [50].
To address this issue, this study compared whether a low (0.1%) or standard (0.2%) dose of
CPZ when combined with disruption of the BBB by PT recruited peripheral immune cells into the
CNS in mice. At first, a low and a standard dose of CPZ were used for 5 weeks and the amount
of oligodendrocytosis (i.e., degeneration or loss of OLG), gliosis and demyelination was quantified;
the low dose produced significant demyelination of the corpus callosum (CC), with limited suppression
of splenic CD4/8 and no change in overall splenic mass. Having observed that 0.1% CPZ produced
comparable oligodendrocytosis, but had less severe effects on the peripheral immune system, in the
second study, 0.1% CPZ-feeding was extended to 12 weeks (±PT) to test whether a slower, progressive
demyelination (i.e., more reminiscent of MS) and less severe effects on the peripheral immune organs
could trigger an adaptive immune response in the CNS. Histological analyses were used to assess
oligodendrocytosis, demyelination and gliosis in the CNS, as well as the levels of adaptive immune
cells (CD4 and CD8) in brain and spleen.
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In a subset of the mice in both experiments, the whole brain proteome was assessed using a
well-established ‘top-down’ approach (i.e., two-dimensional gel electrophoresis coupled with liquid
chromatography and tandem mass spectrometry) to identify changes in protein abundance correlated
with key changes in molecular pathways [49,51–53]. To best understand the underlying molecular/cellular
processes, a ‘top-down’ proteomic analysis was critical to identifying key protein species or proteoforms,
the biologically active entities [54–56]. Thus, while much is assumed in the literature regarding the actions of
CPZ at the molecular level by extrapolation of effects in vitro or at the cellular level, only such quantitative
analyses can help to directly understand the underlying effects of CPZ(±PT).
2. Materials and Methods
2.1. Animals, Feeding, Injection and Monitoring
Seven-week-old male C57Bl/6 mice (n = 108) were purchased from the Animal Resources Centre,
Murdoch, WA, Australia (www.arc.wa.gov.au) and co-housed (2 mice) in individual ventilated GM500 cages
(Tecniplast, Buguggiate, VA, Italy) in the local animal care facility (School of Medicine, Western Sydney
University). Animals were allowed to acclimatise for one week to the new environment prior to initiation of
CPZ-feeding. Mice were maintained in a controlled environment (12-hour (h) light/dark cycle: 8am–8pm
light, 8pm–8am dark, 50–60% humidity and at 21–23 ◦C, room temperature (RT)) throughout the entire period.
Standard rodent powder chow (Gordon’s specialty stockfeeds, Yanderra, NSW, Australia) and water were
available ad libitum. Oral feeding of CPZ ([Bis(cyclohexanone)oxaldihydrazone, Sigma-Aldrich, St. Louis, MO,
USA], 0.1–0.2% w/w freshly mixed with rodent chow) was used to induce oligodendrocytosis as previously
described [2,57–59]. To breach the BBB, the same methods as previously established for EAE were used i.e.,
2–3 intraperitoneal (IP) injections of PT [8,60–63]—but adapted so that the breach of the BBB was timed
(i.e., 400 ng on days 14, 16, and 23) to coincide with the reported onset of CPZ-induced oligodendrocytosis,
demyelination and gliosis [2,57–59]. The efficacy of BBB breach has been shown using immunoglobulin
G staining in the CPZ-fed mice [64]. CPZ groups (0.1% and 0.2%) were fed freshly prepared (daily) CPZ
in rodent chow for either 5 (n = 10/group) or 12 (n = 12/group) weeks. Age-matched, naïve control (Ctrl,
5-week study n = 10 and 12-week study n = 12) and PT only (5-week study n = 10 and 12-week study n = 12)
groups were used. Mice were weighed at the beginning of the studies, weekly throughout, and prior to
culling, and the data from both groups (5 and 12 weeks) were combined (Figure 1). Research and animal
care procedures were approved by the Western Sydney University Animal Ethics Committee (ethics code:
A10394) in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific
Purposes as laid out by the National Health and Medical Research Council of Australia.
2.2. Histology and Immunohistochemistry
2.2.1. Tissue Preparation
At the end of each feeding period (5 or 12 weeks), all mice were terminally overdosed
with sodium pentabarbitone (250 mg/kg, LethobarbTM, Tory laboratories, Glendenning, NSW,
Australia) and perfused with 30 mL of 0.9% saline followed by 50 mL of cold 4% paraformaldehyde
(PFA, Sigma-Aldrich) for ~5 minutes (min). Brain and spleen samples were collected and post fixed
with 4% PFA at 4 ◦C for one week and stored in 0.01 M phosphate buffered saline (PBS, Sigma-Aldrich)
solution containing 0.02% sodium azide (Amresco, Solon, OH, USA) at 4 ◦C for ≤1 month or until
sectioned. Spleen weights were measured (n = 3 and 5 from 5- and 12-week studies, respectively) and
expressed as a function of body weight (Supplementary Figure S5c). Prior to sectioning, whole brain
and spleen were immersed in 30% sucrose for 48 h at RT for cryo-protection followed by embedding in
4% gelatine (Chem-Supply, Gillman, SA, Australia) at −20 ◦C. Brains (5 weeks: 50 µm and 12 weeks:
40 µm) and spleen (20 µm) were sectioned coronally on a Leica cryostat (Leica, Wetzlar, HE, Germany).
Sections were transferred to either 6-well plate (Sakura, Torrance, CA, USA) containing cold (5–6 ◦C)
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0.01 M PBS (free floating) or mounted onto 0.5% gelatine-coated slides (Knittel Glass, Braunschweig,
NI, Germany) as described previously [65].
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2.5. Statistical Analysis and Graphing 
Statistical analyses were performed using GraphPad Prism-version 7.03 (www.graphpad.com, 
San Diego, CA, USA) software. Data were analysed using either one or two-way analysis of 
variance (ANOVA) or an unpaired two-tailed t-test and, where appropriate, Newman-Keuls or 
Tukey post hoc analyses to determine specific differences among groups. Data are presented as 
means ± standard error of the mean (SEM), otherwise indicated in the text. Statistical significance 
was accepted when p < 0.05. Figures were assembled using CorelDRAW-version 2018 
(www.coreldraw.com, Ottawa, ON, Canada) and Photoshop CS6 (Adobe, San Jose, CA, USA) 
image processing software. All Nogo A images were adjusted only for colour contrast 
(Supplementary Figures S1 and S2). 
3. Results 
3.1. Body Weight 
Mice in all groups gained weight over the duration of feeding, but this was significantly slower 
in CPZ(±PT)-fed animals (p < 0.05, Figure 1). Significant reductions in weight gain started at week 1 
after 0.2% CPZ±PT and week 2 after 0.1% CPZ±PT-feeding and continued until week 11. At week 
12, 0.1% CPZ±PT groups were significantly (p < 0.05) different compared to the Ctrl group but not 
to the PT group. No direct or combined effect (p > 0.05) of PT was found in any group at any time 
point. 
 
Figure 1. Body weight changes induced by CPZ-feeding. All mice gained weight over time. Groups 
fed the highest dose of CPZ(±PT) in each experiment gained weight significantly more slowly 
compared to other groups. Vertical dash lines indicate the timing of individual PT injections (i.e., 
days 14, 16, and 23). Data are expressed as mean ± SEM. Two-way ANOVA and Tukey post hoc 
analysis were used to determine differences among groups (* p < 0.05, ^ p < 0.0001, 5-week study n = 
22 animals/group of which n = 12 animals/group continued feeding for 12 weeks). 
3.2. Marked Demyelination, Oligodendrocytosis and Gliosis 
In both the 5- and 12-week studies, the Ctrl and PT groups exhibited intense silver staining of 
myelin in the midline corpus callosum (MCC) and lateral corpus callosum (LCC), whereas the 0.1% 
and 0.2% CPZ-fed(±PT) groups displayed a marked, concentration-dependent loss of silver staining 
(p < 0.05, Figure 2a; Supplementary Figures S1a, S2a, S3a). No differences in the extent of 
Figure 1. Body weight changes induced by CPZ-feeding. All mice gained weight over time. Groups fed
the highest dose of CPZ(±PT) in each experiment gained weight significantly more slowly compared
to other groups. Vertical dash lines indicate the timing of individual PT injections (i.e., days 14, 16,
and 23). Data are expressed s m an ± SEM. Two-way ANOVA and Tukey post hoc analysis were used
to determine diff rences among groups (* p < 0.05, ˆ p < 0.0001, 5-week study n = 22 animals/group of
which n = 12 animals/group continued feeding for 12 weeks).
2.2.2. Silver Myelin Staining and Analysis
Silver staining of myelin was performed at RT as previously described [66,67]. Briefly, tissue sections
were mounted onto 0.5% gelatine-coated slides and air dried for 48 h before immersion in 10% formalin
(Sigma-Aldrich) for 2 weeks to increase the contrast of the staining. Sections were stained in a large
glass container in parallel to maintain the consistency of staining. Slides were washed with distilled
water and pre-treated with lipid-solvent pyridine and acetic anhydride solution (ratio 2:1) for 30 min.
Sections were then rehydrated with serial dilutions of ethanol 80, 60, 40 and 20% for 20 seconds (sec) in
each step followed by two washes with distilled water. Slides were then immersed in ammonical silver
nitrate (Chem-Supply) containing developing solution (0.2% ammonium nitrate, 0.2% silver nitrate
and 5% sodium carbonate) for 45 min. Sections were then dehydrated by rinsing sequentially using
20, 40, 60, 80, and 100% ethanol for 20 sec in each step. Sections were cleared by immersing the slides
in xylene for 5 min and then sealed using cover slips (Knittel Glass) and ~1 mL mounting medium
(Merck, Darmstadt, HE, Germany), and air dried for 72 h. The sections were viewed with an Olympus
Carl Zeiss Bright Field Microscope (Zeiss, Jena, TH, Germany) and all images were captured at the same
microscope settings (i.e., a fixed exposure time, magnification and illumination intensity). In ImageJ
(https://imagej.nih.gov/) software, the region of interest (ROI) was contoured, and the mean optical
density quantified (sum of each pixel intensity [range black (0) to white (256)] divided by the number of
pixels in the ROI). To quantify the amount of myelin present (which stains black), data were expressed
as the reciprocal of the light intensity (i.e., the smaller the value, the lower the myelin content) and
normalised to the Ctrl groups (n = 3–5 animals/group and 5–9 sections/animal). The effectiveness of
CPZ-feeding is frequently determined by loss of myelin from the midline corpus callosum (MCC),
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in this study the effectiveness of CPZ-induced demyelination was confirmed in the MCC and lateral
corpus callosum (LCC). Anatomical landmarks were identified as described previously [68,69].
2.2.3. Immunofluorescence Staining and Analysis
All staining was performed at RT. Free floating brain (40–50 µm) and slide-mounted spleen
(20 µm) coronal tissue sections were washed thrice with warm (40–50 ◦C) 0.01 M PBS to remove the
gelatine and then immersed in 5–10% goat serum (Sigma-Aldrich) for 2 h with agitation at 50 rpm
on a shaker table to block non-specific antibody (Ab) binding sites. Sections were then incubated
(12 h) with primary monoclonal Ab to either neurite outgrowth inhibitor A (rabbit anti-Nogo A, 1:500,
Merck-Millipore, Burlington, MA, USA), glial fibrillary acidic protein (mouse anti-Gfap-Alexa 488,
1:1000, Merck-Millipore), ionized calcium-binding adapter molecule 1 (rabbit anti-Iba 1, 1:1000, Wako,
Chuo-Ku, OSA, Japan), anti-cluster of differentiation (rabbit anti-CD4, 1:200, Abcam, Cambridge, UK),
or anti-CD8 (mouse anti-CD8, 1:100, Santa-Cruz Biotechnology, Dallas, TX, USA) diluted in 0.01 M
PBS containing 0.1% Triton X100 (Tx100). Sections were then washed thrice with 0.01 M PBS and
incubated with corresponding Alexa Fluor (either 488 or 555, dilution: 1:500) secondary Ab (diluted in
0.01 M PBS/0.1% Tx100 solution for 2 h while shaking at 50 rpm). Sections were then rinsed thrice
with 0.01 M PBS and 1.5 µg/mL Vectasheild™ plus 4′,6-diamidino-2-phenylindole (DAPI, Vector
Laboratories, Burlingame, CA, USA) to counterstain nuclei. Slides were sealed with cover slips
and stored in the dark at 4 ◦C until analysis. Images were captured as before (using an Olympus
Carl Zeiss Fluorescence Microscope) using the same fixed parameters (exposure and magnification).
Quantification was performed using ImageJ, measuring the fluorescence intensity of Gfap, Iba 1, CD4
and CD8 from each ROI as described in silver myelin staining and analysis (n = 3–5 animals/group and
5–10 sections/animal). Cells positively stained for Gfap, Iba 1 and Nogo A (and co-stained with DAPI)
were counted using the unbiased stereo investigator optical fractionator workflow software [65,70].
To obtain the cell density, total cell number was divided by total measured volume and the data
expressed as 104 cells/mm3 (n = 3–5 animals/group and 5–9 sections/animal).
2.3. Two-Dimensional Gel Electrophoresis (2DE) and Analysis
2.3.1. Sample Collection, Homogenisation and Protein Estimation
At the end of each experiment (i.e., 5 or 12 weeks) period, mice (n = 5 animals/group) were
euthanized by overdose of isoflurane (Cenvet, Blacktown, NSW, Australia) exposure. Whole brains
were collected following decapitation and immediately rinsed with ice cold 0.01 M PBS containing
a cocktail of protease, kinase, and phosphatase inhibitors (Sigma-Aldrich, [51,52]) to remove any
traces of blood. Tissue homogenisation was accomplished by automated frozen disruption using
a Mikro-Dismembrator (40 Hz for 1 min, Sartorius, Göttingen, NI, Germany) to facilitate optimal
protein extraction [52,71]. Powdered tissue samples were mixed with cold 20 mM HEPES hypotonic
lysis buffer (Amresco) containing the cocktail of protease, kinase, and phosphatase inhibitors and
vortexed for 90 sec followed by the restoration of isotonicity using the addition of an equivalent
volume of ice cold 0.02 M PBS and incubated for 5 min on ice. The samples were then centrifuged
(Beckman Coulter, Indianapolis, IN, USA) at 125,000× g (using a SW 55 Ti rotor) at 4 ◦C for 2 h.
The resulting first supernatant (SP1) was collected as total cytosolic soluble protein (SP). The pellet was
washed with ice cold 0.01 M PBS to extract any remaining cytosolic proteins (SP2) and centrifuged 8 h
at 125,000× g. The resulting supernatant (SP2) was pooled with the SP1 fraction, and this combined
soluble protein fraction was concentrated using an Amicon Ultra-4 centrifugal 3 KD cut-off filter column
(Merck-Millipore). To prevent salt interference during the 1st dimension isoelectric focussing step,
the resulting SP samples were washed three times using cold 4 M urea (Amresco) buffer supplemented
with the inhibitor cocktail. The pellet containing membrane proteins (MP) was resuspended with
cold 2DE solubilisation buffer (8 M urea, 2 M thiourea and 4% CHAPS) containing the inhibitor
cocktail [71,72]. Total protein concentrations in SP and MP fractions were measured using the EZQ™
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Protein Quantitation Kit (Life Technologies, Eugene, OR, USA) according to the manufacturer’s
instructions, using bovine serum albumin (Amresco) as the standard.
2.3.2. Protein Separation
At first, proteins were separated based on their isoelectric point (1st dimension) as follows: 100 µg
of proteins were loaded onto an immobilised pH gradient (IPG, 7 cm, non-linear, Bio-Rad, Hercules, CA,
USA) strips and passively rehydrated for 16 h at RT. Rehydrated IPG strips were placed in the Protean
isoelectric focusing (IEF) tray (Bio-Rad) and IEF was carried out in a PROTEAN IEF system (Bio-Rad)
for high-throughput protein resolution, initially at 250 V for 15 min which then increased linearly to
4000 V at 50 µA/gel for 2 h, with multiple electrode wick changes during voltage ramping to facilitate
desalting. The following parameters were used during IEF: focus temperature: 17 ◦C, desalting: 15 min,
linear gradient: 2 h, holding voltage: 500 V. Following IEF, IPG strips were either stored at −20 ◦C
or immediately resolved in the second dimension using sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE). Second dimension (2D) was carried out using 1 × 84 × 70 mm 12.5%
acrylamide SDS-PAGE gels. Prior to 2D, IPG strips were incubated for 10 min with 130 mM DTT in
equilibration buffer (6 M urea, 20% glycerol, 2% SDS and 375 mM tris) followed by 10 min alkylation
in equilibration buffer containing 350 mM acrylamide. IPG strips were then inserted on top of the
SDS-PAGE gels and covered with warm (40–50 ◦C) ~300 µL agarose solution (0.5% low melting agarose,
Bio-Rad) containing 2% bromophenol blue (Bio-Rad). Electrophoresis was carried out at 4 ◦C by
applying 150 V for 5 min followed by 90 V for 3 h or until the bromophenol dye reached the bottom of
the gels as described previously [51,52,71,73].
2.3.3. Protein Fixation and Staining
Upon completion of electrophoresis, gels (5-week study n = 180 gels and 12-week study
n = 120 gels) were fixed in 10% methanol and 7% acetic acid solution for 1 h at RT (on a shaker
at 50 rpm). Gels were rinsed with distilled water for 3 × 20 min to remove residual methanol and
acetic acid followed by staining with 50 mL of high sensitive colloidal Coomassie Brilliant Blue
(G-250, Amresco) and continuous shaking, as previously described [52,74–78]. After 20 h, the solution
was discarded and stained gels were washed using 50 mL of 0.5 M sodium chloride solution for
3 × 15 min to remove excess Coomassie dye. Scanning of gels was carried out at 100 µm resolution
using a TyphoonTM FLA-9000 gel imager (GE Healthcare, Chicago, IL, USA). Excitation/emission wave
lengths were 685/>750 nm and the photomultiplier tube was set to 600 V. Gels were preserved in 20%
ammonium sulphate (50 mL/gel) and stored at 4 ◦C until spot excision [52].
2.3.4. Protein Resolution, Detection and Image Analysis
Quantitative analysis of gels was carried out using Delta 2D image analysis software
(www.decodon.com/delta2d-version4.0.8, DECODON, Greifswald, MV, Germany) as described
previously [49,52,53,74,78]. Briefly, total spot numbers were calculated from the raw images using the
Delta 2D automated spot detection system, while gel edges and the protein ladder were excluded [52,79].
Gel images were warped and fused to generate a master image ensuring consistent spot matching.
The fluorescent volumes of individual spots (i.e., protein abundance) were expressed as a function of
all spot volumes detected and were measured using Delta 2D to assess changes across the different
experimental groups. Four spot inclusion criteria were applied: 1) any changes in spot volumes
were detectable in all biological replicates (n = 5 animals/group) and their associated technical
replicate gels (n = 3 gels/fraction/animal, i.e., 15 gels/experimental group); 2) the relative standard
deviation for technical replicates did not exceed 30% within individual animals; 3) values had to
differ significantly (p < 0.05, t-test) between the naïve Ctrl group and at least one test group; and 4)
have a fold change of ≥1.5 (increased/decreased fluorescence), to be considered genuine changes,
and thus candidates for analysis by LC/MS/MS. These criteria allowed for reliable and reproducible
identification of CPZ, CPZ+PT or PT associated proteoform changes. The fold change (p < 0.05,
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one-way ANOVA) of differentially abundant protein spots was calculated by dividing the average
grey value (i.e., fluorescence intensity of the protein spot of each experimental group compared to the
naïve Ctrl group) and presented in log2 scale as fold change relative to Ctrl. Precision Plus Protein
Kaleidoscope molecular weight (MW) and 2DE isoelectric point (pI) standard (Bio-Rad) calibration gels
(n = 3) were used to calculate the experimental pI and MW of resolved proteoforms. The coefficient of
variation (standard deviation/mean) for the MW and pI migration was 2.6% and 1.4% for 2DE standards,
respectively (n = 3), and 4% for MW ladders for experimental gels (n = 20). To quantify the gel shift
indicative of protein post-translational modification (PTM), experimental MW and pI values were
plotted relative to theoretical values; significant changes were indicated when the experimental measure
fell above or below the 95% confidence intervals of the MW and pI calibration curves. The results are
plotted as the average for both 5 and 12 weeks combined.
2.3.5. In-Gel Protein Spot Digestion
Protein spots of interest were excised manually and de-stained for 2× 15 min with 50 mM ammonium
bicarbonate (Sigma-Aldrich) solution containing 50% acetonitrile (Sigma-Aldrich). After complete removal
of Coomassie dye, gel pieces were dehydrated using 100% acetonitrile. In-gel digestion was carried out
by adding 20 µL of freshly prepared trypsin (12.5 ng/µL, Promega Corporation, Madison, WI, USA) to a
solution of 50 mM ammonium bicarbonate for 8 h at 4 ◦C. Digested peptides were removed from the
gel by 30 min sonication. The solution was then acidified by the addition of 2 µL of 2% formic acid
(Merck-Millipore). The resulting peptide solution was concentrated to 10 µL using a Speed Vac™ vacuum
concentrator (1400 rpm for 10–15 min, John Morris Scientific, Chatswood, NSW, Australia) and stored at
-80 ◦C for future use or immediately subjected to LC/MS/MS [52].
2.3.6. Liquid Chromatography Tandem Mass Spectrometry (LC/MS/MS)
The concentrated peptide solutions were analysed by LC/MS/MS using a nanoAcquity ultra
performance liquid chromatography system linked to a Xevo QToF mass spectrometer as previously
described [49,52,80,81]. In brief, peptide sample solutions (3 µL) were loaded onto a C18 symmetry
trapping column (20 mm × 180 µm), and desalted for 3 min at 5 µL/min flow rate using 1% solvent B
(LC/MS grade 1% acetonitrile and 0.1% formic acid) in solvent A (Mili-Q water + 0.1% formic acid).
The peptides were washed off the trapping column at 400 nL/min onto a C18 BEH analytical column
(75 µm × 100 mm), packed with 1.7 µm particles of pore size 130 Å using a 60 min ramped LC protocol.
The initial solvent composition was held at 1% B for 1 min followed by linear ramping to 50% B
over 30 min. A further linear ramp to 85% B commenced at 31 min and held until 37 min before the
solvent composition was returned to 1% B. Separated peptides were analysed using tandem mass
spectrometry with a constant cone voltage of 25 V and source temperature of 100 ◦C, implementing
an emitter tip that tapered to 10 µm at 2.3 kV. A data-directed acquisition (DDA) approach was
performed, which continuously scanned across the m/z range 350–1500 for peptides of charge state
2+–4+ with an intensity of more than 50 counts/sec, with a maximum of three ions in any given 3 sec
scan. Selected peptides were de-isotoped, fragmented and the masses measured. The ramped collision
energy profile was set to 15–35 V at low mass and 30–40 V at high mass. The mass of the precursor
peptide was then excluded for 30 sec. The DDA was via Masslynx software (version 4.1, Micromass,
Manchester, UK) and converted to a peak list file (PKL) format using the ProteinLynx Global Server
(Waters, Milford, CT, USA). Data were analysed using MASCOT Daemon (www.matrixscience.com)
and queried against the SwissProt and MSPnr100 databases (see www.wehi.edu.au) using delimited
and species-specific searches to identify the protein species using the following MASCOT parameter
settings: the enzyme trypsin and taxonomy Mus musculus (mouse) were fixed. Moreover, no fixed
modification was selected whereas variable modifications were carbamidomethyl (C), deamidated
(NQ), oxidation (M) and propionamide (C). Only two missed cleavages of lysine or arginine residues
were allowed; mass tolerance of parent and MS/MS ions was set to ±0.05 Da and peptide charge state
was 2+–4+. The results of the search were filtered by excluding peptide hits with a p-value greater
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than 0.05. While the SwissProt and MSPnr100 databases were both used to best ensure confirmation of
a protein identity, the higher of the two scores was documented in Table 1. When multiple proteins
were detected from the same spot, the following criteria were applied to identify the most abundant
and thus the most likely to have contributed to the originally detected change in spot volume: 1) The
highest MASCOT score (>100) with a sequence coverage ≥5%; and 2) ≥4 unique matched peptides.
2.3.7. Literature Mining and Bioinformatics
A PubMed (www.ncbi.nlm.nih.gov/pubmed/) literature search was carried out for papers
published in the English language using the identified canonical protein name with either CPZ,
EAE or MS to find literature relevant to molecular/cellular functions. The UniProt (www.uniprot.org)
database was used to obtain the gene and UniProt accession number (ID) of the identified protein
species and analysis of subcellular localization [82]. A mapping of genes according to their
classification and molecular functions was derived from protein analysis through evolutionary
relationships (PANTHER, www.pantherdb.org) database using gene IDs of each identified protein [53].
Cellular components, biological processes and physiological pathways of the identified protein
species were categorised using the database for annotation, visualization and integrated discovery
(DAVID, version 6.8, david.ncifcrf.gov) database. UniProt accession IDs were used in the DAVID
database to categorise proteins according to their GO (gene ontology, www.geneontology.org) cellular
components, and biological processes. DAVID also characterised the physiological pathways associated
with the identified protein species according to the Kyoto encyclopaedia of genes and genomes
(KEGG, www.genome.jp/kegg) category [83]. Protein species were further characterised and grouped
using the search tool for retrieval of interacting genes/proteins (STRING; version 10, string-db.org)
to identify potential protein–protein interactions (PPI, [84]). Using the STRING database, a PPI map
was generated in which each node represents a protein and connecting lines represent evidence of
association (with line thickness indicating the strength of the potential interaction). Such associations
are based on text mining, co-expression, co-occurrence, databases, experiments, neighbourhood and
gene fusion of the identified proteins [85,86].
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MW/pI Highest Fold Change Data
Base
Reference
Theoretical Experimental 5 W 12 W CPZ EAE MS
A4/MP G3UVV4 Hexokinase 1 Hk1 270/10 10 101.8/6.2 220/6.4 0.66(0.2)↓ 0.48(0.1PT)↓ M - - [87]
5N3/SP P05063 Fructose-bisphosphate aldolase C Aldoc 510/33 12 39.3/6.6 73.4/5.9 0.32(PT)↓ × S - [88] [89]
D2/MP Q99KI0 Aconitate hydratase Aco2 407/25 18 85.4/8.1 182.9/8.2 2.37(0.2PT)↑ 0.23(PT)↓ M - - [90]
A10/MP Q8K2B3 Succinate dehydrogenase flavoproteinsubunit Sdha 230/12 8 72.5/7 96/6 0.57(0.1PT)↓ 0.61(0.1PT)↓ M [91] - -
F2/MP P08249 Malate dehydrogenase Mdh2 983/57 25 36/8.9 70.2/6.9 2.30(0.1PT)↑ × S - [88] [92]
5O5R/MP Q91WD5 NADH dehydrogenase iron-sulfurprotein 2 Ndufs2 173/10 5 52.5/6.5 52.2/5.5 0.59(PT)↓ 1.77(0.1PT)↑ M [91] - -
5R5/SP Q03265 ATP synthase subunit-α Atp5a1 177/26 15 59.7/9.2 117.4/8.2 2.76(PT)↑ 0.37(0.1)↓ S [91] - [89]
A37/MP Q60930 Voltage-dependent anion-selectivechannel protein Vdac2 155/14 5 31.6/7.4 18.7/6.6 0.42(0.2PT)↓ 0.5(0.1PT)↓ M - - [90]
A34/MP P05201 Aspartate aminotransferase Got1 350/26 12 46.2/6.6 29.5/7.4 0.69(0.2PT)↓ 0.38(0.1PT)↓ M - - [89]
A1/MP B2RXT3 Ogdhl protein Ogdhl 291/10 10 114.5/6.4 243.3/5.9 0.69(0.2)↓ 0.65(0.1PT)↓ M - - -
B23/MP Q8VDQ8 NAD-dependent protein deacetylasesirtuin-2 Sirt2 529/36 13 39.4/6.35 27.8/7 0.69(0.1PT)↓ 0.33(0.1PT)↓ M - [93] [93]
5C1/SP Q9JHI5 Isovaleryl-CoA dehydrogenase Ivd 650/39 17 46.3/8.5 79.4/6.2 0.42(0.2PT)↓ 1.80(PT)↑ S [49] - -
5G5/SP Q91WQ3 Tyrosine-tRNA ligase Yars 333/28 17 59/6.57 124.9/6.4 0.32(0.2PT)↓ 1.97(PT)↑ S - - -
A22/MP P26443 Glutamate dehydrogenase 1 Glud1 324/12 7 61.3/8 106.8/6.8 2.24(0.2PT)↑ × M - [94] [95]
A16/MP Q99MN9 Propionyl co-enzyme A carboxylase-β Pccb 277/16 6 50.4/5.7 60.5/6.3 × 0.43(0.1PT)↓ M - - -
B20/MP P30275 Creatine kinase U-type Ckmt1 137/22 11 46.9/8.4 83.2/7.5 0.44(0.2PT)↓ 0.35(0.1)↓ S - - -
A14/MP P50396 Rab GDP dissociation inhibitor-α Gdi1 227/20 8 50.5/4.9 77/5.9 0.6(0.2)↓ 0.56(0.1PT)↓ M - - [96]
5O4/MP Q61598 Rab GDP dissociation inhibitor-β Gdi2 148/10 5 50.5/5.9 55.6/5.7 0.38(PT)↓ × M - - [96]
5L6/MP P46460 Vesicle-fusing ATPase Nsf 466/36 33 82.6/6.5 116/6.3 0.52(0.2PT)↓ 0.71(0.1PT)↓ S - - -
B17/MP P11798 Calcium/calmodulin-dependentprotein kinase type II subunit-α Camk2a 225/16 7 54/6.6 53.2/7 × 0.42(PT)↓ M [97] [98] -
A11/MP O08599 Syntaxin-binding protein 1 Stxbp1 244/12 5 68.7/6.3 90.6/6.3 0.71(0.2)↓ 1.61(PT)↑ M - [94] -
A5/MP A0A0J9YUE9 Dynamin 1 Dnm1 172/9 8 93.9/6.2 200/6.2 1.61(0.2PT)↑ 0.46(0.1PT)↓ M [49] - -
E14/MP Q9D8B3 Charged multivesicular body protein Chmp4b 176/15 4 24.9/4.6 23.7/5 × 1.65(0.1PT)↑ M - - -
5H2R/MP P03995 Glial fibrillary acidic protein Gfap 1802/72 45 49.8/5.2 83.7/5.0 1.86(0.2PT)↑ 1.58(PT)↑ S [99] [100] [101]
E2/MP P08551 Neurofilament light polypeptide Nefl 1594/57 92 61.4/4.6 53/4.9 0.71(0.2)↓ 2.08(0.1PT)↑ S - [102] [103]
5G3/SP Q9D898 Actin-related protein 2/3 complexsubunit 5 Arpc5l 152/26 4 16.9/6.3 26/5.9 0.62(0.2PT)↓ × M - - -
5I1/SP P42208 Septin-2 Sept2 180/21 7 41.5/6.1 81/5.7 0.30(PT)↓ 1.53(PT)↑ S - [93] [104]
5I2/SP Q9Z2Q6 Septin-5 Sept5 159/22 9 42.7/6.2 80.4/5.9 0.36(0.2PT)↓ 0.46(0.1PT)↓ S - [100] -
4L1/MP P18872 Guanine nucleotide-binding proteinG(o) subunit-α Gnao1 186/15 5 40.6/5.3 68.5/4.7 7.35(0.2)↑ 1.48(0.1PT)↑ S - [105] -
4O3/MP Q9D7N9 Adipocyte plasmamembrane-associated protein Apmap 148/8 5 46.4/5.9 85/5.6 4.09(0.1)↑ 1.46(0.1PT)↑ M - - -
5R1/MP P14211 Calreticulin Calr 187/13 7 47.9/4.3 155/4.4 2.50(0.2PT)↑ 1.83(0.1PT)↑ S - [105] [106]
5G2/SP P62259 14-3-3 protein epsilon Ywhae 110/23 6 29.1/4.6 49.9/4.5 0.66(0.2PT)↓ × S - [100] [107]
5E1/SP Q9D154 Leukocyte elastase inhibitor A Serpinb1a 191/36 18 42.5/5.8 76.7/5.5 0.28(0.2PT)↓ × S [49] - -
Key: MP, membrane protein; SP, soluble protein; MW, molecular weight; pI, isoelectric point; S, Swiss-Prot; M, MSPnr100; PT, pertussis toxin; 0.1, 0.1% CPZ; 0.1PT, 0.1% CPZ+PT; 0.2, 0.2%
CPZ; 0.2PT, 0.2% CPZ+PT; W, week; ×, unchanged; ↑, increase; ↓, decrease; -, not found or investigated (details are shown in Figure 5). Some of the spots contained more than one clearly
identifiable protein; presented here are the hits with the highest score, coverage and peptide count. UniProt and gene IDs were derived from the UniProt database. MASCOT score,
sequence coverage, theoretical (MW/pI), and unique peptides number were acquired from the MASCOT database search. Experimental (MW/pI) was derived from 2D gels of identified
protein spot. References are from the published literature in PubMed on CPZ, EAE and MS and used to compare currently identified proteins with the existing literature.
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2.4. Western Blot (WB)
2.4.1. Sample Preparation
Stored brain, spinal cord and spleen samples (n = 3/group) were homogenised in the deep-frozen
state as described earlier. Equal ratios (~1 µL/1 µg tissue) of sample and pre-chilled lysis buffer (25 mM
Tris, 1 mM EDTA and 1 mM EGTA) containing the inhibitor cocktail were used to solubilize the
powdered samples and protein was recovered using centrifugation (at 125,000× g, 4 ◦C, for 1 h). Protein
quantification was then carried out as previously described using the EZQ protein quantitation kit
(see above).
2.4.2. Procedure
Total protein extract (brain, spinal cord and spleen) and CD4/8 recombinant proteins were resolved
by 10% SDS-PAGE (100 V for 2 h at 4 ◦C) and transferred (100 V for 2 h at 4 ◦C) onto 0.22 µm pore size
polyvinylidene difluoride (PVDF, Merck-Millipore) membrane using transfer buffer containing 25 mM
tris, 192 mM glycine and 20% methanol. The membranes were incubated in blocking buffer containing
non-fat dry skimmed milk (5% w/v, Coles, Hawthorn East, VIC, Australia) and polyvinylpyrrolidone
(1% w/v, Sigma-Aldrich), in 0.05% Tris buffered saline-Tween 20 (TBST) for 1 h at RT on an orbital
shaker (at 50 rpm). Primary Abs for CD4 (rabbit anti-CD4, 1:500, Abcam) and CD8 (mouse anti-CD8,
1:75, Santa-Cruz Biotechnology) were incubated for 1 h at RT. Blots were then washed thrice with 0.05%
TBST at 10 min intervals and horseradish peroxidase-conjugated (HRP) secondary Ab (goat anti-rabbit-
or goat anti-mouse-HRP: CD8 1:500, Santa-Cruz Biotechnology and CD4 1:2000, Abcam) was added
and incubated for 1 h at RT. Chemiluminescent visualization of the transferred proteins was carried out
using an enhanced chemiluminescence detection reagent (500 µL/cm2 membrane, Merck-Millipore).
Blots were scanned for 2 sec on the ImageQuantTM FUJI LAS-4000 biomolecular imager (GE Healthcare).
ImageJ software was used to quantify the density of a band of interest on a blot by using a rectangular
box to define the band. This band intensity was expressed as a raw value (n = 3 bands/animal, n = 3
animals/group) and presented relative to Ctrl.
2.4.3. Transfer Efficiency
Replicate 1D SDS-PAGE gels were resolved in parallel and one stained with Coomassie Brilliant
Blue prior to, and the other after, transfer onto PVDF membrane to determine the transfer efficiency of
proteins. Imaging was carried out using a TyphoonTM FLA-9000 gel imager. The density of the bands
(n = 3 bands/gel) with the molecular weights corresponding to the known molecular weights of CD4/8
(37 and 50 KD, respectively) were quantified using Multigauge image analysis software-version 3.0
(Fujifilm, Minato-Ku, TYO, Japan).
2.4.4. T-Cell Detection Limits in Peripheral and CNS Tissues
To measure the detection limit of CD4 and CD8 antibody signals in WBs, spleen samples from
naïve mice and commercial CD4/8 recombinant proteins (Sino Biological, Wayne, PA, USA) were used.
For CD4, the lowest detectable signal was achieved using 5 µg of spleen protein, whereas 10 µg of
total spleen protein was needed to detect a CD8 band. The minimal detectable concentrations of
the commercial recombinant protein standards were 5 ng and 5 µg for CD4 and CD8, respectively
(Figure 3a). These lowest detectable concentrations for both groups (spleen and commercial samples)
were used as positive (spike) controls to establish the expected minimal detection of CD4 and CD8 in
WBs of total brain protein from the different experimental groups.
2.5. Statistical Analysis and Graphing
Statistical analyses were performed using GraphPad Prism-version 7.03 (www.graphpad.com,
San Diego, CA, USA) software. Data were analysed using either one or two-way analysis of variance
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(ANOVA) or an unpaired two-tailed t-test and, where appropriate, Newman-Keuls or Tukey post hoc
analyses to determine specific differences among groups. Data are presented as means ± standard
error of the mean (SEM), otherwise indicated in the text. Statistical significance was accepted when
p < 0.05. Figures were assembled using CorelDRAW-version 2018 (www.coreldraw.com, Ottawa, ON,
Canada) and Photoshop CS6 (Adobe, San Jose, CA, USA) image processing software. All Nogo A
images were adjusted only for colour contrast (Supplementary Figures S1 and S2).
3. Results
3.1. Body Weight
Mice in all groups gained weight over the duration of feeding, but this was significantly slower in
CPZ(±PT)-fed animals (p < 0.05, Figure 1). Significant reductions in weight gain started at week 1 after
0.2% CPZ±PT and week 2 after 0.1% CPZ±PT-feeding and continued until week 11. At week 12, 0.1%
CPZ±PT groups were significantly (p < 0.05) different compared to the Ctrl group but not to the PT
group. No direct or combined effect (p > 0.05) of PT was found in any group at any time point.
3.2. Marked Demyelination, Oligodendrocytosis and Gliosis
In both the 5- and 12-week studies, the Ctrl and PT groups exhibited intense silver staining of
myelin in the midline corpus callosum (MCC) and lateral corpus callosum (LCC), whereas the 0.1%
and 0.2% CPZ-fed(±PT) groups displayed a marked, concentration-dependent loss of silver staining
(p < 0.05, Figure 2a; Supplementary Figures S1a, S2a, S3a). No differences in the extent of demyelination
were found between the MCC and LCC regions in any of the groups with either duration of CPZ-feeding
[(p > 0.05, Figure 2a, (MCC); Supplementary Figure S3a, (LCC)]. Importantly, prolonged 0.1% CPZ
(±PT)-feeding for 12 weeks produced a similar amount of demyelination to that seen at 5 weeks
with 0.2% CPZ (p < 0.05, Figure 2a; Supplementary Figures S1a, S2a, and S3a). Consistent with the
significant reduction in silver staining, 5 or 12 weeks of CPZ-feeding produced a significant loss (>90%)
of mature, Nogo A positive OLG in the MCC and LCC; feeding with 0.1% was as effective as 0.2% CPZ
at inducing OLG loss (p < 0.05, Figure 2b; Supplementary Figures S1b, S2b, S3b). Importantly, there
were no differences in OLG loss when using 0.1% or 0.2% CPZ for 5 weeks, and 0.1% CPZ-feeding for 12
weeks produced a comparable loss of OLG to that seen at 5 weeks (p > 0.05, Figure 2b; Supplementary
Figures S1b, S2b, S3b). Similarly, there were marked dose-dependent increases (p < 0.05) in the number
and intensity of Gfap and Iba 1 staining (Figure 2c,d; Supplementary Figures S1c,d, S2c,d, S3c,d) in
the CPZ-fed(±PT) groups compared to Ctrl or PT only animals (which were not different from each
other, p > 0.05). Taken together, these results indicate that low dose CPZ-feeding for 5 weeks produced
an almost complete loss of OLG but a more limited (i.e., slower) demyelination and gliosis response.
When this feeding regime was prolonged for 12 weeks, it produced comparable changes to those seen
at 5 weeks using 0.2% CPZ. PT had no direct or synergistic effects on any of the histological parameters
studied at either time point.
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Figure 2. Quantification of demyelination, cell death and gliosis in the midline corpus callosum.
(a) Silver staining. CPZ-feeding(±PT) led to significant demyelination and reduced silver staining
intensity at 5 and 12 weeks. PT alone had no effect. Feeding 0.1% CPZ for longer (12 weeks) produced
a comparable demyelination to that seen with 0.2% for 5 weeks. (b) Nogo A. CPZ-feeding(±PT) led to
significant oligodendrocytosis with 0.1% CPZ was as effective as 0.2% CPZ at either time point. PT
alone had no effect. (c) Gfap. Staining intensity increased in a dose dependent manner, in the CPZ(±PT)
treated groups and this was associated with an increase the number of Gfap positive astrocytes at
both time points. PT only did not evoke a Gfap response. (d) Iba 1. Increased Iba 1 fluorescence
intensity and number of Iba 1 positive microglia were seen in both 5- and 12-week groups. PT alone
produced no microglial response. Data are presented as mean ± SEM. One-way ANOVA and Tukey
post hoc analysis was used to determine differences among groups (* p < 0.05, # p < 0.01, $ p < 0.001
and ˆ p < 0.0001). Quantitation based on analysis of 5–9 sections/animal, 3–5 animals/group.
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3.3. Detection and Localisation of CD4 and CD8 T Cells
Immunofluorescence staining of brain sections failed to detect CD4+ and CD8+ positive cells in
the CC in CPZ(±PT) groups (Supplementary Figure S4a, even when using high antibody titres and
long incubation times). This was not due to the lack of antibody sensitivity, as immunofluorescent
CD4 and CD8 positive cells were seen in histological sections of spleen (Supplementary Figure S6a).
Likewise, CD4/8 signals in whole brain protein samples were undetectable by western blot (WB)
analysis (Figure 3c), even at high protein loads (up to 120 µg). This was not due to the lack of
protein transfer from SDS-PAGE gel to PVDF membrane, as transfer efficacy at the molecular weights
corresponding to CD4/8 (37 and 50 KD, respectively) were 93 ± 1.6% and 98 ± 0.7%, respectively
(Supplementary Figure S4b). Furthermore, CD4/8 signals were also detected by WB analysis when
spleen (Figure 3a,c) and EAE spinal cord were used as positive controls (Supplementary Figure S4c;
EAE was induced using an established method [8]). The capacity and sensitivity of WB to detect
CD4/8 signal was also confirmed by other control experiments in which brain homogenates were
spiked with spleen homogenate or commercially available CD4/8 recombinant proteins (Figure 3b).
Notably, measurement of splenic weight showed a significant (p < 0.05) decrease in splenic mass
(37 ± 0.1%) in 0.2% CPZ-fed(±PT) groups whereas no change was observed in 0.1% CPZ(±PT) groups
at 5 weeks (Supplementary Figure S5a,c). In contrast, a significant (p < 0.05) reduction of splenic mass
was observed in 0.1% CPZ(±PT) groups at 12 weeks (Supplementary Figure S5b,c). Moreover, 5 weeks
of CPZ-feeding also resulted in a significant dose-dependent reduction in CD4/8 in spleen compared to
Ctrl (Figure 3d, 0.2% > 0.1%, p < 0.05). Following 5 weeks of 0.1% CPZ-feeding(±PT), the reduction of
CD4 (11 ± 0.03%) and CD8 (14 ± 0.03%) signal intensity was less marked than that seen with 0.2%
CPZ(±PT) groups (CD4 44 ± 0.03% and CD8 61 ± 0.04%). Following 12 weeks of 0.1% CPZ(±PT),
further reductions in spleen CD4 (27 ± 0.01%) and CD8 (43 ± 0.02%) signal intensity and splenic
atrophy (33 ± 0.1%) were observed. In addition, immunofluorescence staining of spleen sections
(n = 10 sections/animal and n = 3 animals/group) indicated a significant (p < 0.05) reduction of CD4
and CD8 in the 0.2% CPZ-fed group (Supplementary Figure S6a,b).
3.4. Brain Proteome Changes
All samples yielded well-resolved proteomes encompassing the full MW/pI range of the gels.
Representative images of soluble (SP) and membrane (MP) proteomes from Ctrl and 0.2% CPZ-fed mice
are shown in Figure 4a. A total of ~1650 consensus spots (i.e., protein spots that resolved consistently
and were analysed across all gels) were detected from the combined analyses of whole brain soluble
and membrane proteomes (Figure 4a; Supplementary Table S1). The spot quantification from the
different groups from both time points is summarized in Supplementary Table S1. The different groups
yielded comparable numbers of resolved protein spots at 5 weeks (p > 0.05), and this was also true for
the 12-week samples (p > 0.05, Supplementary Table S1). In total, 845 ± 8 and 793 ± 11 spots were
resolved from the soluble and membrane fractions, respectively, in the 5-week study, whereas 824 ± 11
and 717 ± 3 spots were resolved from the soluble and membrane fractions, respectively, in the 12-week
study. Database hits of high-quality and confidence were returned following LC/MS/MS analysis and
identified 33 different proteoforms from these spots including 73% in the membrane proteome and
27% in the soluble proteome (Table 1).
Table 1 summarizes the best identified proteoforms within each spot that displayed a 100%
reproducible change across technical (n = 3 gels/fraction) and biological (n = 5 animals/group)
replicates. All identified proteins had a MASCOT score exceeding 100, with 46% between 100–200;
21% between 201–300; 9% between 301–400; 6% between 401–500; and 18% exceeding 500. Moreover,
each identification was based on at least 4 unique peptides: 61% based on 4–10 peptides; 27% based
on 11–20 peptides; and 9% based on over 30 peptides. Similarly, sequence coverage was always ≥5%
with 5–10% for 6 proteins; 11–20% for 11 proteins; 21–30% for 8 proteins; 31–40% for 5 proteins; and
>50% for 3 proteins (Table 1). The combination of high MASCOT scores and the presence of ≥4 unique
peptides with high coverage highlight the high confidence of the protein identifications.
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As also shown in Table 1 and Figure 4b, several of the identified proteoforms displayed a mismatch
between their theoretical and experimental MW and pI, indicative of post-translational modifications
(e.g., phosphorylation and glycosylation). Only, 1 proteoform showed an increase whereas 19 (58%)
showed a decrease and 13 (39%) showed the same experimental pI relative to the theoretical pI. In contrast,
twenty-five (75%) proteoforms increased, 4 (12%) decreased, while another 4 remained unchanged
in their experimental MW relative to theoretical MW. Interestingly, a subset of proteoforms was
found showing an approximate doubling of the experimental MW relative to theoretical—hexokinase
1, aconitate hydratase, ATP synthase subunit-α, ogdhl protein, tyrosine-tRNA ligase and dynamin
1—potentially indicative of dimerization, whereas an approximate tripling of MW may indicate
calreticulin trimers (Table 1) suggesting a possible increase in oligomerization/self-association of
proteoforms due to CPZ-feeding(±PT).
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Figure 3. Western blot analysis. (a) Measurement of the detection limit of CD4/8 signal using naïve 
Ctrl spleen homogenates and CD4/8 recombinant proteins in gels. (b) Confirmation of CD4/8 signal 
detection using brain tissue samples (60 μg) spiked with either 5 μg or 10 μg of spleen homogenate 
or 5 ng and 5 µg commercial CD4 and CD8 recombinant proteins. (c) No CD4/8 signal was detected 
in CPZ(±PT) brain samples whereas a reduced CD4/8 signal intensity was found in spleen. (d) 
Quantification of splenic CD4/8 blots showed a significant reduction of CD4 and CD8 signal 
intensity in spleens of specific groups. Cropped CD4/8 western blots are presented unaltered and 
shown in their entirety in Supplementary Figure S7. Data are presented as mean (±SEM) relative to 
the Ctrl mice. One-way ANOVA and Newman-Keuls Multiple Comparison post hoc analysis were 
used to determine differences among groups (* p < 0.05, # p < 0.01 and ^ p < 0.0001). 
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Figure 3. Western blot analysis. (a) Measure nt of the detection limit of CD4/8 signal using naïve Ctrl
spleen homogenates and CD4/8 recombinant proteins in gels. (b) Confirmation of CD4/8 signal detection
using brain tissue s mples (60 µg) spiked with e ther 5 µg or 10 µg of spleen homogenate or 5 ng and
5 µg commercial CD4 and CD8 recombinant proteins. (c) No CD4/8 signal was detected in CPZ(±PT)
brain samples wherea a reduced CD4/8 signal inten ity was found in sple n. (d) Quantification of
splenic CD4/8 blots showed a significant reduction of CD4 and CD8 signal intensity in spleens of
specific groups. Cropped CD4/8 weste n blots are resented unaltered and shown in their entirety
in Supplementary Figure S7. Data are presented as mean (±SEM) relative to the Ctrl mice. One-way
ANOVA and Newman-Keuls Multiple Comparison post hoc analysis were used to determine differences
among grou s (* p < 0.05, # p < 0.01 and ˆ p < 0.0001).
Statistical comparisons of the spot intensities between all groups revealed significant and
reproducible ch nges (p < 0.05) i 33 spots across Ctrls and experimental groups in the 5- and
12-week studies (Figure 5). Among the identified proteoforms, not all changes were sustained,
or shared, between the 5- and 12-week studies (Supple e tary Figure S8). In total, 23 shared
proteoform changes were found in both the 5- and 12- week studies (i.e., ≥1.5-fold change in both
studies), whereas 7 proteoforms that changed in the 5-week study (≥1.5-fold) did not in the 12-week
study (<1.5 fold) and 3 other proteoforms were changed by 12 weeks (≥1.5-fold) but not at 5 weeks
(<1.5 fold). The presence of changes at 5 weeks that were not evident at 12 weeks indicates that,
relative to their age matched controls, such changes are time-dependent and resolved by 12 weeks.
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Whether this return to control levels during prolonged feeding with 0.1% CPZ is due to compensatory
mechanisms, aging or other processes remains unknown.
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Figure 4. Top-down proteomic analysis. (a) Representative two-dimensional gel images of soluble (SP)
and membrane (MP) brain proteomes from naïve Ctrl and 0.2% CPZ-fed groups used to detect proteoform
changes. Proteoforms were resolved on the basis of their isoelectric point (pI) and molecular weight (MW).
The total number of spots across different groups at both 5 and 12 weeks is given in Supplementary Table
S1. Delta 2D software analysis revealed 33 unique spots for which the spot volume changed by at least
1.5-fold in at least one experimental group; soluble proteoforms are indicated by red circles and membrane
proteoforms by green circles. The identities of the protein species are shown in Table 1 (n = 15 gels/fraction,
n = 5 animals/fraction, 5-week study n = 180 gels and 12-week study n = 120 gels). (b) Comparison between
theoretical and experimental MW (left) and pI (right) of identified proteoforms. Red represents increase, green
decrease and blue indicates no statistically significant difference between the experimental and theoretical
values. Purple dashed lines indicate 95% confidence intervals and the solid line represents full agreement
between experimental and theoretical values.
Cells 2019, 8, 1314 16 of 33Cells 2019, 8, 1314 18 of 34 
 
Figure 5. Log2 fold changes in abundance for 33 proteoforms relative to Ctrl. Each point is the average 
change in spot volume ratio from all treated groups (PT, 0.1% CPZ, 0.1% CPZ+PT, 0.2% CPZ and 0.2% 
CPZ+PT) relative to Ctrls from the triplicate gels resolved for each of the 5- and 12-week samples. 
Only significant changes in abundance (p < 0.05) that exceeded the established 1.5-fold criteria (dash 
lines) in at least 1 experimental group were selected for excision, processing, and protein 
identification. Solid and dashed lines connect the protein changes within each experimental group 
with and without PT injection, respectively. Proteoforms (top left) indicate the different functional 
categories including metabolic (red), synaptic (blue), structural (purple) and signalling (green). 
Analysis was based on n = 180 gels (5-week study) and, n = 120 gels (12-week study); n = 5 
animals/group. 
Figure 5. Log2 fold changes in abu dance for 33 proteofo ms relative to Ctrl. Each point is the
average change in spot volume ratio from all treated groups (PT, 0.1% CPZ, 0.1% CPZ+PT, 0.2% CPZ
and 0.2% CPZ+PT) relative to Ctrls from the triplicate gels resolved for each of the 5- and 12-week
samples. Only significant changes in abundance (p < 0.05) that exceeded the established 1.5-fold
criteria (dash lines) in at least 1 experimental group were selected for excision, processing, and protein
identification. Solid and dashed lines connect the protein changes within each experimental group with
and without PT injection, respectively. Proteoforms (top left) indicate the different functional categories
including metabolic (red), synaptic (blue), structural (purple) and signalling (green). Analysis was
based on n = 180 gels (5-week study) and, n = 120 gels (12-week study); n = 5 animals/group.
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Key: MP, membrane protein; SP, soluble protein; MW, molecular weight; pI, isoelectric point; S,
Swiss-Prot; M, MSPnr100; PT, pertussis toxin; 0.1, 0.1% CPZ; 0.1PT, 0.1% CPZ+PT; 0.2, 0.2% CPZ; 0.2PT,
0.2% CPZ+PT; W, week; ×, unchanged; ↑, increase; ↓, decrease; -, not found or investigated (details are
shown in Figure 5). Some of the spots contained more than one clearly identifiable protein; presented
here are the hits with the highest score, coverage and peptide count. UniProt and gene IDs were derived
from the UniProt database. MASCOT score, sequence coverage, theoretical (MW/pI), and unique
peptides number were acquired from the MASCOT database search. Experimental (MW/pI) was
derived from 2D gels of identified protein spot. References are from the published literature in PubMed
on CPZ, EAE and MS and used to compare currently identified proteins with the existing literature.
3.5. Literature Mining
Literature mining via PubMed was used to assess the likely function(s) of identified proteoforms.
This confirmed 8 proteoforms (creatine kinase U-type, glutamate dehydrogenase 1, vesicle-fusing
ATPase, propionyl co-enzyme A carboxylase-β, tyrosine-tRNA ligase, actin-related protein 2/3 complex
subunit 5, charged multi-vesicular body protein and adipocyte plasma membrane-associated protein)
not previously related to CPZ, EAE or MS, and 25 proteins (but not specific proteoforms) previously
associated with CPZ (8), EAE (13) and MS (16) studies (Table 1).
3.6. Biological Processes and Pathways
The 33 differentially expressed proteoforms were subjected to bioinformatic analysis using
PANTHER, DAVID, UniProt and STRING for association with protein classes, molecular functions,
physiological pathways, biological processes, cellular components, subcellular localizations and
protein–protein interactions. Analysis using PANTHER indicated that the main protein classes
were enzyme modulator (15%), nucleic acid binding (10%), oxidoreductase (10%) with 19%
unclassified (Supplementary Figure S9a). Molecular function analysis using PANTHER indicated
catalytic activity (40%) and binding (26%) roles with 18% unclassified (Figure 6a). However, the
potential functions of all the proteoforms were inferred by literature mining for information on
the canonical proteins (see Discussion). Physiological pathway analysis associated 26% of the
proteins with KEGG metabolic pathways categories using DAVID (Figure 6b). GO biological
process analysis showed the main categories were oxidation-reduction (13%) and transportation
(13%), with 15% unclassified (Supplementary Figure S9b). Moreover, GO cellular component
analysis (Figure 6c) indicated that most of the proteins were either cytoplasmic (25%), extracellular
exosome (21%), mitochondrial (20%) or related to the myelin sheath (20%). Furthermore, subcellular
localization analysis using UniProt revealed the main categories to be mitochondrial (31%) and
cytoplasmic (26%; Supplementary Figure S9c). The identified proteoforms were also analysed
using STRING software, providing PPI maps; this indicated that 15 of the 33 proteoforms
(hexokinase 1, fructose-bisphosphate aldolase C, aconitate hydratase, succinate dehydrogenase
flavoprotein subunit, malate dehydrogenase, NADH dehydrogenase iron-sulfur protein 2, ATP
synthase subunit-α, voltage-dependent anion-selective channel protein, aspartate aminotransferase,
ogdhl protein, isovaleryl-CoA dehydrogenase, tyrosine-tRNA ligase, glutamate dehydrogenase 1,
propionyl co-enzyme A carboxylase-β and creatine kinase U-type) were potentially involved in
major ‘functional interactions’ particularly with regard to the metabolic proteins (Figure 6d). Strong
one-to-one connections were also indicated between synaptic (rab GDP dissociation inhibitor-α, rab
GDP dissociation inhibitor-β, vesicle-fusing ATPase, calcium/calmodulin-dependent protein kinase
type II subunit-α and dynamin 1) and structural (glial fibrillary acidic protein and neurofilament light
polypeptide) proteoforms. This therefore, also revealed a second cluster of structural and signalling
proteoforms. Among the connected proteoforms, 38% showed the highest connecting value (0.9),
and 29% and 33% were high (0.7) and medium (0.4), respectively; no low value (0.15) connections
were found.
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Figure 6. Functional clustering and protein–protein interactions. Pie charts show the distribution of 
proteins according to (a) Molecular functions (characterized using PANTHER), (b) Physiological 
pathways (categorised using KEGG), (c) GO cellular components. (d) Protein–protein interaction 
association network maps. The strength of connections is based on co-expression, gene fusion, co-
occurrence, neighbourhood, databases, experiments, and text-mining collated in the STRING 
database. The strength of interactions is indicated by the thickness of the lines. STRING analysis 
revealed 4 protein clusters involved in metabolic (red), synaptic (blue), structural (purple) and 
signalling (green). Collectively, these proteins and their associations suggest that CPZ induced 
metabolic dysregulations and mitochondrial dysfunction. 
Although the addition of PT injections during CPZ-feeding did not enhance the extent of OLG 
degeneration, demyelination and gliosis, it did produce several proteoform changes (Figures 5,7; 
Supplementary Figure S10a–c, Table S2). This is the first study to assess changes in the mouse brain 
Figure 6. Functional clustering and protein–protein interactions. Pie charts show the distribution
of proteins according to (a) Molecular functions (characterized using PANTHER), (b) Physiological
pathways (categorised using KEGG), (c) GO cellular components. (d) Protein–protein interaction
association network maps. The strength of connections is based on co-expression, gene fusion,
co-occurrence, neighbourhood, databases, experiments, and text-mining collated in the STRING
database. The strength of interactions is indicated by the thickness of the lines. STRING analysis
revealed 4 protein clusters involved in metabolic (red), synaptic (blue), structural (purple) and
signalling (green). Collectively, these proteins and their associations suggest that CPZ induced
metabolic dysregulations and mitochondrial dysfunction.
Although the addition f PT injections during CPZ-feeding did not enhance the extent of OLG
degeneration, demyelination and gliosis, it did produce several proteoform c anges (Figures 5
and 7; Supplementary Figure S10a–c, Table S2). This is the first study to assess changes in
the mouse brain proteome profile when the BBB is compromised by PT. Following 5 weeks of
CPZ-feeding, PT injection more than doubled the number of significant CPZ-associated changes
(18–46%), with PT alone contributing 15% of all proteoform changes, including fructose-bisphosphate
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aldolase C, NADH dehydrogenase iron-sulfur protein 2, ATP synthase subunit-α, rab GDP dissociation
inhibitor-β, septin-2 and 5, guanine nucleotide-binding protein G(o) subunit-α, adipocyte plasma
membrane-associated protein and leukocyte elastase inhibitor A. Likewise, in the 12-week study, the
small number of proteins identified following CPZ-feeding (6%) increased following the addition of
PT (52%), with PT alone contributing 21% including aconitate hydratase, succinate dehydrogenase
flavoprotein subunit, NADH dehydrogenase iron-sulphur protein 2, isovaleryl-CoA dehydrogenase,
tyrosine-tRNA ligase, syntaxin-binding protein 1, glial fibrillary acidic protein, neurofilament light
polypeptide, septin-2 and calreticulin. Statistical comparisons of the CPZ(+PT) groups with the PT only
group (Supplementary Table S2) revealed that at least 50% of the PT-mediated proteoform changes were
either increased (or decreased) when combined with CPZ-feeding; in the 5-week study, 25% increased
(27% decreased) whereas, in the 12-week study 52% increased (6% decreased).
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Figure 7. Highest fold change. Pie charts showing the highest increase or decrease fold change in 
abundance of the 33 proteoforms relative to Ctrls in the 5- and 12-week studies. PT alone or when PT 
was combined with CPZ showed greater change than CPZ alone. Quantification is based on ≥1.5-fold 
changes. 
4. Discussion 
The present study was designed to test whether CPZ-induced oligodendrocytosis, when 
combined with PT-induced BBB disruption, could induce an ‘inside-out’ activation of the immune 
system causing infiltration and detection of CD4/8 immune cells into the brain parenchyma. The 
effectiveness of CPZ-feeding was confirmed by the reduced weight gain in these groups, the almost 
complete demyelination of the corpus callosum using the standard feeding paradigm of 0.2% CPZ for 
5 weeks, and changes to the brain proteome [58,59,108,109]. The results also demonstrated that 0.2% 
or 0.1% CPZ(±PT) produced comparable oligodendrocytosis but dose- and time-dependent 
demyelination and gliosis within the corpus callosum, indicating that 0.1% CPZ is as effective as 
Figure 7. ighest fold change. Pie charts sho ing the highest increase or decrease fold change in
abundance of the 33 proteoforms relative to Ctrls in the 5- and 12-week studies. PT alone or when
PT was combined with CPZ showed greater change than CPZ alone. Quantification is based on
≥1.5-fold changes.
4. Discussion
The present study was designed to test whether CPZ-induced oligodendrocytosis, when combined
with PT-induced BBB disruption, could induce an ‘inside-out’ activation of the immune system
causing infiltration and detection of CD4/8 immune cells into the brain parenchyma. The effectiveness
of CPZ-feeding was confirmed by the reduced weight gain in these groups, the almost complete
demyelination of the corpus callosum using the standard feeding paradigm of 0.2% CPZ for 5 weeks,
and changes to the brain proteome [58,59,108,109]. The results also demonstrated that 0.2% or 0.1%
CPZ(±PT) produced comparable oligodendrocytosis but dose- and time-dependent demyelination
and gliosis within the corpus callosum, indicating that 0.1% CPZ is as effective as higher doses when
fed for a longer period of time. The presence of comparable oligodendrocytosis, but less marked
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demyelination and gliosis following 5 weeks of 0.1% CPZ-feeding, suggested a slower transition between
oligodendrocytosis and demyelination and/or better clearance of myelin debris. In this transition
state, limited gliosis may impede subsequent remyelination [110] and induce a slow, progressive
demyelination reminiscent of MS. CPZ-induced a dose dependent (0.2% > 0.1%) atrophy of the spleen
and extending the CPZ-feeding resulted in time dependent atrophy in 0.1% CPZ(±PT)-fed groups as
well. Likewise, CPZ produced a dose-dependent (0.2% > 0.1%) suppression of CD4/8 in the spleen.
Prolonged low-dose feeding of CPZ for 12 weeks did not cause a further decrease in CD4 compared to
5 weeks; however, with prolonged feeding, the reduction of CD8 deteriorated to levels seen at 5 weeks
using the standard CPZ-feeding. Our results are thus consistent with a previous study where apoptosis
of CD4 and CD8 positive cells and atrophy of thymus were observed following 0.2% CPZ-feeding [50].
In contrast, 5 weeks of 0.1% CPZ-feeding produced less CD4 and CD8 suppression and no splenic
atrophy, suggesting this lower dose may be a better model to examine the aetiology of MS.
Following CPZ-feeding(±PT) in either experiment, there were no detectable CD4 or CD8 signals in
brain tissue. There are several possible reasons for this: firstly, insensitivity of the immunohistological
or biochemical assays. This is unlikely, as WB sensitivity was confirmed by spiking whole brain
homogenates with biological (spleen) and commercially available CD4/8 recombinant proteins, and both
high protein loads (60–120 µg) and high antibody titres were used [111]. Additionally, these results are
consistent with previous studies using immunofluorescence and flow cytometry [48,112] as well as BBB
disruption using ethidium bromide or lysolecithin [48]. Secondly, the BBB was breached during weeks
1–2 of CPZ-feeding, and this is a transient event [113]. However, whether infiltration occurred at this
early time point, but resolved before the 5- or 12-week endpoints remains unknown. Was the lack of a
detectable adaptive immune response the result of failure to generate an antigen? This seems unlikely,
as marked gliosis, demyelination and oligodendrocytosis occurred. Alternatively, was there a direct
effect of CPZ on peripheral immune function? This would be consistent with the observed suppression
of CD4/8 signal in the spleens of CPZ-fed animals. It was recently reported that combining two weeks
of 0.2% CPZ-feeding with an ‘immune booster’ (CFA) produced a secondary CD3+ (pan T-cell marker)
response, a response that was not observed with 0.2% CPZ-feeding alone or when CPZ-feeding was
continued [31]. Consequently, it can be expected that prolonged CPZ-feeding is unlikely to facilitate
infiltration of immune cells into the CNS as continued feeding would result in sustained immune
suppression (and reduction of mitochondrial ATP production) which is known to lead to declining
health and death of mice. Likewise, extending observations beyond the cessation of CPZ-feeding
is unlikely to reveal immune cell infiltration since cessation of CPZ-feeding results in spontaneous
remyelination, reduction in myelin debris (a potential antigen), and cessation of glial activation (i.e., the
antigen presenting cells) (reviewed in [2,39,57,58,114]).
Notably, the prolonged CPZ-feeding preferentially suppressed CD8 signal intensity in the spleen,
and these are the cells that predominate in human MS CNS pathology [22]. These observations are
further supported by the large number of changes in spleen (n = 22) and peripheral blood mononuclear
cell-derived (n = 5) proteoforms in the CPZ-fed animals [49]. In the spleen, the vast majority (87%) of
these changes included membrane associated structural and metabolic proteins suggesting perturbation
of adaptive immune function [49]. The spleen and thymus are responsible for the maturation, selection
and proliferation of T-cells [115,116], key functions that are impeded by the ion dishomeostasis induced
by CPZ [41–44]. Such effects on the peripheral immune system may explain why the severity of
disease and extent of peripheral immune involvement in EAE and Theiler’s murine encephalomyelitis
were suppressed by CPZ [117–119]. Although, there is no evidence as to whether T-cells become
functionally inactivated (’T-cell anergy’; [120,121]) due to the suppression of adaptive immune organs
(e.g., thymus) following CPZ-feeding, there is some evidence indicating that CPZ may otherwise affect
T-cell functions. Copper plays both direct and indirect roles (via interleukin-2) in the maturation and
production of functional T-cells [122]. Consequently, it can be argued that CPZ, like other copper
chelators (e.g., 2,3,2-tetraamine), can reduce T-cell function [123,124]. Moreover, it has been shown that
when lymph node cells harvested from CPZ-fed mice are exposed to neuroantigens (e.g., concanavalin
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A and MBP) in vitro, there is reduced cellular proliferation. Likewise, reduced T-helper cell 1 cytokines
(e.g., interferon-γ and tumor necrosis factor-α) and CD4 T-cell response to interleukin-17 are observed
in EAE mice fed with CPZ [119]. Together, these findings indicate that CPZ can modify the functional
capacity of T-cells, and this may potentially affect migration into the CNS.
The suppression of CD4/8 in the spleen indicated that CPZ has direct effects on the peripheral
immune system that may limit the maturation and migration of adaptive immune cells to the CNS.
Moreover, calcium/calmodulin-dependent protein kinase type II subunit-α, a protein known to play
a role in CD8 T-cell proliferation and the transition to a cytotoxic phenotype [125,126] decreased in
abundance following CPZ-feeding. Likewise, leukocyte elastase inhibitor A, a protein that supresses
proteases including those released by T-cells [127], also decreased in abundance. These findings extend
earlier proteomic analyses [49] that found CPZ reduced the abundance of protein disulphide isomerase
(subunits A2, A3 and A6) in spleen, a protein involved with folding and assembly of functional major
histocompatibility complex class I molecules [128]. In addition, the CPZ-induced dysregulation of
mitochondria identified in the present study presumably extends to the immune system as several
studies have shown that mitochondrial dysfunction leads to the suppression of T-cell function and a
compromised immune system [129,130]. Collectively, these findings indicate that CPZ has suppressive
effects on the capacity of the peripheral immune system to launch a response, making it more difficult
to address the ‘inside-out hypothesis’. Therefore, strategies to overcome peripheral immune organ
suppression should be the next stage of investigation in evaluating the ‘inside-out’ hypothesis of MS
using the CPZ model.
While there is growing evidence that MS may initiate as a slow, low-grade primary
oligodendrocytosis, a substantial gap still exists in our understanding of the molecular
mechanisms underlying the fundamental susceptibility to and initiation of oligodendrocytosis [1–4].
Therefore, a quantitative ‘top-down’ proteomic approach was carried out to resolve protein species
from whole brains of the CPZ-fed(±PT) mice. To date, proteome analyses of MS have mainly
assessed tissue from late-stage post mortem brain samples and cerebrospinal fluid [89,96] or EAE
animals [88,93,100,105]; these analyses provide useful insight into the ‘final readout’ of the disease or
its autoimmune aspects [131–133] but not necessarily insight into the processes involved in disease
aetiology and progression, including the role of oligodendrocytosis [1,49].
Here, CPZ-mediated oligodendrocytosis and glial activation were confirmed using histology,
and the changes in protein abundance were quantified using a high sensitivity ‘top-down’ analysis
rather than the more common ‘bottom-up’ (i.e., ‘shotgun’) analyses; this is critical, as the ‘top-down’
approach has the highest inherent capacity to resolve intact proteoforms (i.e., isoforms, splice variants,
and post-translationally modified species) as well as provide better sequence coverage, and assessment
of lower molecular weight species, with a high degree of consistency across technical and biological
replicates [54,55,134]. This approach thus detected changes in 33 proteoforms (16 metabolic, 7
synaptic, 5 structural and 5 signalling), of which 8 have not been previously associated with CPZ,
EAE or MS. Furthermore, it also provided high quality confirmation of changes in the abundance of
25 proteoforms of proteins previously related to MS or animal models of the disorder. In contrast to
earlier work [49,91,97,99,135], this study used three technical replicates for each of the 5 biological
replicates per experimental group, ensuring that only the most reproducible changes in proteoform
abundance were assessed. Consequently, in contrast to the detection of ~700–1200 spots in previous
studies [49,88,100,105], ~1650 protein spots per condition were resolved in this study.
The most striking observation to emerge from the proteomic analysis was the large number of
changes in metabolic proteoforms involved in glycolysis, Krebs cycle and oxidative phosphorylation
pathways and the regulation of mitochondrial function. Bioinformatics platforms (DAVID, PANTHER,
UniProt and STRING) further revealed the likely association between metabolic dysregulation and
CPZ-feeding. Understanding the molecular pathways and potential PPI is important to understanding
how dysregulation of biological processes may lead to a disease [132,136]. It is thus notable that over
80% of proteins do not function alone but in complexes [136]. The data here suggested that 79% of the
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identified proteoforms may be clustered in two complexes, with 58% being metabolic in origin, which
is consistent with previous observations [136,137]. The strong PPI highlight the likely cross-talk and
shared biochemical reactions among the metabolic proteoforms [136]. Interestingly, protein-to-protein
connection analysis revealed that malate dehydrogenase may have 11 connections with other identified
proteoforms, which was the highest seen, and that the ATP synthase subunit-α had the second highest
with 7 connections (Figure 6d). The central placement and increased inter-connectedness of malate
dehydrogenase or ATP synthase subunit-α with other proteoforms implies that these proteoforms
may be pivotal for CPZ-induced metabolic dysregulation. This explanation is further supported by
the increased abundance of ATP synthase subunit-α and malate dehydrogenase (in contrast to the
decreased abundance of most of the other identified metabolic proteoforms), perhaps as a compensatory
response to the CPZ-induced metabolic perturbations. The increased abundance of ATP synthase
subunit-α after CPZ-feeding leads to the accumulation of protons in the inter-membrane space of
mitochondria and increased generation of reactive oxygen species [91]. Likewise, an increase in the
abundance of aconitate hydratase (6 PPI connections, Figure 6d), an iron-sulphur protein containing
4Fe-4S clusters, is likely to regulate iron-induced oxidative stress in the CPZ model. Disruption of
iron metabolism is linked to increased oxidative stress and lipid peroxidation [138]; CPZ-feeding is
associated with the dysregulation of iron [43] and thus increased oxidative stress results in accentuation
of mitochondrial perturbations [139]. Moreover, we observed a synergy between CPZ-feeding(±PT)
with regard to synaptic protein dynamin 1 (increased at 5 weeks but decreased at 12 weeks) suggesting
that CPZ-feeding interferes with the fission and fusion dynamics of mitochondria. The initial increase
in dynamin 1 is consistent with mitochondrial response to metabolic stress, wherein the mitochondria
divide, generating new functional mitochondria, and target damaged mitochondria for autophagy
[140]. Perturbations to the fission and fusion dynamics of mitochondria are consistent with the
formation of mega-mitochondria reported in the CNS, in particular in OLG [141,142]. The current
data are consistent with previous investigations [49,50,91,99] corroborating the hypothesised link
between mitochondrial dysregulation with CPZ-feeding and the emergence of structural and functional
abnormalities that may predispose OLG to degeneration and death [1].
This susceptibility of OLG may be explained, in part, by the intense energy requirements
associated with the production and maintenance of the expansive myelin sheath [143,144]. The high
metabolic rate of OLG means that the increased production of reactive oxygen (and nitrogen) species,
coupled with their low levels of anti-oxidants (e.g., glutathione [145], metallothionein [146] and
manganese superoxide dismutase [147]) predisposes them to oxidative injury [45,148]. In addition,
increased abundance (in 5- and 12-week studies) of the endoplasmic reticulum (ER) stress-related
chaperone protein calreticulin may be associated with unfolded protein responses that enhance
oligodendrocytosis [144,149]. This finding extends previously observed changes in ER proteins such
as ribosome-binding protein 1, endoplasmin [49] and heat shock protein [99] reinforcing the role of ER
stress in the CPZ-fed mice. The presence of heat shock protein and activating transcription factor 4 in
MS [89,150,151] and EAE [105,150] indicate the association of protein misfolding and ER stress with
OLG degeneration and demyelination.
The apparent oligomerization of some proteoforms in response to CPZ-feeding(±PT) may be
indicative of toxic protein aggregation [152,153], effects that have also been observed in an EAE
study [154] and MS patients [155]. The oligomerization of proteoforms has been documented
in other studies, as with calreticulin and dynamin, assessed using SDS-PAGE or crystallographic
analysis [156–158]. Likewise, the divergence of molecular weight was also observed in other proteomic
studies of CPZ-fed mice (protein phosphatase 1G, 59.38 vs. 104.7 KD) and MS cerebrospinal fluid
(albumin, 67 vs. 180 KD and alpha 1 antitrypsin, 47 vs. 100 KD) [49,159]. Indeed, changes in theoretical
vs. experimentally observed isoelectric point have also been reported in previous studies on CPZ
(ornithine carbamoyltransferase, 8.81 vs. 6.9 and ribosome-binding protein 1, 9.35 vs. 5.0) [49],
EAE (septin-8, 5.7 vs. 6.4 and cytochrome c oxidase, 9.2 vs. 5.8) [100] and MS (Ig kappa chain NIG 93
precursor, 8.1 vs. 6.5 and albumin, 5.5 vs. 9) [159,160]. Naturally, none of this key data, upon which to
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better design future studies to identify critical proteoforms (rather than just amino acid sequences),
would be routinely available using any other current approach.
Within the demyelinated regions, the hypertrophy of astrocytes and microglia, compounded by
increased microglia numbers, may intensify the local energy imbalance and further compromise the
function of OLG. Moreover, hypertrophied microglia and astrocytes may diminish the supportive
roles played by glia at synapses leading to a pre-disposition to excitotoxicity [161–163]—a disturbance
further implicated by changes in other synaptic proteoforms identified in this study.
The abundance of synaptic-regulatory proteoforms was either decreased (rab GDP dissociation
inhibitor-α/β and vesicle-fusing ATPase), elevated (charged multivesicular body protein) or displayed
opposing changes (syntaxin-binding protein 1) across the two time points—changes in synaptic
function that may contribute to alteration of mood or behaviour in humans or animal models [164–166].
Likewise, the changes of abundance of proteins such as calcineurin, calbindin 2 and parvalbumin-α,
involved in neurotransmitter release, has also been reported in EAE [100]. Although CPZ-feeding
induce a wide range of behavioural deficits including motor, anxiety and cognition [reviewed by 2];
the present proteome analysis did not seek correlation with behavioural phenotypes, other studies
have argued that CPZ-induced alteration of proteoforms involved in neurotransmitter release can
result in cognitive decline [166] or increased climbing, rearing and ambulatory behaviours [99,108,109].
This study also revealed a marked change in neuronal and glial structural proteoforms, including
Gfap, neurofilament light polypeptide, actin-related protein 2/3 complex subunit 5, and septins-2
and -5, at both time points, indicating axonal and glial remodelling. Consistent with the capacity for
CPZ to induce the hypertrophy of astrocytes and increase microglia in the innate immune system
(Figure 2a; Supplementary Figures S1–3), a marked increase in proteoforms involved in structural
(Gfap), signalling, and inflammatory pathways were observed.
For some proteoforms, breaching the BBB negated the effects of 5 weeks of CPZ-feeding
(e.g., septin-5, creatine kinase U-type and 14-3-3 protein epsilon). The effects of PT alone, or in
combination with CPZ, indicate that PT did have an effect on the brain proteome, likely, in part at least,
by altering the capacity of the BBB to regulate access to the CNS [60,113,167]. This is the first study to
document the effects of giving PT alone on the CD4/8+ cell migration and the whole brain proteome.
In EAE, when PT is given together with adjuvant (CFA) and antigen stimulation (e.g., MOG), increased
disruption of tight junctions at sites of perivascular inflammation and demyelination occurs [63].
In addition, increased rates of relapsing-remitting episodes [60], increased infiltration of serum albumin
in the spinal cord [131] and suppression of the anti-inflammatory interleukin-10 [168] are observed.
However, the extent to which these changes are attributable to PT alone, or the combined treatments
used to induce EAE, remains un-documented. However, other studies have shown that PT alone
evokes changes in BBB function leading to increased protein infiltration into the brain (~15 days; [169]),
or disruption of G-protein function (~40 days; [170]) following PT administration. In the present study,
repeated injections of PT during the second and third weeks of CPZ-feeding resulted in proteoform
changes after 5 or 12 weeks indicating that PT injections alone have long-term effects at least on the
brain proteome. Moreover, the proteomic analysis highlighted proteoform differences between the
CPZ vs. EAE models; specifically, CPZ-feeding resulted in increased guanine nucleotide-binding
protein G(o) subunit-α, glutamate dehydrogenase 1 and malate dehydrogenase, which decrease in
EAE [88,94,105], perhaps reflecting the different underlying aetiologies (potentially including changes
in specific proteoforms). Whether these opposing changes result specifically from the use of peripherally
administered exogenous myelin antigens (e.g., MBP, PLP and MOG) in EAE or endogenously generated
antigens (i.e., myelin debris) in the brain of CPZ-fed mice remains unclear but would seem likely.
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Despite our rigorous efforts to minimize the experimental variables, we acknowledge certain
inherent limitations in the analytical approach. This study relied on only two time points (i.e.,
5 and 12 weeks) of CPZ-feeding(±PT), which did not allow us to determine if or when the
identified proteoforms returned to baseline nor to correlate proteome changes with the initiation
of oligodendrocytosis, demyelination and gliosis. Moreover, the sub-femtomole in-gel detection
sensitivity may well have missed significant changes in very low abundance species, although these
remain a substantial issue with all available analytical approaches if high quality final identifications
are a serious expectation [78]. Furthermore, reliance on existing databases that address only amino acid
sequences, as well as an apparent developing reliance in the field for online bioinformatics platforms
that also largely address only what is known about canonical proteins [171–173], tends to further
emphasize the fundamental importance of developing even more sensitive analytical approaches
to routinely quantifying and fully characterizing proteoforms in order to provide the most direct
understanding of the molecular mechanism underlying human diseases like MS.
5. Conclusions
This study confirmed that CPZ-feeding(±PT) in mice induced dose- and time-dependent
oligodendrocytosis, demyelination and gliosis, but was not associated with any detectable invasion
of peripheral adaptive (CD4/8) immune cells into the CNS. In the periphery, CPZ-feeding induced a
dose-dependent suppression of splenic CD4/8 and organ mass, suggesting that this peripheral action
of CPZ was a major impediment to studying the role of the peripheral immune system following
demyelination and disruption of the BBB. Notably, oligodendrocytosis, demyelination and gliosis
with the low dose of CPZ for 5 weeks resulted in minimal splenic atrophy and less severe adaptive
immune system suppression, indicating that this might be a better model to test the ‘inside-out’
theory of MS. Moreover, using a highly sensitive ‘top-down’ proteomic approach, changes in 33 brain
proteoforms were identified in the CPZ-fed mice, the majority of which were found to be associated
with mitochondrial function. This strongly suggests that mitochondrial perturbations may elicit
oligodendrocytosis and demyelination.
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Figure 1: Histological effects of different treatments on the midline corpus callosum 
Representative images of silver-stained brain sections from 5- and 12- week experimental groups to 
assess demyelination (a), or immunohistochemistry to identify the cell bodies of mature 
oligodendrocytes using Nogo A (b), astrocytes using Gfap (c) or microglia using Iba 1 (d) antibodies. 
Dashed lines represent the upper and lower borders of the MCC. Arrows indicate Nogo A positive 
cells. 
 





Figure 2: Histological effects of different treatments on the lateral corpus callosum 
Representative images of silver-stained brain sections from 5- and 12- week experimental groups to 
assess demyelination (a), or immunohistochemistry to identify the cell bodies of mature 
oligodendrocytes using Nogo A (b), astrocytes using Gfap (c) or microglia using Iba 1 (d) antibodies. 
Dashed lines represent the upper and lower borders of the LCC. Arrows indicate Nogo A positive 
cells. 
 





Figure 3: Quantification of demyelination, cell death and gliosis in lateral corpus callosum 
a) Silver staining. CPZ-feeding(±PT) led to significant demyelination and reduced silver staining 
intensity at 5 and 12 weeks in the LCC. PT alone had no effect. Feeding 0.1% CPZ for longer (12 
weeks) produced a comparable demyelination to that seen with 0.2% for 5 weeks. b) Nogo A. CPZ-
feeding(±PT) led to significant oligodendrocytosis with 0.1% CPZ as effective as 0.2% CPZ at either 
time point. PT alone had no effect. c) Gfap. Staining intensity increased in a dose dependent fashion 
the CPZ(±PT) treated groups and this was associated with an increase the number of Gfap positive 
astrocytes at both time points. PT only did not evoke a Gfap response. d) Iba 1. Increased Iba 1 
fluorescence intensity and number of Iba 1 positive microglia were seen in both 5-and 12-week 
groups. Significant effects were best seen at the highest doses used at each time point. PT only 
produced no microglial response. Data are presented as mean ± SEM. One-way ANOVA and Tukey 
post hoc analysis was used to determine differences among groups (*p<0.05, #p<0.01, $p<0.001 and 
^p<0.0001). Quantitation based on analysis of 5-9 sections/animal, 3-5 animals/group. 
 





Figure 4: Immune staining and transfer efficiency 
a) Immunofluorescence staining of CD4 and CD8 in the corpus callosum from the 5-week study (n=5 
sections/animal, n=3 animals/group). No positive cells were detected. b) 1D gels used to quantify the 
transfer efficiency of respective regions of CD4 (50 KD) and CD8 (30 KD) proteins from gel to PVDF 
membrane (n=3 bands/gel, n=2 gels). Arrows indicate the bands quantified. c) 40 μg spinal cord 














Figure 5: Dose and time dependent splenic atrophy 
Representative images (a and b) of spleen from 5- and 12-week studies, respectively. Scale bar is 5 
mm. Normalized (spleen tissue mass/body weight) splenic mass is shown in c. Feeding with 0.2% 
CPZ(±PT) for 5 weeks or 0.1% CPZ(±PT) for 12 weeks resulted in a significant reduction of splenic 
mass. Data are presented as mean ± SEM. One-way ANOVA and Tukey post hoc analysis was used to 
determine differences among groups (*p<0.05 and  #p<0.01). Quantitation based on analysis of 3 and 5 















Figure 6: Reduction of T-cell fluorescence intensity  
Representative images of spleen (a) and quantification (b) of CD4 and CD8 from Ctrl and 0.2% CPZ, 
respectively. Scale bar is 50 μm. Feeding with 0.2% CPZ showed a significant reduction of splenic 
CD4 and CD8 T-cells. Data are presented as mean ± SEM. Unpaired two-tailed t test was used to 
determine differences between groups (*p<0.05 and #p<0.01). Quantitation based on analysis of 3 
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Table 1: Quantification of the total number of protein spots in 2D gels of whole 
















SP 829±6 830±15 866±12 871±19 860±12 841±12 5 weeks 
MP 766±10 802±12 798±15 835±21 779±13 778±16 
SP 808±6 802±2 . 791±5 . 789±4 .     - - 12 weeks 
MP 719±2 708 ±5   716 ±4 727±5 . - - 
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Figure 8: Pattern of proteoform change 
Log2 fold changes in abundance for 33 proteoforms relative to Ctrl showing the pattern of changes 
(colour marked in left Y-axis) at both time points. Changes (increase or decrease) in abundance (≥1.5 
fold) shared at both 5 and 12 weeks are shown in orange. Abundance changes observed following 5 
weeks (≥1.5 fold) but not 12 weeks (<1.5 fold) of CPZ-feeding are shown in cyan. Proteoforms 
unchanged at 5 weeks (<1.5 fold) but changed after 12 weeks (≥1.5 fold) are shown in blue. 
 




Figure 9: Functional clustering 
Pie charts show the distribution of proteins according to a) Protein classes (characterized using 
PANTHER), b) Biological processes (categorised using GO) and c) Subcellular locations (categorised 
using UniProt). 
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Figure 10: Duration and treatment-dependent proteoform changes 
Log2 fold changes in abundance for 33 proteoforms relative to Ctrl showing the changes with CPZ 
(±PT) in the a) 5 week study or b) 12 week study. Changes only in PT groups at both 5 and 12 weeks 
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Table 2: Comparison of PT group to the PT+CPZ groups only 
Protein name 5 weeks 12 weeks 
Hexokinase 1 0.1PT=PT=0.2PT 0.1PT<PT 
Fructose-bisphosphate aldolase C 0.1PT>PT<0.2PT 0.1PT=PT 
Aconitate hydratase 0.1PT>PT<0.2PT 0.1PT>PT 
Succinate dehydrogenase flavoprotein subunit 0.1PT<PT>0.2PT 0.1PT<PT 
Malate dehydrogenase 0.1PT=PT>0.2PT 0.1PT=PT 
NADH dehydrogenase iron-sulfur protein 2 0.1PT>PT<0.2PT 0.1PT=PT 
ATP synthase subunit-α 0.1PT=PT=0.2PT 0.1PT<PT 
Voltage-dependent anion-selective channel protein 0.1PT<PT>0.2PT 0.1PT=PT 
Aspartate aminotransferase 0.1PT<PT>0.2PT 0.1PT<PT 
Ogdhl protein 0.1PT=PT=0.2PT 0.1PT<PT 
NAD-dependent protein deacetylase sirtuin-2 0.1PT>PT=0.2PT 0.1PT<PT 
Isovaleryl-CoA dehydrogenase 0.1PT=PT=0.2PT 0.1PT<PT 
Tyrosine-tRNA ligase 0.1PT<PT>0.2PT 0.1PT<PT 
Glutamate dehydrogenase 1 0.1PT=PT<0.2PT 0.1PT<PT 
Propionyl co-enzyme A carboxylase-β 0.1PT=PT=0.2PT 0.1PT<PT 
Creatine kinase U-type 0.1PT=PT>0.2PT 0.1PT=PT 
Rab GDP dissociation inhibitor-α 0.1PT<PT>0.2PT 0.1PT<PT 
Rab GDP dissociation inhibitor-β 0.1PT=PT=0.2PT 0.1PT=PT 
Vesicle-fusing ATPase 0.1PT=PT>0.2PT 0.1PT<PT 
Calcium/calmodulin-dependent protein kinase type II subunit-α  0.1PT=PT<0.2PT 0.1PT=PT 
Syntaxin-binding protein 1 0.1PT=PT=0.2PT 0.1PT<PT 
Dynamin 1 0.1PT>PT<0.2PT 0.1PT<PT 
Charged multivesicular body protein 0.1PT=PT=0.2PT 0.1PT=PT 
Glial fibrillary acidic protein 0.1PT=PT<0.2PT 0.1PT=PT 
Neurofilament light polypeptide 0.1PT<PT=0.2PT 0.1PT=PT 
Actin-related protein 2/3 complex subunit 5 0.1PT<PT>0.2PT 0.1PT=PT 
Septin-2 0.1PT>PT<0.2PT 0.1PT<PT 
Septin-5 0.1PT>PT=0.2PT 0.1PT<PT 
Guanine nucleotide-binding protein G(o) subunit-α 0.1PT=PT<0.2PT 0.1PT>PT 
Adipocyte plasma membrane-associated protein 0.1PT>PT<0.2PT 0.1PT=PT 
Calreticulin 0.1PT=PT<0.2PT 0.1PT=PT 
14-3-3 protein epsilon 0.1PT=PT=0.2PT 0.1PT=PT 
Leukocyte elastase inhibitor A 0.1PT=PT=0.2PT 0.1PT<PT 
Key: Significant (p<0.05) increases and decreases relative to PT are indicated by < and > symbols, 





In the behavioural tests, there were no detectable differences (p>0.05) between any groups in 
the latency to fall from the rotarod (Figure 1a) or inverted screen apparatus (Figure 1b). 
 
 
Figure 1: Behavioural changes induced by CPZ-feeding  
There were no significant differences between groups in the latency to fall using the rotarod 
(a) or inverted screen (b) tests in either study. Data are expressed as mean ± SEM. Two-way 
ANOVA and Tukey post hoc analysis were used to determine differences among groups (5-
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A B S T R A C T
The feeding of cuprizone (CPZ) to animals has been extensively used to model the processes of demyelination
and remyelination, with many papers adopting a narrative linked to demyelinating conditions like multiple
sclerosis (MS), the aetiology of which is unknown. However, no current animal model faithfully replicates the
myriad of symptoms seen in the clinical condition of MS. CPZ ingestion causes mitochondrial and endoplasmic
reticulum stress and subsequent apoptosis of oligodendrocytes leads to central nervous system demyelination
and glial cell activation. Although there are a wide variety of behavioural tests available for characterizing the
functional deficits in animal models of disease, including that of CPZ-induced deficits, they have focused on a
narrow subset of outcomes such as motor performance, cognition, and anxiety. The literature has not been
systematically reviewed in relation to these or other symptoms associated with clinical MS. This paper reviews
these tests and makes recommendations as to which are the most important in order to better understand the role
of this model in examining aspects of demyelinating diseases like MS.
1. Introduction
Demyelination in the human central nervous system (CNS) and the
resulting inflammatory responses are hallmarks of multiple sclerosis
(MS; Barnett and Prineas, 2004; Frischer et al., 2009; Stys et al., 2012).
MS is an incurable and chronic disease, often initiating in young adults
(Abe et al., 2000; Sivaraman and Moodley, 2016), that results in life-
long health, psychological, economic as well as social and healthcare
burdens (Compston and Coles, 2008; Constantinescu et al., 2011;
Hemmer et al., 2015). It affects approximately 2–3 million people
worldwide and is 2–3 times more prevalent in women than men
(Compston and Coles, 2008; Filippi et al., 2018). Patients with MS
suffer from a wide range of clinical symptoms which include motor
dysfunctions, pain, cognitive complications, depression, visual dis-
turbances, fatigue, sleep disorders and anxiety, all of which have a
detrimental effect on quality of life (Braley and Chervin, 2010; Cattaneo
et al., 2002; Goldenberg, 2012; Haussleiter et al., 2009; Jongen et al.,
2012; Kister et al., 2013; Larocca, 2011; O’Connor et al., 2008; Rahn
et al., 2012). Despite extensive research on MS since its first description
by the French neurologist Jean-Martin Charcot in 1868, the underlying
aetiology remains enigmatic (Clanet, 2008). The sheer number of re-
search publications on MS patients and animal models highlights the
significant effort invested to understand the disease process and de-
velop new medications. As of July 2018 there were over 79,584 pub-
lished articles on MS, with 12,629 on experimental autoimmune en-
cephalomyelitis (EAE) and 694 on cuprizone (CPZ) intoxication, the
two most widely used ‘animal models of MS’, listed in PubMed (https://
www.ncbi.nlm.nih.gov/pubmed/).
Approximately 85% of newly diagnosed patients, three-quarters of
whom are young women, have the relapsing remitting (RRMS) form of
https://doi.org/10.1016/j.neubiorev.2019.08.008
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MS, characterized by the disruption of the blood brain barrier (BBB)
and recurring episodes of focal demyelination in the brain, spinal cord
and/or optic nerve that result in neurological dysfunction followed by
spontaneous partial or complete remission (Compston and Coles, 2008;
Harbo et al., 2013; Partridge et al., 2015; Stys et al., 2012). After 8–20
years, the majority of RRMS patients (65–75%) transition to a sec-
ondary slow progressive form of MS (SPMS, non-relapsing) with less
inflammation but continuous neurological decline and atrophy in the
CNS (Compston and Coles, 2008; Kamm et al., 2014; Rovaris et al.,
2006; Stys et al., 2012; Trapp and Nave, 2008). A further 10% of pa-
tients suffer primary progressive MS (PPMS) that presents as a gradual
increase in neurological disability over time (Abdelhak et al., 2017;
Goldenberg, 2012). Compared with RRMS, PPMS onset appears later in
life and is more prevalent (˜70%) in men (Miller and Leary, 2007;
Nakahara et al., 2012). The fourth form is progressive relapsing MS
(PRMS), a relatively rare variant that affects only a small percentage of
MS patients (˜5%). PRMS is characterized by early disease onset with an
unpredictable combination of relapses and progression (Kremenchutzky
et al., 1999; Rovaris et al., 2006; Tullman et al., 2004). Depending upon
the severity of MS, it can also be divided into acute and/or chronic
stages. When patients die within a few years (˜1-2) of disease onset, this
is termed acute (i.e. very aggressive, Marburg type), whereas long term
ongoing disability is referred to as chronic (Lucchinetti et al., 2000; Stys
et al., 2012; Tievsky et al., 1999; Wood et al., 1996).
Many studies have considered MS as an autoreactive, ‘outside-in’
peripheral immune cell (T and/or B-cells) mediated attack on the CNS
components (e.g. myelin) that results in demyelination and an in-
flammatory response (Bernard and Kerlero de Rosbo, 1992; Compston
and Coles, 2008; Constantinescu et al., 2011; McFarland and Martin,
2007). However, others have focused on whether the aetiology is an
initial CNS oligodendrocytosis (i.e. degeneration and death of oligo-
dendrocytes) that leads to subsequent activation (and invasion) of
peripheral immune cells. Consequently, demyelination followed by an
autoimmune response in the CNS has been termed the ‘inside-out’ hy-
pothesis (Caprariello et al., 2018; Chaudhuri and Behan, 2004; Gulcher
et al., 1994; Partridge et al., 2015; Stys, 2013; Stys et al., 2012; Traka
et al., 2016; Trapp and Nave, 2008).
2. Multiple sclerosis (MS) patients and animal models
Detailed histological analyses of biopsy and autopsy samples from
MS patients have revealed a heterogeneous pattern of demyelination
and inflammation. Active lesions are categorized into four types (I-IV)
that share common features such as a reduction in myelin basic protein
(MBP), proteolipid protein (PLP), myelin oligodendrocyte glycoprotein
(MOG), or myelin associated glycoprotein (MAG) and an infiltration of
T-lymphocytes and macrophages. Type I and II lesions are defined by
the involvement of immunoglobulin G/complement complexes, with
limited oligodendrocyte (OLG) dystrophy, whereas type III and IV le-
sions are defined by marked apoptosis and depletion of mature OLG and
an intact BBB (Lassmann et al., 2001; Lucchinetti et al., 2000, 1996;
Popescu and Lucchinetti, 2012). The progression of pathological
changes appears as hyper-intense focal demyelination which is diag-
nosed clinically using magnetic resonance imaging (Hemond and
Bakshi, 2018).
In many fields of biomedical research animal models are used in an
effort to better understand disease pathophysiology and thus facilitate
biomarker identification and drug development (Perlman, 2016;
Rosenthal and Brown, 2007; Rust, 1982). The original observation that
repeated intramuscular injection of naïve rabbit brain extracts (derived
using Locke's solution with alcohol or alcohol/ether) resulted in
weakness, ataxia, weight loss in naïve monkeys and histological
changes including gliosis and perivascular demyelination in the CNS
demonstrated that demyelinating diseases can be modelled in animals
(Rivers et al., 1933). Extending this approach, peripheral injections
(e.g. peritoneal) of ‘myelin antigens’ into rodents has been widely used
to induce a state of experimental autoimmune encephalomyelitis (EAE).
In EAE, animals are injected with exogenous CNS antigens: either in
MBP, MOG, PLP or MAG plus complete Freund's adjuvant (CFA) that
activates and boosts peripheral immune cells (e.g. T and/or B-cells).
Upon subsequent breach of the BBB using pertussis toxin (PT), per-
ipheral autoreactive immune cells migrate into the CNS resulting in
demyelination. Approximately 6–10 days post immunization animals
begin to exhibit subtle motor deficits (e.g. a limp tail and hind limb
weakness) termed ‘early EAE’ and after 15–20 days (‘later EAE’), more
advanced symptoms of motor deterioration (e.g. hind limb paralysis)
are observed (Bjelobaba et al., 2018; Constantinescu et al., 2011;
Croxford et al., 2011; Jorgensen et al., 2007; Procaccini et al., 2015;
Terry et al., 2016). Although EAE is very heterogeneous in terms of the
induction and clinical presentation (Constantinescu et al., 2011), it is
the model of choice for immunologists as it is involving important
cellular immune mechanisms such as regulation of autoimmunity
(Krishnamoorthy and Wekerle, 2009). In contrast, in toxin-induced
models, such as CPZ, primary progressive oligodendrocytosis leads to
gliosis and demyelination in the apparent absence of autoimmunity
and/or BBB disruption (Partridge et al., 2016, 2015; Praet et al., 2014;
Skripuletz et al., 2011). Withdrawing CPZ results in the regeneration of
mature OLG from proliferating oligodendrocyte progenitor cells (OPC)
followed by remyelination (Bjelobaba et al., 2018; Kipp et al., 2009;
Mason et al., 2000; Praet et al., 2014; Skripuletz et al., 2011; Vega-
Riquer et al., 2017).
The extent to which behavioural and histological features of ex-
perimental models mimic the clinical features of human MS varies ac-
cording to the animal model used. In EAE, key features such as T-cell
invasion of the CNS, emergence of type I and II lesions (most notably in
the spinal cord), and the decline of motor functions, mimic those ob-
served in MS (Bjelobaba et al., 2018; Constantinescu et al., 2011)
whereas other clinical features such as oligodendrocytosis, demyelina-
tion, microglia/ macrophage activation and the emergence of type III
and IV lesions are observed in the CPZ model (Acs and Komoly, 2012;
Kipp et al., 2009; Torkildsen et al., 2008). The concordance and dis-
cordance (highlighted in bold black and bold grey, respectively, in
Table 1) in the pathological and functional features of MS with those
observed in EAE and CPZ animal models are summarised in Table 1.
The EAE animal model has proven useful to investigate autoimmune
mechanisms potentially involved in MS and the C57Bl/6 (B6) mouse
EAE model is the favoured paradigm to examine gene effects on auto-
immunity and T-cell responsiveness in transgenic/knockout mice
(Krishnamoorthy and Wekerle, 2009). This model has provided a
platform for preclinical assessment of therapeutics (e.g. Mitoxantrone,
Interferon-β and Fingolimod) which are now used as disease modifying
agents for MS patients (Constantinescu et al., 2011; Farooqi et al., 2010;
Vargas and Tyor, 2017). However, as EAE only and perhaps indirectly
mimics some aspects of the human disease, there is a need for alternate
animal models to better understand disease aetiology and develop more
broadly effective therapeutics (Table 1). The best alternative animal
model is CPZ due to its capacity to model demyelination and re-
myelination in the absence of a peripheral immune response. CPZ may
therefore be more useful to study the early, initiating events associated
with demyelinating diseases.
Feeding CPZ to rodents has been used extensively since the 1960s to
model and understand the processes underlying CNS oligoden-
drocytosis, demyelination, remyelination and glial cell activation;
however, very little is known regarding the resulting behavioural def-
icits. Behavioural assessments using animal models are particularly
important to understanding the pathophysiology of a disease and
identifying potential therapeutics (Sukoff Rizzo and Crawley, 2017).
There are more than 100 behavioural assays, including for motor
function, pain, anxiety, cognition, fatigue and depression-like pheno-
types that have been developed for assessing animal models of disease
(Crawley, 2008; Crawley and Paylor, 1997; Hanell and Marklund,
2014; Karl et al., 2003; Puzzo et al., 2014; Taylor et al., 2010; Van Meer
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and Raber, 2005). These are used as surrogate indicators of disease
states. Surprisingly, behavioural studies in the CPZ model are quite
limited and only concentrate on a small subset of outcomes such as
anxiety, motor functions and cognition (summarised in Table 2). Al-
though clinical MS includes a wide range of other symptoms such as
pain, depression, fatigue, visual and sleeping disturbances, these have
not been well characterized or reviewed systematically in the CPZ
model. Here, we critically review the CPZ behavioural literature ap-
pearing in PubMed from 1960 to 2018, and recommend better strate-
gies to improve understanding of the behavioural consequences of CPZ-
feeding in terms of clinical MS.
3. Search strategy and selection criteria
A PubMed literature search was carried out for papers published in
the English language between 1960 and July 2018 with the main focus
on studies published in the last 10 years due to the increasing number of
publications reporting behavioural testing in the CPZ model (Fig. 1).
3.1. Inclusion criteria
The search was carried out by combining the terms ‘MS and clinical
symptoms (motor, pain, fatigue, cognition, vision, depression, sleep,
anxiety and epileptic seizure), animal model of MS, CPZ animal model,
EAE animal model, behaviour and CPZ, behaviour and EAE’. The re-
ference lists associated with the identified publications were also as-
sessed and considered in preparing this review. In total, the present
literature search identified in total 694 publications listed from 1966 to
July 2018, of which 60 were behavioural studies and 24 were reviews
(Fig. 1).
3.2. Exclusion criteria
CPZ is also used to model Schizophrenia due to some similarities in
the changes of brain pathology and cognitive function (Praet et al.,
2014). In the assessment of the literature the analysis of ‘Schizophrenia-
like behaviour and therapeutics’ was limited by the small number of
relevant papers (Herring and Konradi, 2011; Sun et al., 2017; Wang
et al., 2013, 2015; Xiao et al., 2008; Xu et al., 2010, 2009). These were
considered to the extent that they examined the link between demye-
lination behaviour.
4. Cuprizone (CPZ) model
4.1. A brief history of the CPZ animal model
CPZ is an organic compound synthesized by reacting cyclohexanone
with oxaldyhydrazone (Carlton, 1967; Messori et al., 2007). It is com-
monly used to investigate the mechanisms of demyelination and re-
myelination in an effort to model human diseases such as MS (Kipp
et al., 2009; Matsushima and Morell, 2001; Praet et al., 2014; Skripuletz
et al., 2011; Vega-Riquer et al., 2017). The first observations of the
demyelinating properties of CPZ was reported in the mid-1960s
(Carlton, 1966, 1967; Carlton, 1969). From 1960–2000, papers largely
described the formation of mega-mitochondria in liver and CNS, oli-
godendrocytosis, inflammatory (especially innate immunity) responses,
demyelination and remyelination (Blakemore, 1972, 1973; Blakemore,
1974; Blakemore and Irvine, 2008; Hiremath et al., 1998; Hoppel and
Tandler, 1973; Mason et al., 2000; Morell et al., 1998; Petronilli and
Zoratti, 1990; Suzuki, 1969). A key study by Hiremath et al. (Hiremath
et al., 1998) characterized the optimal CPZ dose in B6 mice (the most
frequently used strain) to study de- and remyelination. From 2001
onwards, a substantial increase in the number of papers appearing in
PubMed (Fig. 1) reflected the increasing importance of CPZ in MS re-
search as this model was used to study the dynamics of oligoden-
drocytosis, demyelination and remyelination (Caprariello et al., 2018;
Gudi et al., 2014; Kipp et al., 2009; Tejedor et al., 2017; Traka et al.,
2016). Initially, changes in animal wellbeing, including weakness,
weight loss and lethargy, were assessed qualitatively using only un-
substantiated visual observations (De and Subramanian, 1982;
Petronilli and Zoratti, 1990; Suzuki and Kikkawa, 1969). However, the
first quantitative behavioural assessment was reported in 2006
(Liebetanz and Merkler, 2006) and coincided with the onset of a second
wave of publications (Fig. 1) examining CPZ-induced changes in be-
haviour (Franco-Pons et al., 2007). By comparing the histopathology
and apparent behavioural changes induced by CPZ, the first therapeutic
intervention trial, using a ‘Salmon diet’, showed decreased demyelina-
tion coupled with reduction of anxiety-like behavioural deficits
(Torkildsen et al., 2009).
4.2. Mode of induction and mechanism(s) of action of CPZ
To study behavioural deficits thought to model the different phases
of human MS, 0.2% (w/w) CPZ is fed to mice for 5–6 weeks resulting in
progressive, dose-dependent and highly reproducible demyelination in
CNS structures such as the corpus callosum, hippocampus, thalamus
and cerebellum (Goldberg et al., 2015; Hibbits et al., 2009; Kipp et al.,
2009; Praet et al., 2014; Skripuletz et al., 2010a; Vega-Riquer et al.,
2017; Yang et al., 2009). Within the first 1–3 weeks of CPZ-feeding
oligodendrocytosis is initiated and robust demyelination occurs by 4–5
weeks with the appearance of a glial (e.g. microglia and astrocytes)
response (summarized in Fig. 2; Gudi et al., 2014; Hiremath et al.,
1998) and this is termed the ‘acute phase’. Resolution of gliosis and
remyelination occurs when new mature OLG regenerate from OPC
following cessation of CPZ-feeding at this early time point (Gudi et al.,
2014, 2009; Hiremath et al., 1998; Mason et al., 2000). Prolonged
feeding of CPZ for 12–14 weeks produces a ‘chronic response’ thought
Table 2
Comparison of clinical symptoms of MS vs. behavioural assessment used in CPZ
studies. The frequency of MS was measured from clinical prevalence whereas
CPZ was measured by the number of publications.









Epileptic seizure 2-3 2
Fig. 1. Timeline of publications using the CPZ model.
Studies after 2000 are plotted on an expanded time scale. The vertical dashed
line denotes the start of publications reporting quantitative behavioural testing
in CPZ.
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to model the later stages of MS. This prolonged feeding results in long-
term demyelination, extensive gliosis, a marked decrease of the normal
age related weight gain and increased mortality (Hibbits et al., 2009,
2012; Kipp et al., 2009; Lindner et al., 2009; Skripuletz et al., 2011).
The aetiology of CPZ-induced demyelination is incompletely un-
derstood. Studies have defined CPZ as an ‘oligotoxic’ compound,
somewhat selectively affecting mature OLG, both in vitro and in vivo,
leading to demyelination (Benardais et al., 2013; Cammer, 1999; Gudi
et al., 2014; Mason et al., 2000; Matsushima and Morell, 2001). CPZ
causes copper chelation (Matsushima and Morell, 2001) that may
subsequently lead to other metal ion imbalances (e.g. iron, zinc, sodium
and manganese) in different parts of the body such as the brain and
liver (Moldovan et al., 2015; Varga et al., 2018; Venturini, 1973; Zatta
et al., 2005). Consequently, mitochondrial (Acs et al., 2013; Benardais
et al., 2013; Hoppel and Tandler, 1973; Partridge et al., 2016; Pasquini
et al., 2007; Solti et al., 2015; Werner et al., 2010) and endoplasmic
reticulum (ER; Abe et al., 2015; Hemm et al., 1971; Lin et al., 2006;
Love, 1988; Partridge et al., 2016; Praet et al., 2014; Stone and Lin,
2015; Suzuki and Kikkawa, 1969) stress occur. This then results in re-
duced adenosine triphosphate production, the unfolded protein re-
sponse and increased production of reactive oxygen and nitrogen spe-
cies (Faizi et al., 2016; Praet et al., 2014; Wagner and Rafael, 1977).
OLG stress results due to the reduced energy supply from mitochondria
and reduced levels of detoxifying enzymes such as manganese super-
oxide dismutase and glutathione peroxidase (Liblau et al., 2001;
McLaurin and Yong, 1995; McTigue and Tripathi, 2008; Omotoso et al.,
2018). The cumulative result is oligodendrocytosis resulting in the loss
of myelin from axons (Gudi et al., 2014; Kipp et al., 2009; Matsushima
and Morell, 2001; Praet et al., 2014). Microglia and astrocytes are ac-
tivated to facilitate clearance of myelin debris. Inadequate clearance of
myelin debris and extensive gliosis are associated with the secretion of
toxic substances such as nitric oxide that exacerbate oligodendrocytosis
and demyelination (summarized in Fig. 3; Gudi et al., 2014; Lampron
et al., 2015; Linares et al., 2006; Skripuletz et al., 2013). All of these
processes can contribute to axonal damage (see below).
As well as causing white matter axonal damage (Clarner et al., 2015;
Hoflich et al., 2016; Schultz et al., 2017; Slowik et al., 2015), CPZ can
also induce axonal damage identified by the histological accumulation
of amyloid precursor protein along axons in grey matter regions such as
the thalamus (Wagenknecht et al., 2016). This persists even after re-
myelination occurs (Lindner et al., 2009; Manrique-Hoyos et al., 2012).
Axonal damage can evoke Wallerian degeneration of the distal axon
and loss of synaptic contacts, and so can contribute to the prolonged
disability and functional deficits (reviewed by Nyamoya et al., 2017).
Although both in vitro and in vivo studies have argued that CNS neu-
rons are resistant to CPZ-induced injury (Acs and Komoly, 2012;
Benardais et al., 2013; Benetti et al., 2010; Namekata et al., 2014; Sun
et al., 2016). CPZ has been reported to induce glutamate excitotoxicity
/ synaptotoxicity (Azami Tameh et al., 2013; Dutta et al., 2013) via
differential effects on the expression of glutamate receptor subunits. For
example, CPZ-feeding produced upregulation of the NR2A subunit of
the N-methyl-D-aspartate receptor in the corpus callosum and down
regulation of the metabotropic glutamate receptor subunit mGluR2 in
the cortex (Azami Tameh et al., 2013). Similarly, reduced expression of
ionotropic amino-3-hydroxy-5-methyl-4-isoxazole propionic acid glu-
tamate receptors was found in hippocampal neurons (Dutta et al.,
2013). These events were associated with reduced spatial memory
functions suggesting that synaptotoxicity, in addition to demyelination,
contributes to altered behavioural outcomes (Dutta et al., 2013).
The BBB remains intact following CPZ-feeding restricts peripheral
adaptive immune cell (i.e. T or B-cell) infiltration into the CNS
(McMahon et al., 2002), whereas reactive adaptive immune cells pre-
dominate in human MS. Thus, the CPZ model may be useful to explore
the underlying mechanisms involved in both the earliest as well as the
later progressive stages of MS that are not dependent on the infiltration
of adaptive immune cells into the CNS. However, T-cell infiltration into
the CNS in the CPZ model has recently been reported when BBB dis-
ruption was combined with an ‘immune booster’ to investigate the
Fig. 2. Schematic representation of CPZ-in-
duced demyelination and remyelination in the
corpus callosum.
CPZ-feeding causes depletion of mature OLG
that starts within 1 week and results in con-
tinuous demyelination until the cessation of
CPZ-feeding or death. The appearance of OPC
occurs simultaneously with the degeneration of
mature OLG leading to remyelination. Glial
(microglia and astrocytes) activation is in-
versely proportional to mature OLG damage;
increasing degeneration of mature OLG accel-
erates the activation of glial reactivity.
Commonly, 7–8 week old B6 mice are fed 0.2%
CPZ for 5–6 weeks in order to develop ‘acute’
demyelination. Feeding for 10–15 weeks
causes ‘chronic’ demyelination. Greater than
0.2% CPZ or prolonged feeding induces ‘se-
vere’ demyelination and increases mortality
rates.
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‘inside-out’ hypothesis of MS (Caprariello et al., 2018), suggesting that
human MS may well start via a CNS dysregulation that then leads to
infiltration by peripheral cells.
5. Behaviour
5.1. Behavioural phenotypes
Although MS is considered a highly debilitating neurological dis-
order, there are many aspects of health that remain relatively normal
despite the emergence of symptoms linked to different parts of the CNS
(e.g. brain and spinal cord). For example, comparing the age and weight
of MS patients with healthy matched controls, only small differences in
total life span (Compston and Coles, 2008) and weight gain are ob-
served (Markianos et al., 2013). However, EAE animals are lethargic
and show weight loss, presumably as a consequence of motor paralysis
restricting their ability to eat (Jorgensen et al., 2007; Xin et al., 2015).
Qualitative observations between 1969–1990 suggested that CPZ in-
gestion produced ‘sickness-like behaviour,’ and increased mental
weakness in juvenile mice (De and Subramanian, 1982; Morell et al.,
1998; Petronilli and Zoratti, 1990; Suzuki and Kikkawa, 1969). In
contrast, since 1998, young (7–8 weeks old) B6 mice are widely used,
and quantitative assessment documented reduced weight gain and in-
creased activities such as locomotion, climbing and rearing but without
muscle paralysis (Chang et al., 2017; Franco-Pons et al., 2007; Morell
et al., 1998; Stidworthy et al., 2003; Yang et al., 2009).
Quantitative measurements of aspects of CPZ-induced behavioural
deficits have been investigated with a preferential focus on motor,
anxiety and cognitive behaviours. However, there is a clear mismatch
between the prevalence of clinical symptoms observed in human MS
and the application of relevant behavioural assessments in CPZ-fed
animals (see Table 2). This was most notable for the more prevalent
symptoms of pain and visual disturbances, for which there are well
validated animal behavioural tests (Deuis et al., 2017; Karl et al., 2003;
Namekata et al., 2014). A limited number of recent CPZ studies have
also assessed animals for depression and epileptic seizures (Hoffmann
et al., 2008; Kondo et al., 2016; Lapato et al., 2017). The general
parameters for the various quantitative behavioural tests assessing
changes in motor function, pain, fatigue, cognition, vision, depression,
sleep, seizure and anxiety in animal models are documented in Table 3.
5.2. Motor phenotypes in CPZ studies
Around 80% of MS patients have disturbances in motor functions
including difficulties in maintaining balance, reduced walking speed
and impaired dexterity of the hands and feet (Benedict et al., 2011;
Cattaneo et al., 2002; Larocca, 2011; Pellegrino et al., 2018). Human
studies show demyelination in different CNS structures including the
Fig. 3. Schematic representation of the proposed mechanism of action underlying CPZ-induced OLG stress and demyelination.
Oral ingestion of CPZ in rodents leads to a dysregulation of ER and mitochondrial functions resulting in apoptosis of OLG and subsequent formation of myelin debris
that, in turn, activates glial cells such as microglia and astrocytes that produce inflammatory molecules, further exacerbating the OLG degeneration process. The
intact BBB limits peripheral B or T-cell entry into the CNS.
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































M.K. Sen, et al. Neuroscience and Biobehavioral Reviews 107 (2019) 23–46
29
cerebellum and spinal cord (Cameron et al., 2008; Gilmore et al., 2006)
which have been associated with these motor deficits (D’Ambrosio
et al., 2017; Parmar et al., 2018; Wilkins, 2017). In animal models,
deficits in motor function can be investigated using a wide range of
behavioural tools including rotarod, complex wheel, walking beam,
walking ladder, pole, negative geotaxis, hanging steel wire and forelimb
reaching tests (Elbaz et al., 2018; Hibbits et al., 2009; Karl et al., 2003;
Klein and Dunnett, 2012; Ray et al., 2017; Schaar et al., 2010; Soblosky
et al., 2001).
The rotarod apparatus is one of the most widely used tools to
measure motor phenotypes in CPZ-fed mice (Abakumova et al., 2015;
Bolcskei et al., 2018; Chang et al., 2017; Elbaz et al., 2018; Faizi et al.,
2016; Franco-Pons et al., 2007; Hagemeyer et al., 2012; Hashimoto
et al., 2017; Iwasa et al., 2014; Kondo et al., 2016; Kumar et al., 2018;
Sanadgol et al., 2018; Wang et al., 2016; Yamamoto et al., 2014, 2017;
Ye et al., 2013; Yoshikawa et al., 2011; Zhang et al., 2016). In this test,
rodents are placed on a rotating drum that progressively increases its
speed (from 4 to 40 rpm) over the course of the testing period (˜300 s).
Animals with motor and/or coordination impairment show a decreased
capacity to remain on the rod (latency to fall), decreased time to first
rolling and increased number of rotations/flips (i.e. the animal rotates
freely with the rod, but does not fall off; Bolcskei et al., 2018; Chang
et al., 2017; Franco-Pons et al., 2007; Hagemeyer et al., 2012; Kondo
et al., 2016). For example, in the EAE model, the latency to fall from the
rod correlated with the severity of the clinical motor score (Miller and
Karpus, 2007; van den Berg et al., 2016). In CPZ studies, while some
groups reported decreased latency to fall (Abakumova et al., 2015;
Elbaz et al., 2018; Faizi et al., 2016; Franco-Pons et al., 2007;
Hashimoto et al., 2017; Iwasa et al., 2014; Kumar et al., 2018; Sanadgol
et al., 2018; Wang et al., 2016; Yamamoto et al., 2017; Yoshikawa et al.,
2011; Zhang et al., 2016) others reported no change in rotarod per-
formance (Bolcskei et al., 2018; Chang et al., 2017; Hagemeyer et al.,
2012; Kondo et al., 2016). Conflicting reports by different groups using
the same instrument highlight the need for comprehensive reporting of
all test parameters; for instance, when the latency to fall was reported
with a duration of 300 s results were variable, whereas attention to
other parameters, such as the number of flips (Yamamoto et al., 2014)
or increasing the duration of the test to 600 s revealed changes in motor
function (Iwasa et al., 2014). Alternatively, the demands of the test may
be insufficient to detect subtle changes in coordination. Such arguments
are supported by the capacity of the complex wheel (complex wheel;
see below) apparatus to detect changes within 2 weeks of CPZ-feeding
and consistent results in the walking beam test within 5 weeks of CPZ-
feeding (see below). There have been attempts to account for this
variability by relating changes in motor performance with the presence
of demyelination within the corpus callosum (Franco-Pons et al., 2007;
Hagemeyer et al., 2012; Liebetanz and Merkler, 2006; Manrique-Hoyos
et al., 2012; Skripuletz et al., 2015, 2010b; Yoshikawa et al., 2011);
however, these analyses did not include an animal-by-animal correla-
tion between motor performance and the extent of demyelination.
Four studies used the complex wheel to test for changes in motor
performance and deficits were found within 2–3 weeks of CPZ-feeding
(Hibbits et al., 2009; Liebetanz and Merkler, 2006; Manrique-Hoyos
et al., 2012; Mierzwa et al., 2013). In this test, animals are familiarized
and trained on a freely accessible, automated running wheel (˜38 reg-
ularly spaced rungs) in their home cage. During the testing session the
wheel is made complex by randomly removing rungs (˜10 rungs) thus
creating variable step intervals. Changes in the total distance run,
maximum velocity during daily runs, number of runs and maximum run
interval are used to quantify motor performance (Hibbits et al., 2009;
Liebetanz and Merkler, 2006; Manrique-Hoyos et al., 2012; Mierzwa
et al., 2013). The presence of a comprehensive suite of variables
(Table 3) such as running speed, distance run in a day and the ability to
assess foot placement precision (motor coordination) suggest that this
test is superior to the rotarod in assessing the impact of CPZ-induced
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If, as indicated above, subtle motor changes can be detected with
increasing task complexity, it is equally plausible that a more detailed
assessment of normal locomotor function can provide increased sensi-
tivity and thus detect earlier changes in motor behaviour. For example,
when the capacity of animals to cross an elevated (˜40-50 cm) hor-
izontal walking beam that becomes progressively narrower at one end
(e.g. decreasing from 10 to 11 mm to 7–8 mm over a length of 70–80 cm
- the walking beam test) was quantified, CPZ-fed animals took longer to
cross the beam and showed more foot slips (mainly hind limbs) than
controls (Hagemeyer et al., 2012; Ray et al., 2017; Skripuletz et al.,
2015, 2010b; Zheng et al., 2017). However, even using this test, in-
consistent and/or unclear observations were found. For example, in
some cases, only the time to cross the narrowing beam was measured,
without assessing foot slips (Skripuletz et al., 2015, 2010b; Zheng et al.,
2017) or which limbs slipped (Ray et al., 2017). Moreover, the studies
were conducted only once or twice during the 5–6 weeks of CPZ-
feeding, and thus did not describe the progression of motor decline
during CPZ-feeding (Ray et al., 2017; Skripuletz et al., 2015, 2010b;
Zheng et al., 2017), nor did they provide behavioural baseline data
prior to CPZ-feeding (i.e. animals were learning the test during the
experimental period). It is recommended that all parameters (e.g.
crossing time, number of fore- and hind foot slips) be assessed in order
to detect any possible motor deficits in the CPZ model.
Another complex locomotor task is the walking ladder (or grid
walk) test. This enables the measurement of fore- and hind-limb co-
ordination and accuracy of paw placement on the rungs. The apparatus
is constructed as an elevated (13–16 cm) horizontal walk-way 60–70 cm
long, in which the width of the walkway approximates the girth of the
test animal (e.g. ˜3–4 cm for mice and 8–10 cm for rats). A lamp is
placed at the start to encourage the animal to cross the narrow and
confined corridor with evenly spaced rungs along the base. The com-
plexity of the task can be increased by withdrawing rungs from the base
of the walkway. The time to cross the ladder and the number of foot
slips are recorded (Table 3). Deficits in motor function correlate with
increased foot slips and longer crossing times (Jacobi et al., 2015; Kim
et al., 2013; Pollak et al., 2012; Schaar et al., 2010). The main ad-
vantage of the walking ladder over instruments such as the rotarod or
walking beam is that the walking ladder apparatus can readily detect
foot placement errors and that fore limb impairment is easier to mea-
sure. Therefore, it can be hypothesised that due to the complexity of the
walking ladder the foot misplacement of CPZ-fed animals will increase,
which remains to be tested.
In contrast to the walking beam and walking ladder tests, the pole
test assesses the ability of an animal to descend a vertical pole. In this
test, animals are placed head-up on the top of a vertical pole (generally
50–60 cm long, ˜1 cm2 diameter) with the base typically located in their
home cage. Again, the complexity of the test can be increased by pla-
cing regular (or irregular) windings around the circumference to vary
the capacity of the animal to grip the pole during its descent. The time
to turn head downward (T-turn) and total time to descend to the base
are recorded. Animals with impaired coordination take more time to T-
turn and to descend (Matsuura et al., 1997; Rommelfanger et al., 2007;
Zieba et al., 2015). Only one publication has used this test, showing that
CPZ-fed animals took longer to descend the pole, thus suggesting im-
paired motor function (Zheng et al., 2017).
In the negative geotaxis test, animals are placed head facing down
on an inclined (30-45°) platform; the greater the time taken to reor-
ientate the head to an upward direction and to reach the top of the
inclined platform, the greater the presumed deficits in motor function
(Heier and DiDonato, 2009; Thiessen and Lindzey, 1967). In a single
study, CPZ-fed mice took more time to reach the top of the platform
suggesting diminished motor function (Ray et al., 2017). Likewise, a
single study used a hanging steel wire (2 mm in diameter and 35 cm
long) to measure strength/motor function of CPZ-fed mice. When mice
were allowed to hang using their forepaws, the duration time to release
was reduced in CPZ-fed animals suggesting decreased muscle strength
and/or motor functions (Elbaz et al., 2018).
The forelimb reaching is a sensitive test used to evaluate fine, vo-
luntary motor function after stroke, spinal cord injury or unilateral
brain damage (Klein and Dunnett, 2012; Schaar et al., 2010; Streijger
et al., 2013). In this test, rodents are placed in a clear plexiglass box
with a narrow slit through which to grab a food pellet placed outside.
The animals are first trained in the task, followed by actual test ses-
sions. To motivate pellet retrieval, animals can be deprived of food (e.g.
overnight) prior to testing (Chen et al., 2014; Schaar et al., 2010). The
frame-by-frame assessment of the actual grasping movement includes
quantification of the time to reach the pellet, success rate, paw pre-
ference, and number of pellets consumed in a given time is recorded.
Animals with compromised motor function show a reduced success rate
to grasp food. The unique advantage of this task is that the capacity of
the fore limb can be easily assessed (Klein and Dunnett, 2012; Schaar
et al., 2010). For example, following brain or spinal cord injury in ro-
dents, a reduced success rate of reaching for a food pellet is seen,
suggesting motor impairment (Gharbawie et al., 2005; Metz et al.,
2005; Streijger et al., 2013). Unfortunately, this test has never been
used in the CPZ model.
In summary, a wide variety of tests exist to assess motor function.
Whilst the rotarod is the most commonly used test, it is the least sen-
sitive and reliable. Subtle deficits (e.g. decreased walking speed and
increased limb misplacement) that arise from CPZ-feeding become
evident as the complexity of the test is increased. For instance, the
walking beam and complex wheel tests detected changes in motor co-
ordination activity (Hagemeyer et al., 2012; Hibbits et al., 2009;
Skripuletz et al., 2010b; Yokoi et al., 2011). Moreover, most published
CPZ motor studies only used a single motor test, the rotarod. Only three
papers used two motor tests in the same study and these produced
conflicting results depending on the test used i.e. deficits were detected
in walking beam, pole and negative geotaxis tests but not with the
rotarod (Hagemeyer et al., 2012; Ray et al., 2017; Zheng et al., 2017).
Indeed, the more complex tasks appear to measure quite different as-
pects of motor performance: whereas the rotarod assesses the capacity
of a quadruped to maintain their centre of gravity over a rotating beam
(i.e. not fall off), a task that may be equally well resolved by poorly
coordinated foot placement or holding onto and rotating with the rod.
In contrast, the walking beam, walking ladder and complex wheel
measure the capacity of animals to make coordinated limb placements
when challenged by a narrow walkway or the complex/varying foot
placements demanded by the complex wheel, conditions that reveal
functional deficits not detected by the rotarod (Table 3).
Since the complex wheel has the capacity to measure multiple
parameters and animals are free to engage in the task within their home
cage without experimenter intervention, this test is able to discern
early, developing deficits (i.e. within 2–3 weeks of CPZ-feeding) and
provide reproducible results across different labs; this would thus ap-
pear to be one of the best available tools to measure motor performance
(Hibbits et al., 2009; Liebetanz and Merkler, 2006; Manrique-Hoyos
et al., 2012; Mierzwa et al., 2013). However, the attribution of deficits
to motor functions may be confounded when cognitive function is also
compromised (Cui et al., 2018; Dutta et al., 2013; Li et al., 2015;
Murakami et al., 2017; Omotoso et al., 2018; Shao et al., 2015; Tezuka
et al., 2013) due to demyelination and gliosis in cortical memory cir-
cuits and cerebellar systems (Goldberg et al., 2015; Koutsoudaki et al.,
2009; Norkute et al., 2009; Skripuletz et al., 2010a). Therefore, it be-
comes difficult, if not impossible, to separate the contribution of the
cognitive versus motor systems based only on behavioral readouts.
Importantly, pathological changes in the areas/pathways re-
sponsible for behavioural motor deficits in the CPZ model have been
poorly studied. Many papers use demyelination of the corpus callosum
as a proxy for demyelination of the CNS as a whole, rather than fo-
cusing on demyelination in CNS regions relevant to, for example, motor
function, making correlations to causality less reliable (Abakumova
et al., 2015; Bolcskei et al., 2018; Chang et al., 2017; Faizi et al., 2016;
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Franco-Pons et al., 2007; Hagemeyer et al., 2012; Hashimoto et al.,
2017; Hibbits et al., 2009; Iwasa et al., 2014; Kumar et al., 2018;
Liebetanz and Merkler, 2006; Manrique-Hoyos et al., 2012; Sanadgol
et al., 2018; Wang et al., 2016; Yamamoto et al., 2014, 2017; Yu et al.,
2018). In this context, it is essential to point out that current reports
have failed to show spinal cord demyelination and gliosis with CPZ (Acs
et al., 2013; Herder et al., 2011; Love, 1988; Ray et al., 2017). This is
unlike the EAE animal model in which the major site of demyelination
and gliosis is the spinal cord white matter (Table 1), and at least cor-
relates with the severe difficulty in walking that occurs ˜10-14 days
after induction (Duffy et al., 2016; Dutra et al., 2013; Heckman et al.,
2013). Further, far more detailed studies are required to closely ex-
amine CPZ-induced changes in the ascending and descending pathways
involved in motor behaviour.
5.3. Pain-like symptoms
Many MS patients (29–86%) report pain-related symptoms such as
mechanical, heat and/or cold hyperalgesia (Table 2; Hadjimichael
et al., 2007; Kenner et al., 2007; Khan et al., 2018; Khan and Smith,
2014; Svendsen et al., 2003). The mechanism(s) of neuropathic pain in
MS is not clearly understood. In the context of MS, the mechanisms
involved in pain-like behaviours have been inferred from animal studies
on peripheral nerve injury (Wang et al., 2017a), oligodendrocytosis
(Gritsch et al., 2014), and inflammation in the spinal cord (Duffy et al.,
2016; Lu et al., 2012) and brain stem (Duffy et al., 2016; Thorburn
et al., 2016). Given the marked incidence of painful sensations in MS
patients, it is surprising that only a few studies have assessed pain-re-
lated behaviour in the CPZ model (Table 3). Pain-like behaviours in
animals are most often measured using flexion withdrawal reflexes
evoked by electrical, mechanical and heat or cold stimuli (Barrot, 2012;
Deuis et al., 2017; Deuis and Vetter, 2016; Duffy et al., 2016; Savage
and Ma, 2015; Thorburn et al., 2016).
Mechanical stimuli can be measured using manual von Frey fila-
ment or electronic devices such as the Dynamic plantar aesthesiometer
apparatus (Chew et al., 2013; Deuis et al., 2017; Shaikh et al., 2016).
The use of manual von Frey filament commonly involves the use of the
‘up-down’ method (Chaplan et al., 1994) to determine the withdrawal
threshold. This is subject to inter-experimenter variability as well as
differential application of filament bending strength (on a logarithmic
scale) to the paw (i.e. not a true reflection of the applied force). The
electronic von Frey filament uses a linear, increasing force to elicit
withdrawal in an automated controlled manner. However, in some test
areas, such as the face, it is more practical to use manual von Frey
filament to examine threshold changes than electronic von Frey fila-
ment (Duffy et al., 2016). Only one study has evaluated mechanical
threshold changes in CPZ-fed animals (Bolcskei et al., 2018). Both
manual and electronic von Frey filaments stimuli have been applied to
the hind paws of mice. The results showed no differences between CPZ
and control mice with either method; however, more consistent and
reliable results were obtained using electronic than manual von Frey
filaments (Bolcskei et al., 2018). In EAE, studies using both electronic
(Rodrigues et al., 2009) and manual von Frey filaments (Duffy et al.,
2016; Lu et al., 2012; Serizawa et al., 2018) indicated mechanical hy-
persensitivity in the early stage (i.e. prior to motor paralysis), sug-
gesting increased pain-like behavioural deficits.
Similar flexion withdrawal responses to heat sources are measured
using the Hargraves apparatus, or the tail flick test in which a heat
source is applied to the tail or paw with a set cut-off time to avoid tissue
burn and the time taken to elicit a withdrawal reflex is recorded (Deuis
and Vetter, 2016; Samour et al., 2017). In a single study using the tail
flick response to immersion in hot water (50–60 °C), no difference be-
tween control and CPZ-fed animals was observed (Vakilzadeh et al.,
2016). In contrast, development of thermal hyperalgesia occurs during
the early (Lu et al., 2012; Thibault et al., 2011) and later stages of the
EAE model (Lu et al., 2012; Schmitz et al., 2014). Histological
examination of EAE mice revealed a reduction in abundance of neu-
ronal nuclei (a neuron-specific nuclear protein), gliosis (Duffy et al.,
2016; Lu et al., 2012; Schmitz et al., 2014), demyelination, and T-cell
infiltration (Duffy et al., 2016; Schmitz et al., 2014) mainly in the
lumbar spinal cord. However, in CPZ, the single study examining gliosis
did not identify an effect in the spinal cord (Herder et al., 2011), con-
sistent with other studies that have shown no evidence of CPZ-induced
demyelination in this area (Herder et al., 2011; Love, 1988; Ray et al.,
2017). In contrast, a recent study using electrical activation of per-
ipheral nerves revealed a decrease in the electrical threshold to evoke a
withdrawal response following 2 weeks of CPZ-feeding suggesting that
sensory information may be subtly altered even at this early stage
(Tsukahara et al., 2018).
Sensitivity to cold in rodents is measured using the cold plantar,
temperature preference, cold plate or acetone evaporation tests (Deuis
et al., 2017; Shaikh et al., 2016). In these tests, animals are placed on a
cold plate (or exposed to focal cooling stimuli) and the emergence of
nociceptive responses such as jumping, shaking, flinching or licking are
taken to be indicative of pain-like symptoms (Deuis et al., 2017; Shaikh
et al., 2016). The emergence of pain-like behaviours to cool stimuli
(that do not normally evoke pain-like behaviours) is referred to as cold
allodynia and appears to be a more sensitive measure of changes in
sensory function (Samour et al., 2017; Shaikh et al., 2016). No studies
have evaluated cold hypersensitivity in CPZ-treated animals whereas
increased paw withdrawal responses are found early in EAE animals
(Table 3; Schmitz et al., 2014; Thibault et al., 2011).
Trigeminal neuralgia, sudden and sharp episodes of facial pain, is
more prevalent in patients with MS (Fallata et al., 2017; Khan and
Smith, 2014). It is suggested that facial pain in rodents can be measured
using the air puff or manual von Frey filament tests, although the po-
tential relationship to trigeminal neuralgia (or an animal correlate) has
not been directly established (Duffy et al., 2016; Thorburn et al., 2016).
In the air puff test, facial hypersensitivity is quantified by measuring
parameters such withdrawal of head from the stimulus probe and/or
forepaw swipes down the snout. The increased frequency of these ac-
tivities is suggested to indicate pain-like symptoms such as allodynia
and hyperalgesia. One study using EAE showed that during the early
and late (i.e. motor decline stage) stages air puff scores increased sug-
gesting facial pain sensitivity (Thorburn et al., 2016). In addition,
spontaneous pain can be measured by quantifying changes in facial
expression using a grimace scale that includes orbital tightening, nose
bulge, cheek bulge, ear position and whisker change, with scores of ‘not
present’ to ‘severe’ (Langford et al., 2010; Sotocinal et al., 2011).
During the later stages of EAE, changes in facial expression were also
found, further suggesting increased pain-like behaviour (Duffy et al.,
2016). T-cell recruitment, glial activation and demyelination in the
trigeminal primary afferent pathway, trigeminal sensory root and the
spinal trigeminal tract have been suggested to trigger facial hy-
persensitivity in EAE (Duffy et al., 2016; Thorburn et al., 2016).
However, no studies have assessed facial sensitivity in CPZ animals.
In summary, limited studies in CPZ-fed animals have not provided
reliable evidence of changes in nociceptive reflex thresholds. In addi-
tion, as with motor behaviour, histological investigations in these stu-
dies were conducted only in the corpus callosum (Bolcskei et al., 2018;
Tsukahara et al., 2018; Vakilzadeh et al., 2016) rather than in relevant
regions of the pain matrix such as the dorsal root ganglia, spinal cord or
trigeminal grey and white matter, thalamus, somatosensory and limbic
cortices. Therefore, further studies are necessary to draw clearer con-
clusions about nociceptive behavioural deficits in the CPZ model.
5.4. Fatigue
Exhaustion, physical tiredness and insomnia are common clinical
symptoms reported by ˜75% of MS patients (Table 2), commonly coa-
lescing as a sense of fatigue (Braley and Chervin, 2010; Lerdal et al.,
2007; Mills and Young, 2011). The mechanisms leading to increased
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fatigue in MS are poorly understood but have been loosely attributed to
neurochemical imbalances (i.e. of dopamine, serotonin (Dobryakova
et al., 2015; Newland et al., 2016) or melatonin (Melamud et al., 2012))
or thalamic (Minagar et al., 2013) and hypothalamic (Burfeind et al.,
2016) demyelination. Interestingly, in animal models, the behavioural
focus has been on tests of physical endurance such as the upside down
grid (Bolcskei et al., 2018; Ruiz et al., 2015) and voluntary wheel
running (Grace et al., 2017; Hicks et al., 2016) to measure fatigue-like
behaviour (Table 3).
The upside down grid test is used to quantify fatigue-like behaviour
and strength (Bolcskei et al., 2018; Ruiz et al., 2015). Briefly, test an-
imals are placed on a wire mesh which is inverted and the time taken to
release their grasp is measured, with decreased time representing fa-
tigue-like behaviour (Bolcskei et al., 2018; Deacon, 2013; Meinen et al.,
2012; Ruiz et al., 2015). CPZ-fed mice displayed responses indis-
tinguishable from controls in this test (Bolcskei et al., 2018). The vo-
luntary wheel running test lacks the complexity of complex wheel but
does allow individually housed animals unrestricted access; total run-
ning time, distance travelled and speed parameters can be recorded
(Grace et al., 2017; Hicks et al., 2016). The advantage of voluntary
wheel running over the upside down grid is the autonomous nature of
the instrument which allows animals to move freely and spontaneous
activities over time can be observed. Decreased voluntary movement in
EAE animals indicates fatigue-like symptoms in the early and later
stages (Grace et al., 2017). However, in EAE animals, many behavioural
tests are limited to the early phase as the later phase is confounded by
progressive motor paralysis. In CPZ-fed animals, the usefulness of the
voluntary wheel running test has not yet been determined. In addition,
results of fatigue studies may be confounded by sensorimotor deficits,
sleep disturbances or depression. For example, people with MS have
high rates of fatigue, depression, and sleep disturbances coupled with
decreased motor function (Attarian et al., 2004; Pardini et al., 2013;
Pokryszko-Dragan et al., 2013). Whether such motor and sleep deficits,
or depression also affect fatigue measures in CPZ-fed animals remain to
be investigated.
5.5. Cognitive deficits
MS patients (40–65%) experience cognitive impairment (Table 2)
that manifests as decreased memory, language, executive functions and
social interactions (Jongen et al., 2012; Rahn et al., 2012). The extent of
demyelination and inflammation processes in the CNS, especially in the
limbic system (e.g. hippocampus, fornix and cingulum; Damjanovic
et al., 2017; Keser et al., 2018; Rocca et al., 2018; Sacco et al., 2015),
and cerebellum (Valentino et al., 2009; Weier et al., 2014; Wilkins,
2017) have been suggested to have a role in the cognitive decline.
Cognitive behaviour in animals can be assessed using the Y-maze, novel
object recognition, social interaction, Morris water maze and fear
conditioning tests (Table 3; Campos et al., 2013; Karl et al., 2003;
Taylor et al., 2010; Webster et al., 2014; Zhang et al., 2012; Zieba et al.,
2015). CPZ-fed animals showed decreased memory functions and im-
paired social interaction as assessed by these tests (Abakumova et al.,
2015; Adilijiang et al., 2015; Aryanpour et al., 2017; Chang et al., 2017;
Cui et al., 2018; Dutta et al., 2013; Hibbits et al., 2009; Kondo et al.,
2016; Li et al., 2015; Makinodan et al., 2009; Murakami et al., 2017;
Omotoso et al., 2018; Ray et al., 2017; Serra-de-Oliveira et al., 2015;
Shao et al., 2015; Sun et al., 2017; Tezuka et al., 2013; Valeiras et al.,
2014; Wang et al., 2015; Xiao et al., 2008; Xu et al., 2010, 2011; Xu
et al., 2009).
The Y-maze test is used to measure the exploration of novelty which
infers potential deficits in spatial memory function, using a three arm
‘maze’ (Makinodan et al., 2009; Wolf et al., 2016). Animals are placed
at the end of the ‘start’ arm and allowed to explore the new environ-
ment. Reduced exploration/alteration frequency, but increase fre-
quency of entry into the other arms indicates declining cognitive
function and this has been observed in CPZ-fed animals (Adilijiang
et al., 2015; Kondo et al., 2016; Li et al., 2015; Makinodan et al., 2009;
Murakami et al., 2017; Omotoso et al., 2018; Sun et al., 2017; Tezuka
et al., 2013; Wang et al., 2015; Xiao et al., 2008; Xu et al., 2010, 2011).
In contrast, two studies reported no changes compared to naïve controls
using the Y-maze test after 0.4% CPZ-feeding for 3 weeks or 0.2% CPZ
for 1 week (Chang et al., 2017; Shao et al., 2015) and correlative his-
tological examination showed no demyelination in the hippocampus
(Shao et al., 2015), suggesting that short term (1–3 week) exposure to
CPZ did not evoke memory dysregulation; complete demyelination of
this region takes 5–6 weeks (Koutsoudaki et al., 2009; Norkute et al.,
2009).
In the social interaction test, animals are allowed to meet one an-
other in an open environment. The number of close contacts (e.g. ˜5 cm,
0.2 s) are scored as a measure of social interaction for rodents (Thanos
et al., 2017; Wilson and Koenig, 2014). Less interaction with another
animal has been documented in CPZ-fed animals, indicating impaired
social interaction (Abakumova et al., 2015; Adilijiang et al., 2015;
Hibbits et al., 2009; Makinodan et al., 2009; Mierzwa et al., 2013;
Valeiras et al., 2014; Wang et al., 2015; Xu et al., 2010, 2011; Xu et al.,
2009).
The novel object recognition test is used to assess recognition
memory tasks. It consists of three phases: habituation, familiarization
and the test phase. In the habituation phase, each animal is allowed to
freely explore in an open-field arena. During the familiarization phase,
a single animal is placed in the open-field arena containing two iden-
tical sample objects for a brief period of time. During testing, the ratio
of the time spent exploring novel vs. old items is measured (Broadbent
et al., 2010; Leger et al., 2013). CPZ-fed animals invested more time
exploring the familiar object, with less preference for exploring new
objects, suggesting decreased cognitive function (Chang et al., 2017;
Kondo et al., 2016; Murakami et al., 2017; Ray et al., 2017; Serra-de-
Oliveira et al., 2015; Shao et al., 2015; Tezuka et al., 2013). In contrast,
0.2% CPZ-feeding for 4 weeks and testing for 6–10 weeks after CPZ-
feeding was stopped revealed no memory deficit, most probably be-
cause of remyelination (Makinodan et al., 2009), suggesting that
pathways for recognition memory depend to some extent on myelina-
tion.
The Morris water maze is used to investigate spatial memory and
learning. The test depends on the ability of animals to find a submerged
platform. A round pool about 90–100 cm in diameter and 30–40 cm
high, filled with cloudy water (25–26 °C) is used. The test comprises
two phases: training and testing. In the training phase, animals learn to
locate a visible platform (e.g. 1–1.5 cm above the water); during the test
phase the platform is submerged (by 1–1.5 cm below the water) and the
time (and path) taken to locate the platform is recorded (Anisman and
McIntyre, 2002; Barnhart et al., 2015; Vorhees and Williams, 2006). In
CPZ-fed animals, an increased distance travelled and increased time to
reach the goal quadrant was indicative of decreased memory and
learning function (Aryanpour et al., 2017; Cui et al., 2018; Dutta et al.,
2013; Omotoso et al., 2018; Zhang et al., 2016).
To measure associative learning skills related to aversive experience
or environmental cues, the fear conditioning test is used. In this test,
fear responses, such as defensive activity (immobility/freezing), startle
reflex response and stress-induced hormones such as corticosterone and
renin secretion (LeDoux, 2000; Van de Kar et al., 1991) are measured in
response to an external stimulus such as an electric shock (Campos
et al., 2013; Webster et al., 2014). Lower scores (e.g. less freezing)
suggest hippocampus-dependent memory deficits and learning. For
example, fractalkine (CX3CL1−/−) knockout mice showed reduced
freezing responses, suggestive of deficits in associative learning beha-
viour (Rogers et al., 2011). Likewise, in the early stage of EAE, de-
creased freezing reflects reduced hippocampal function and learning
skills (Acharjee et al., 2013). A single study using the fear conditioning
test in animals fed 0.2% CPZ for 1 week showed no significant differ-
ence in freezing responses compared to controls suggesting no deficit in
associative learning and memory (Kondo et al., 2016), likely due to the
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lack of demyelination in the hippocampus after this short period of
CPZ-feeding (Koutsoudaki et al., 2009; Norkute et al., 2009). Whether,
the increase in duration and/or dose of CPZ-feeding changes the fear
response remains untested.
Thus, cognitive deficits are prominent in CPZ-fed animals with re-
gard to well-established tests such as the novel object recognition,
Morris water maze, Y-maze and social interaction (Abakumova et al.,
2015; Adilijiang et al., 2015; Aryanpour et al., 2017; Chang et al., 2017;
Cui et al., 2018; Dutta et al., 2013; Hibbits et al., 2009; Kondo et al.,
2016; Li et al., 2015; Makinodan et al., 2009; Murakami et al., 2017;
Omotoso et al., 2018; Ray et al., 2017; Serra-de-Oliveira et al., 2015;
Shao et al., 2015; Sun et al., 2017; Tezuka et al., 2013; Valeiras et al.,
2014; Wang et al., 2015; Xiao et al., 2008; Xu et al., 2010, 2011; Xu
et al., 2009), with the Y-maze test being the most frequently used
(Adilijiang et al., 2015; Chang et al., 2017; Kondo et al., 2016; Li et al.,
2015; Makinodan et al., 2009; Murakami et al., 2017; Omotoso et al.,
2018; Shao et al., 2015; Sun et al., 2017; Tezuka et al., 2013; Wang
et al., 2015; Xiao et al., 2008; Xu et al., 2010, 2011). However, task
selection during study design is a critical aspect in cognitive testing due
to the existence of multiple paradigms of cognition (e.g. spatial
memory, social interaction and recognition memory) and the lack of a
single instrument that measures all aspects of cognition (Karl et al.,
2003; Taylor et al., 2010). For example, social impairment of the an-
imal is tested using the social interaction test (Abakumova et al., 2015;
Adilijiang et al., 2015; Hibbits et al., 2009; Mierzwa et al., 2013;
Valeiras et al., 2014; Wang et al., 2015; Xu et al., 2010, 2011; Xu et al.,
2009) whereas spatial learning and memory function can be assessed
using the Morris water maze (Aryanpour et al., 2017; Cui et al., 2018;
Dutta et al., 2013; Omotoso et al., 2018) and Y-maze (Adilijiang et al.,
2015; Kondo et al., 2016; Li et al., 2015; Makinodan et al., 2009;
Murakami et al., 2017; Omotoso et al., 2018; Sun et al., 2017; Tezuka
et al., 2013; Wang et al., 2015; Xiao et al., 2008; Xu et al., 2010, 2011)
tests. Likewise, in order to test recognition memory, the novel object
recognition test is used (Chang et al., 2017; Kondo et al., 2016;
Murakami et al., 2017; Ray et al., 2017; Serra-de-Oliveira et al., 2015;
Shao et al., 2015; Tezuka et al., 2013). This suggests that in order to get
a better indication of cognitive decline, multiple tests are required
(Adilijiang et al., 2015; Chang et al., 2017; Kondo et al., 2016;
Makinodan et al., 2009; Murakami et al., 2017; Omotoso et al., 2018;
Shao et al., 2015; Tezuka et al., 2013; Wang et al., 2015; Xu et al., 2010,
2011). Additionally, results may be confounded by the internal en-
vironment of the test set-up. For example, the Morris water maze test
may be confounded by inherent fear/anxiety responses to water
(Ehninger and Kempermann, 2006; Harrison et al., 2009) or severe
deficits in motor function, as observed in EAE animals (Dutra et al.,
2013). Lastly, the fear conditioning test can be confounded by declining
motor function or fatigue. For example, physical tests (e.g. wheel run-
ning), followed by the fear conditioning test lead to increased tendency
for freezing responses (Hopkins and Bucci, 2010).
In summary, the use of two tests together such as Y-maze (spatial
memory) and novel object recognition (recognition memory) might be
the best choices in order to achieve a better indication of cognitive
deficit as shown in the work of different labs using CPZ (Kondo et al.,
2016; Murakami et al., 2017; Tezuka et al., 2013). Histological analyses
in cognition-based behavioural studies of CPZ were conducted mainly
in corpus callosum (Abakumova et al., 2015; Aryanpour et al., 2017;
Chang et al., 2017; Ray et al., 2017; Serra-de-Oliveira et al., 2015; Sun
et al., 2017), hippocampus (Cui et al., 2018; Dutta et al., 2013; Li et al.,
2015; Murakami et al., 2017; Omotoso et al., 2018; Shao et al., 2015;
Tezuka et al., 2013; Xu et al., 2010), cortex (e.g. prefrontal; Makinodan
et al., 2009; Xu et al., 2010) and basal ganglia (Tezuka et al., 2013;
Wang et al., 2015; Xu et al., 2009; Zhang et al., 2016) whereas other
relevant regions associated with cognitive function such as the fornix,
cingulum and amygdala (Keser et al., 2018; Pessoa, 2010) remain to be
investigated, suggesting more detailed examination of functionally re-
levant regions is required when attempting to explain the outcomes of
cognitive tests in the CPZ model.
5.6. Visual disturbances/optic neuritis
Visual disturbances including blurred vision, reduced perception of
colour, loss of visual fields and pain in the eye are the most frequent
initial manifestations of human MS (˜50%, Table 2; Costello, 2016;
Kale, 2016; Sakai et al., 2011) but are less common in the progressive
(less inflammatory) variants (Confavreux et al., 2003; Henderson et al.,
2008). Demyelination and inflammation in the optic nerve also extends
to the loss of ganglion cells in ˜80% of MS patients (Balcer et al., 2015;
Bermel and Balcer, 2013). In animals, visual disturbances are measured
using multifocal electroretinograms or are inferred based on changed
performance in running wheel or Y-maze tests (which depend upon
visual cues, Table 3; Namekata et al., 2014; Thomas et al., 2007;
Thompson et al., 2008).
A multifocal electroretinogram records the bioelectric potential of
eye. In this system an electrode placed on the corneal surface (at the
limbus, bordering the cornea and the sclera of eye) and response to a
light stimulus is recorded. Typically, light is delivered to the full visual
field in which the spectral composition, duration and light intensity are
defined and varied (Dutescu et al., 2013; Guo et al., 2010; Namekata
et al., 2014). In Olig 1−/− (a transcription factor of mature OLG)
knockout mice subjected to EAE, visual dysfunction was observed using
a multifocal electroretinogram, correlating with demyelination and
cellular infiltration in optic nerve (Guo et al., 2010). Likewise, CPZ-
feeding produced a reduction in the multifocal electroretinogram am-
plitude indicative of disturbances in visual function (Namekata et al.,
2014). Changes in the multifocal electroretinogram are associated with
demyelination in the optic nerve (Bagchi et al., 2014; Namekata et al.,
2014) and subcortical visual system (Araujo et al., 2017) following
0.2% CPZ-feeding for 12 (Namekata et al., 2014), 8 (Bagchi et al.,
2014) and 5 (Araujo et al., 2017) weeks respectively. Interestingly, the
optic tract and optic nerve have not been found to be demyelinated in
the acute phase of CPZ-feeding (Araujo et al., 2017; Goldberg et al.,
2015; Yang et al., 2009) whereas chronic feeding does result in optic
nerve demyelination, suggesting time dependent effects of CPZ in the
visual system (Namekata et al., 2014).
5.7. Depression
Depression-like symptoms including insomnia, suicidal ideation, sad
mood and feelings of guilt affect ˜50% of the MS patients during their
lifetime (Table 2; Siegert and Abernethy, 2005; Sukoff Rizzo and
Crawley, 2017). The pathophysiology of depression is not clearly un-
derstood; however, like other clinical manifestations of the disease,
many have suggested that the demyelination and neuro-inflammation
processes in the CNS are causative factors (Brenner et al., 2018; Byatt
et al., 2011; Rossi et al., 2017). It has been suggested that MS patients
with demyelinating lesions in the brain (Rabins et al., 1986), particu-
larly in the temporal lobe (Ron and Logsdail, 1989), hippocampus (Gold
et al., 2014; Rocca et al., 2018) or arcuate fasciculus of the left hemi-
sphere (Pujol et al., 1997), rather than in the spinal cord have more
depression. Depression-like behaviour in animals can be measured
using the forced swim, tail suspension or sucrose preference tests
(Ayatollahi et al., 2017; Fukui et al., 2007; Kondo et al., 2016; Krishnan
and Nestler, 2011; Porsolt et al., 2001; Strekalova et al., 2011).
In the forced swim test, rodents are placed individually in a clear
plastic/glass cylinder (typically 25–30 cm high and 10 cm diameter)
half-filled with water at 21–23 °C and activities like swimming, floating,
climbing or mobility are scored. A decreased level of activity correlates
with a depression-like phenotype (Krishnan and Nestler, 2011; Porsolt
et al., 2001). Studies with EAE mice showed increased immobility in the
early stage, suggesting depression (Acharjee et al., 2013; Ayatollahi
et al., 2017). In contrast, a single study using the forced swim test with
CPZ-fed animals detected no differences from controls (Kondo et al.,
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2016).
In the tail suspension test, rodents are suspended above an experi-
mental surface (typically 25–30 cm) and escape-oriented activities and
mobility are recorded. Decreased activity indicated depression-like
behaviour. For example, mice deficient in a transmembrane protein
responsible for transporting cytoplasmic monoamines into secretory
vesicles, showed decreased mobility in the tail suspension (and forced
swim) test, suggesting depression-like behaviour (Fukui et al., 2007). In
EAE animals, decreased mobility in the early stage suggested the in-
duction of a depression-like behaviour phenotype (Majidi-Zolbanin
et al., 2015). In contrast, a single study using the tail suspension test did
not find evidence of a depressive phenotype following 1 week of CPZ-
feeding (in 8 week old B6 mice), a result attributed to the limited de-
myelination and inflammation in the CNS at that stage (Kondo et al.,
2016). Whether such phenotypes become more evident with continued
CPZ-feeding and thus at latter time points remains untested.
Anhedonia is measured using the sucrose preference test (Liu et al.,
2018). In this test, animals have free access to sucrose solution and
depressed and non-depressed animals are identified on the basis of the
amount of sucrose consumed at a given time (Liu et al., 2018;
Strekalova et al., 2011). Healthy animals drink more sucrose as the
sweet taste is desirable whereas animals exhibiting a depressive phe-
notype consume less (Skalisz et al., 2002). In both the earlier and later
stages of EAE, animals showed a reduced preference for sucrose, sug-
gesting increased depression (Pollak et al., 2000). Currently, no study
has assessed depression-like behaviour in CPZ-fed animals using the
sucrose preference test (Table 3).
The physical acts of swimming or tail mobilization, assessed by the
forced swim or tail suspension tests respectively, may be confounded by
diminished motor functions or increased fatigue/tiredness. For ex-
ample, the usefulness of the forced swim test is limited in the later
stages of EAE due to limb or tail paralysis and so may not reflect de-
pressive behaviour, rather motor decline (Majidi-Zolbanin et al., 2015).
In contrast, the sucrose preference test can be used as a simple primary
screening tool as animals can freely access the sucrose solution and it is
not confounded by a foreign environment (e.g. water), handling, or
stress-inducing activity (e.g. climbing; Liu et al., 2018). Since these
factors make depression difficult to assess in animals, it is imperative to
recognise the limitations of the tests when designing behavioural stu-
dies. Importantly, due to the role of stress-induced hormones (e.g.
corticosterone) and neurotransmitters (e.g. dopamine) in the regulation
of affect (e.g. depression and fatigue) the measurement of these hor-
mones during behavioural testing is important to overall interpretation
of the data. For example, a reduction of dopamine release has been
associated with depression and fatigue in MS and other neurological
diseases while increased dopaminergic activity contributes to hyper-
activity or excitement (Diehl and Gershon, 1992; Dobryakova et al.,
2015). CPZ-feeding increases the concentration of dopamine in the
prefrontal cortex (Chang et al., 2017; Valeiras et al., 2014; Xu et al.,
2010) and dopamine transporter expression in the cerebral cortex
(Chang et al., 2017). In addition, an elevated level of corticosterone was
found in the serum of CPZ-fed animals (Serra-de-Oliveira et al., 2015;
Yu et al., 2018). These may provide an explanation for increased ac-
tivities such as climbing (Chang et al., 2017; Franco-Pons et al., 2007;
Werner et al., 2010; Xu et al., 2009), locomotion (Bolcskei et al., 2018;
Chang et al., 2017; Faizi et al., 2016; Franco-Pons et al., 2007; Sun
et al., 2017; Tezuka et al., 2013; Zhang et al., 2013) or rearing (Bolcskei
et al., 2018; Franco-Pons et al., 2007) in CPZ-fed animals. Therefore,
CPZ animals may not be depressed or fatigued (since fatigue often co-
occurs with depression) and further studies are needed to provide more
refined understanding of this behavioural parameter.
5.8. Sleep disorders
Sleep abnormalities are seen in ˜50% of MS patients (Table 2), with
effects including restless leg syndrome, periodic limb movement
disorders, sleep-related breathing disorders and disruptions of normal
sleep patterns (Fleming and Pollak, 2005; Tachibana et al., 1994;
Veauthier, 2015) that are markedly detrimental to quality of life (Brass
et al., 2010). Furthermore, the disruption of night-time sleep leads to
increased daytime sleepiness (Carnicka et al., 2015). Sleep disorders
thus correlate strongly with non-motor symptoms such as fatigue,
cognition, anxiety and depression (Attarian et al., 2004; Braley et al.,
2014; Ghajarzadeh et al., 2012; Nagaraj et al., 2013). While the me-
chanisms are unclear, the presence of demyelinating lesions (Veauthier,
2015) and dysregulation of hormone function (e.g. melatonin;
Melamud et al., 2012) have been implicated in the sleep disturbances
suffered by MS patients. Given the marked abnormalities of sleeping
patterns in human MS, it is surprising that these have not been in-
vestigated in the CPZ model.
To evaluate sleep abnormalities, spontaneous activities in an open
field chamber and electrophysiological measurements such as electro-
myography are used (Taylor et al., 2010; Toth and Bhargava, 2013). In
the open field test, animals are quantitatively assessed with regard to
their posture, breathing and sleeping patterns (e.g. interrupted/unin-
terrupted, Table 3). If sleep is uninterrupted for 2 min then it is re-
corded as sleep, with a ‘good sleep pattern’ being defined by ˜75% of a
10 min period spent sleeping (Taylor et al., 2010). Electromyography
measures the pattern of activation in muscles that should be supressed
in the deeper (slow wave) phases of sleep (Toth and Bhargava, 2013). In
electromyography, electrodes are placed into the muscle to record
electrical activity; data are scored as epochs in different categories re-
presenting wakefulness, slow wave sleep or paradoxical sleep
(Bastianini et al., 2017; Tobler et al., 1997). In the early stage of EAE
increased waking and decreased non-rapid eye movement were asso-
ciated with disruption of sleep (He et al., 2014a, b).
Notably, functional deficits such as disturbances in sleep pattern,
anxiety, cognitive decline and fatigue are all interlinked. For example,
studies with MS patients showed a significant increase in sleep dis-
turbances among those reporting high rates of fatigue whereas matched
healthy controls had natural sleep cycles (Attarian et al., 2004;
Pokryszko-Dragan et al., 2013). Moreover, sleep disturbances affect
memory function (e.g. attention, working, decision and long-term
memory; Alhola and Polo-Kantola, 2007; Braley et al., 2014). Thus, the
normalization of good sleep patterns may manage fatigue and memory
loss, although the causes of sleep disruption in MS are not known. Since
CPZ-fed animals are suggested to have cognitive deficits (see above), it
can be hypothesised that these animals may have disturbed sleeping
patterns, but this remains to be investigated.
5.9. Anxiety-like behaviour
Anxiety is found in ˜35% of MS patients (Table 2; Haussleiter et al.,
2009; Riether, 1999) and there is a significant association with other
common symptoms such as pain, fatigue and depression (Beiske et al.,
2008; Janssens et al., 2006; Korostil and Feinstein, 2007). The patho-
physiology of increasing anxiety in MS is not well understood. Human
studies have indicated that cortical demyelination (Burns et al., 2014;
Riether, 1999), reactive response to psychosocial pressures (Zorzon
et al., 2001) or escalating symptoms such as motor deficits, fatigue and
depression (Marrie et al., 2015; Zorzon et al., 2001) are associated with
increasing anxiety.
Anxiety-like behaviour in rodents can be measured using the open
field, elevated plus maze, hole board and light dark tests (Table 3;
Campos et al., 2013; Karl et al., 2003; Ramos, 2008; Taylor et al.,
2010). Spontaneous activities including walking, rearing (i.e. vertical
activity) and grooming (i.e. fur licking and limb scratching) are typical
behaviours associated with normal activities such as food foraging,
social communication and hygiene (Kalueff et al., 2016; Tanaka et al.,
2012). However, alterations of spontaneous activities and natural be-
haviour (e.g. activity in light vs. dark conditions) in response to fear/
stress can be used as a maker of anxiety-like behaviour (Karl et al.,
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2003; Ramos, 2008; Taylor et al., 2010).
The open field test is a basic technique to measure locomotion and
anxiety-like behaviours of rodents. In this test, rodents are allowed to
explore in a circular or square open environment and the locomotion
(e.g. total distance travel and velocity) and exploratory (curiosity-like)
activities (e.g. rearing) are documented (Karl et al., 2003; Ramos, 2008;
Taylor et al., 2010). Increased activity in the perimeter, compared to
the centre, suggests an attempt to find a safe, ‘enclosed’ environment
(i.e. at the perimeter, in an effort to escape the open central field) due to
inherent fear of an open, ‘unsafe’ place; this is regarded as anxiety-like
behaviour (Karl et al., 2003; Ramos, 2008; Taylor et al., 2010). A si-
milar phenomenon has been reported in some CPZ studies, suggesting
anxiety like behaviour in CPZ-fed animal (Li et al., 2015; Makinodan
et al., 2009; Sanadgol et al., 2018; Serra-de-Oliveira et al., 2015; Wang
et al., 2013, 2016; Ye et al., 2013; Yu et al., 2018; Zhang et al., 2016).
In total, 20 publications were found to use open field to measure
locomotion and anxiety-like behaviours in the CPZ model (Bolcskei
et al., 2018; Cui et al., 2018; Elbaz et al., 2018; Faizi et al., 2016;
Franco-Pons et al., 2007; Li et al., 2015; Makinodan et al., 2009;
Sanadgol et al., 2017; Serra-de-Oliveira et al., 2015; Shao et al., 2015;
Sun et al., 2017; Vakilzadeh et al., 2016; Valeiras et al., 2014; Wang
et al., 2013, 2015; Xu et al., 2009; Ye et al., 2013; Yu et al., 2018; Zhang
et al., 2015, 2016). However, in these studies inconsistent and con-
tradictory results were often found: some groups reported that CPZ-
feeding increased locomotion (Bolcskei et al., 2018; Shao et al., 2015;
Sun et al., 2017; Valeiras et al., 2014) whereas, others reported de-
creased locomotion (Faizi et al., 2016; Sanadgol et al., 2017;
Vakilzadeh et al., 2016; Wang et al., 2016; Ye et al., 2013; Yu et al.,
2018; Zhang et al., 2015). Interestingly, others reported no change in
locomotion even though a similar study design was followed (Cui et al.,
2018; Franco-Pons et al., 2007; Li et al., 2015; Makinodan et al., 2009;
Wang et al., 2013; Xu et al., 2009). In addition, decreased running
frequency in the centre, considered as anxiety-like behaviour, was re-
ported in some studies (Li et al., 2015; Makinodan et al., 2009;
Sanadgol et al., 2018; Serra-de-Oliveira et al., 2015; Wang et al., 2013,
2016; Ye et al., 2013; Yu et al., 2018; Zhang et al., 2016) whereas
others found increased frequency in the centre (Franco-Pons et al.,
2007; Valeiras et al., 2014). These contradictory observations using the
same test raise serious issues concerning the acceptability of using open
field to measure anxiety and highlight the need to use alternative tests
to assess anxiety.
To better assess anxiety-like behaviour, specialized tests such as the
elevated plus maze or light dark tests can be used (Bourin and Hascoet,
2003; Ramos, 2008; Walf and Frye, 2007). In the elevated plus maze
test, rodents are placed in a plus-shaped apparatus with two open and
two closed arms for a fixed period of time (e.g. 8–10 min) with the time
spent exploring, rearing and grooming on the arms and central area, as
well as inspection of the space beneath the platform (head dipping)
being measured (Campos et al., 2013; Paine et al., 2002; Walf and Frye,
2007). In the early stage of EAE, the decreased percentage of time spent
in the open arms is taken as an indication of anxiety (Kocovski et al.,
2018). Likewise, mice that received bilateral injection of 6-hydro-
xydopamine toxin (used to model Parkinson disease) showed a de-
creased amount of time in the open space, suggesting less exploratory
behaviour and thus increased anxiety (Bonito-Oliva et al., 2014). In
CPZ-fed animals, inconsistent results have been reported when the
elevated plus maze test was used. For example, increased time in the
open arms which does not reflect anxiety was found in some
(Torkildsen et al., 2009; Xu et al., 2011, 2009; Zimmermann et al.,
2018), but not other (Abakumova et al., 2015; Serra-de-Oliveira et al.,
2015) studies, whereas two studies found no differences relative to
controls using the elevated plus maze test (Cui et al., 2018; Makinodan
et al., 2009). These inconsistencies arise, in part due to the reliance on
different parameters: one study (Cui et al., 2018) reported exploration
time in both arms and centre whereas others focused on the time spent
in the arms alone (Abakumova et al., 2015; Makinodan et al., 2009;
Serra-de-Oliveira et al., 2015; Torkildsen et al., 2009; Xu et al., 2011,
2009; Zimmermann et al., 2018). None of the studies investigated head
dipping, rearing and grooming behaviours with elevated plus maze in
CPZ studies. Such conflicting observations highlight the need for ad-
ditional elevated plus maze studies using a consistent approach based
on measuring all parameters in order to obtain a far clearer under-
standing of potential anxiety in CPZ model.
The innate aversion of animals to light can be measured using the
light dark test. In this task animals are allowed to explore freely in two
compartments, either the ‘unsafe’ illuminated side or the ‘safe’ dark side
(Bourin and Hascoet, 2003; Campos et al., 2013). This test measures
time in the light arena, time spent between the two areas and head
dipping as surrogate measures of anxiety (Chaouloff et al., 1997; Taylor
et al., 2010). For example, loss of Parkin function (an E3 ubiquitin‐-
protein ligase mutation causing early-onset Parkinson’s disease) in mice
resulted in less exploration time in the light side and decreased tran-
sition between light and dark compartments suggesting increased an-
xiety-like behaviour (Zhu et al., 2007). Likewise, in the acute stages of
EAE, mice spend less time in the light compartment reflecting less ex-
ploratory behaviour and thus increased anxiety-like behaviour (Gentile
et al., 2016; Peruga et al., 2011). Anxiety in EAE has been associated
with demyelination and inflammation in CNS structures such as spinal
cord and hippocampus (Gentile et al., 2015; Peruga et al., 2011). One
light dark study has shown that following 1 week of 0.2% CPZ-feeding
there was less exploration in the illuminated compartment, suggesting
anxiety-like behaviour (Kondo et al., 2016). This is well before marked
demyelination occurs in this model (Hiremath et al., 1998), suggesting
that the early events leading to oligodendrocytosis can result in mea-
surable behavioural changes even before demyelination becomes evi-
dent. However, no significant differences were found in terms of latency
to enter the boxes (Kondo et al., 2016), and other parameters including
head dipping or rearing associated with CPZ-feeding remain untested.
The hole board is the least used test in CPZ experiments to measure
anxiety and the exploration of novelty. It was developed as a more
complex variant of the open field in which novel recesses or holes are
added to the open field and anxiety and exploratory behaviours are
documented. In this test, animals are placed, for a defined period of
time, in a large, clean box with equally distributed holes (e.g. 16).
Activities including distance travelled, number of hole-poking/ex-
ploring attempts, rearing and grooming are measured over a 5-minute
period. Increased frequency of activities is interpreted to indicate in-
creased exploratory behaviour to find a ‘safe’ place to escape/hide and
is thus regarded as an indicator of an anxiety-like phenotype (Crawley,
1985; Karl et al., 2003; van Gaalen and Steckler, 2000). However, the
hole board test has also been suggested to measure cognitive function
by assessing the capacity to locate food pellet rewards. In this proce-
dure, a reward is provided in the holes during a training session and
rodents are allowed to search freely, whereas during the test session the
reward holes are altered or left empty. Increased error numbers are
taken to indicate deficits in working or reference memory (Feyissa
et al., 2017; Kuc et al., 2006). In CPZ-fed animals no changes in hole-
poke frequency were observed relative to naïve controls (Skripuletz
et al., 2010b); however, there have been no investigations reporting on
all the test parameters (e.g. rearing, grooming and distance travelled).
The open field and hole board tests are more useful to screen lo-
comotion in rodents since they consist of an increased open area to
move within (Gellért and Varga, 2016; Tanaka et al., 2012). Reduced
ambulation in the centre of the open field and increased escape-like
behaviour (e.g. rearing) are considered indications of anxiety but the
results are often confounded by the drivers of locomotion. Also, ex-
ploration requires a choice and the open field, which is always brightly
lit, has no choice other than to stay in the centre (i.e. generally disliked
by rodents) or move towards the edge (Mitra et al., 2016; Wang et al.,
2013). In contrast, tests such as elevated plus maze or light dark are
thus recommended to more selectively measure anxiety-like pheno-
types. A key aspect of these tests is the use of heightened natural
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conflict wherein rodents must choose between the tendency to explore
an unsafe open (light) environment and a safe (dark) environment.
‘Anxious’ animals are expected to spend less time exploring the open
space but may increase the number of times they move between open
and closed spaces in an attempt to ensure that they are in the safest
possible place (Bourin and Hascoet, 2003; Karl et al., 2003; Pellow
et al., 1985; Pellow and File, 1986; Walf and Frye, 2007; Zimmermann
et al., 2018). The elevated plus maze test, when combined with detailed
quantification of exploration in multiple compartments with differing
environments (Bourin and Hascoet, 2003; Carola et al., 2002; Ramos,
2008) provides a better, more detailed account of anxiety-like beha-
viours.
Interestingly, as in other CPZ behavioural studies, most histological
analyses of demyelination were assessed in the corpus callosum
(Abakumova et al., 2015; Bolcskei et al., 2018; Faizi et al., 2016;
Franco-Pons et al., 2007; Sanadgol et al., 2018; Serra-de-Oliveira et al.,
2015; Skripuletz et al., 2010b; Sun et al., 2017; Torkildsen et al., 2009;
Vakilzadeh et al., 2016; Valeiras et al., 2014; Wang et al., 2013; Xu
et al., 2011; Ye et al., 2013; Yu et al., 2018; Zhang et al., 2015;
Zimmermann et al., 2018), some in the cerebral cortex, hippocampus,
basal ganglia (Cui et al., 2018; Elbaz et al., 2018; Li et al., 2015; Shao
et al., 2015; Valeiras et al., 2014; Wang et al., 2015; Xu et al., 2011,
2009; Ye et al., 2013; Zhang et al., 2016) but none in limbic regions
associated with anxiety such as cingulum and amygdala (Martin et al.,
2009). Moreover, anxiety has been associated with the increased se-
cretion of modulatory neurotransmitters such as dopamine and ser-
otonin (Martin et al., 2009; Zarrindast and Khakpai, 2015). In CPZ
studies increased levels of brain dopamine were found in some studies
suggestive of anxiety-like behaviour (Chang et al., 2017; Valeiras et al.,
2014; Xu et al., 2010). Therefore, further examination of functionally
relevant regions and biochemical analyses are needed to better inter-
pret anxiety-like behavioural responses in the CPZ model.
In summary, all tests that assess anxiety-like behavioural deficits are
based on changes in normal, spontaneous activities. Unfortunately,
analysis of the conflicting and disparate results due to widely varying
test parameters makes it hard to draw clear conclusions about the
presence of anxiety-like behaviours in CPZ mice. Moreover, there is
clearly no ‘ideal’ test of anxiety as each has its limitations, so systematic
testing and comprehensive reporting of all parameters should be con-
sidered essential for effective interpretations. Moreover, appropriate
histological and biochemical analyses of relevant CNS regions should
always be included so as to better draw correlations of potential anxiety
behaviour associated with CPZ ingestion.
5.10. Epileptic seizures
An epileptic seizure is a transient, abnormal, excessive or synchro-
nous bout of neuronal activity in the brain (Fisher et al., 2005). The
prevalence of epilepsy in the MS patients is 2–3%, six times higher than
the general population (Table 2; Allen et al., 2013; Poser and Brinar,
2003). Demyelination and inflammation in the cortical and subcortical
areas including cerebral cortex and hippocampus, have been associated
with the aetiology of increased epileptic seizure in MS patients
(Calabrese et al., 2017; Hoffmann et al., 2008). However, this hy-
pothetical view of frequency and progression is yet to be clearly elu-
cidated (Kelley and Rodriguez, 2009). In animals, epileptic seizure can
be measured using electroencephalography (Table 3), which records
spontaneous electric activity of the brain. In electroencephalography,
recording electrodes are fixed to the skull or directly to the underlying
cortex (Bergstrom et al., 2013; Hoffmann et al., 2008; Lapato et al.,
2017). In CPZ-fed animals, epileptic seizure were characterized as high-
amplitude discharges in electroencephalography that were associated
with generalized tonic-clonic seizures and loss of righting reflexes,
suggesting demyelination in the hippocampus and cortex may underlie
these events (Hoffmann et al., 2008; Lapato et al., 2017).
6. Other factors contributing to the variability of CPZ-induced
behavioural outcomes
6.1. Strain and gender
C57Bl/6 (B6) mice are used widely in CPZ behavioural studies
(˜77% by publication numbers) due the high reproducibility of de-
myelination and gliosis (Hiremath et al., 1998). Although the B6 strain
is ‘gender indifferent’ in inducing demyelination and glial activation,
surprisingly the majority (84%) of the studies were carried out with
males. However, studies in other strains of mice (e.g. BALB/cJ, CD1 and
SJL) revealed strain specific patterns of pathological changes (Herder
et al., 2011; Skripuletz et al., 2008; Taylor et al., 2009; Yu et al., 2017).
For example, differential levels of demyelination in cortical and callosal
regions have been described in these other strains suggesting the ge-
netic background of the inbred strain may be important (Mahajan et al.,
2016; Skripuletz et al., 2008; Taylor et al., 2009; Yu et al., 2017).
However, no single study using CPZ has systematically compared the
histological changes between strains, their underlying genetic make-up,
and associated behavioural deficits. In addition, whether these funda-
mental factors are also at play in MS and could potentially explain the
heterogeneity observed in disease progression remains to be de-
termined.
6.2. Age, species, dose and duration
The effects of to OLG and demyelination are more marked in ju-
venile (3–4 weeks) compared to older (6–8 months old) animals
(Doucette et al., 2010; Makinodan et al., 2009; Pfeifenbring et al., 2015;
Wang et al., 2013). Demyelination in the juvenile period leads to long
lasting behavioural deficits (e.g. in cognition) relative to older mice,
suggesting age dependent vulnerability to behavioural recovery
(Makinodan et al., 2009). This age-related effect is also evident when
the responses to low (0.1%) and high (≥0.2%) doses of CPZ are com-
pared at different time points; low doses produced marked demyeli-
nation in 3–4 week old animals whereas the same dose was ineffective
when administered to 7–8 week old mice, where higher doses are re-
quired to elicit a comparable response (Blakemore, 1972; Hiremath
et al., 1998; Suzuki and Kikkawa, 1969). Likewise, increasing the
duration of CPZ-feeding increases the severity of demyelination and
behavioural outcomes. For example, dose dependent vulnerability was
found with regard to demyelination in the optic nerve where visual
disturbances were evident only when feeding was continued over 5–6
weeks (Namekata et al., 2014). Rat studies have suggested that in-
creased doses (0.5–2%) of CPZ are required to produce comparable
pathological (e.g. demyelination and gliosis) and behavioural changes
than those are seen in mice (Adamo et al., 2006; Love, 1988; Oakden
et al., 2017; Serra-de-Oliveira et al., 2015). Similarly, in guinea pigs,
1% CPZ caused demyelination in brain and cerebellum following 20
weeks of feeding (Carlton, 1969) whereas no behavioural changes,
demyelination, or inflammation were observed in cynomolgus monkeys
when treated with 3% CPZ for 18 weeks (Chen et al., 2015). Whether
such variations in dose response and the extent of demyelination, which
would seem to correlate with animal size, would persist if CPZ was
administered as a fixed dose (e.g. oral gavage) based on body weight
remains untested.
6.3. Regional variabilities in CPZ-induced demyelination and behavioural
outcomes
The magnitude of CPZ-mediated oligodendrocytosis is not equally
distributed in the CNS. CPZ causes extensive oligodendrocytosis and
demyelination in different parts of the cerebrum (e.g. corpus callosum,
cerebral cortex, basal ganglia and hippocampus) and cerebellum
(Goldberg et al., 2015; Groebe et al., 2009; Gudi et al., 2014, 2009;
Skripuletz et al., 2010a; Yang et al., 2009) with limited, if any, evidence
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in the brainstem (Jurevics et al., 2002) and spinal cord (Herder et al.,
2011). Clearly, this regional variability may affect behavioural pheno-
types. For example, it has been shown that the demyelination and
gliosis in the spinal cord after induction of EAE is associated with
neuropathic pain symptoms (Duffy et al., 2016; Lu et al., 2012; Schmitz
et al., 2014) whereas only one paper has reported limited pathological
changes in the spinal cord of CPZ-fed animals (Herder et al., 2011). The
causes of such regional variability are unknown. Despite equivalent
CPZ-induced inhibition of mitochondrial functions in both corpus cal-
losum and spinal cord, the spinal cord is not demyelinated whereas the
corpus callosum is highly affected (Acs et al., 2013), suggesting that
additional factors determine the sensitivity of these structures in rela-
tion to oligodendrocytosis (Sperber et al., 2001; Vallstedt et al., 2005).
One such factor may be the uneven distribution of different OLG sub-
types in the CNS which could contribute to the regional variability of
OLG loss. Amongst the four different subtypes of OLG, types I and II are
most abundant in cerebrum and cerebellum whereas types III and IV are
mainly found in the brainstem and spinal cord (Butt et al., 1995; Ferrer,
2018; Simons and Nave, 2015). Perhaps CPZ is highly toxic to type I
and II OLG but less so to III and IV. In one study, the increased de-
generation of type I OLG was reported in the cortex suggesting toxicity
in this select subpopulation (Blakemore, 1972). However, the effect on
other subtypes, especially OLG types III and IV which are mainly pre-
sent in the brainstem and spinal cord, remains untested. Likewise, type
IV is more Schwann cell-like and there is no evidence of CPZ affecting
peripheral neurons. Moreover, age and regional variabilities of the
distribution of OPC in the CNS may contribute to the de- and re-
myelination pattern during and following CPZ toxicity (Spitzer et al.,
2019). Furthermore, altered gene expression may increase the sus-
ceptibility of one area over another to injury. For example, the reduc-
tion of expression of the Fyn gene, a member of the Src non-receptor
tyrosine protein kinase family, promotes oligodendrocytosis. Fyn
knockout mice showed a massive loss of OLG in the corpus callosum
and optic nerve whereas the spinal cord remained unaffected (Sperber
et al., 2001) suggesting regional differences in the regulation of OLG
that underpins their susceptibility to CPZ.
6.4. Sample size, time and frequency of tests
Adequate power calculations to determine the correct sample size
for an experiment is an important factor which is often overlooked in
order to reduce the inherent variability between individuals (Charan
and Kantharia, 2013; Crawley and Paylor, 1997; Dell et al., 2002). In
CPZ studies, sample sizes varied from 4 to 20, with most studies using
10–15 mice/group (Chang et al., 2017; Hagemeyer et al., 2012; Hibbits
et al., 2009; Liebetanz and Merkler, 2006; Makinodan et al., 2009;
Tezuka et al., 2013; Xu et al., 2011). Likewise, the choice of the correct
statistical test is also important. Variables between two groups require a
simple unpaired t-test whereas in the case of multiple variables (e.g.
age, gender, strain and different time points), analysis of variance or
multivariate analysis of variance should be used with appropriate post
hoc tests, such as Newman-Keuls or Tukey, which correct for multiple
comparisons between groups based on parametric or non-parametric
variables. In addition, experimental blinding (i.e. the analyst is una-
ware of the identity of the different experimental groups) during be-
havioural testing is essential to avoid experimental bias and to increase
the reliability of data acquisition and analysis (Hånell and Marklund,
2014). Moreover, behavioural studies should report baseline data prior
to CPZ-feeding to gauge any potential differences between animals as-
signed to the experimental vs. the naïve age-matched controls. In some
CPZ studies, acquisition of base line data (Abakumova et al., 2015;
Hibbits et al., 2009; Mierzwa et al., 2013) and a blinded strategy (Cui
et al., 2018; Franco-Pons et al., 2007; Hagemeyer et al., 2012; Omotoso
et al., 2018; Serra-de-Oliveira et al., 2015) were followed whereas the
remaining behavioural studies did not report these details (Adilijiang
et al., 2015; Chang et al., 2017; Dutta et al., 2013; Elbaz et al., 2018;
Faizi et al., 2016; Hashimoto et al., 2017; Iwasa et al., 2014; Li et al.,
2015; Liebetanz and Merkler, 2006; Makinodan et al., 2009; Manrique-
Hoyos et al., 2012; Murakami et al., 2017; Ray et al., 2017; Sanadgol
et al., 2018; Shao et al., 2015; Skripuletz et al., 2015; Skripuletz et al.,
2010b; Sun et al., 2017; Tezuka et al., 2013; Torkildsen et al., 2009;
Vakilzadeh et al., 2016; Wang et al., 2013, 2015; Wang et al., 2016;
Xiao et al., 2008; Xu et al., 2010, 2009; Yamamoto et al., 2014, 2017;
Ye et al., 2013; Yu et al., 2018; Zhang et al., 2016; Zheng et al., 2017;
Zimmermann et al., 2018).
Behaviour experiments in laboratory rodents are usually carried out
in day time. Rodents are nocturnal animals and so training during the
day may influence behavioural results, especially if behaviour is not
performed at the same time in each trial. For example, Dilute, Brown
and non-Agouti mice showed reductions in activities such as rearing,
locomotion and food foraging, and increased cognitive deficits during
day time vs. night time testing (Roedel et al., 2006). However, testing
behaviour early or late in the day might create variability due to
waking up or tiredness/preparation for sleep. With CPZ, some tests (e.g.
complex wheel) were conducted over the entire light-dark cycle
(Hibbits et al., 2009; Liebetanz and Merkler, 2006; Manrique-Hoyos
et al., 2012; Mierzwa et al., 2013) or confined to either of the dark
(Makinodan et al., 2009) or light phase (Franco-Pons et al., 2007).
However, these differences have not been systematically addressed in
the CPZ model.
Lastly, multiple tests can affect the physical condition of the test
animals and so influence results (Hånell and Marklund, 2014). For
example, physical tests (e.g. wheel running and open field) followed by
fear conditioning resulted in increased freezing/immobility behaviour
compared to naïve fear conditioning, suggesting tiredness/fatigue of
the animal (Hopkins and Bucci, 2010). It is recommended either to
extend the time between tests or perform tests in the order of least
stressful to most stressful. Moreover, instead of using multiple instru-
ments, multiple behaviours can be measured using one instrument. For
example, a modified hole board method can be used in which moveable
lids cover the holes to make flat central areas similar to the open field
apparatus. The measurement of anxiety, cognition and locomotion can
then be carried out using one instrument (Ohl and Keck, 2003). This
seems never to have been assessed in CPZ or EAE studies.
7. Conclusions
In addition to demyelination and gliosis in the CNS, there are a
variety of clinical symptoms associated with human MS including
problems with motor function, pain, fatigue, cognition, vision, de-
pression, sleep, anxiety and seizures. To translate neuroscience research
from ‘bench-to-bedside-to-community,’ appropriate animal behavioural
assays are critical to identifying early markers of disease onset and to
evaluate the effectiveness of therapeutics in preventing disease or re-
solving established disease states. This review highlights the similarities
and differences between behavioural assessments and histopathology in
CPZ-fed animal models versus the clinical symptoms seen in MS pa-
tients, with reference also to the EAE model. Despite the apparent
tendency in the literature to anthropomorphize such test results to
human clinical symptoms, one must remain cognizant of species dif-
ferences and thus the inherent assumptions and limitations of such
assessments in animal models. However, since CPZ is extensively used
to model demyelination and remyelination, events commonly asso-
ciated with MS, the detailed behavioural phenotypes associated with
this model must be examined rigorously using appropriate quantitative
tests. Therefore, from the current review we conclude that:
• Although CPZ-feeding has been used to investigate demyelination
and gliosis in the CNS since the 1960s surprisingly few studies have
assessed its effects on behaviour and these not been systematically,
or critically, reviewed.
• Motor behaviour is the most commonly assessed parameter (and the
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most common MS symptom) during CPZ-feeding, but the choice of
test is important in order to identify potential changes. Complexity
allows subtle deficits to be detected earlier, in otherwise pre-
symptomatic animals and so tests like the ladder crossing and
complex wheel tests are recommended. However, these tests are
subject to cognitive confounders and it may not be possible to fully
separate the apparent motor deficits from cognitive impairment
purely on the basis of current behavioural criteria.
• There is a clear mismatch between the most commonly reported
symptoms in MS such as pain and fatigue and the most commonly
used behavioural tests of CPZ-fed animals (e.g. anxiety and cogni-
tion, see Table 2).
• Anxiety is the second most commonly measured behavioural para-
meter in CPZ-fed animals (Table 2). However, due to the multiple
aspects inherent to anxiety, the selection of an appropriate test and
the assessment of multiple parameters are important. The open field
test is recommended for the initial screening for anxiety-like beha-
viour and locomotor deficits followed by assessment of multiple
parameters using the elevated plus maze apparatus (see Table 3).
• Assessment of cognitive function is the third most common beha-
vioural test. The Y-maze and novel object recognition tests are re-
commended due to their reproducibility across different labs, mea-
surement of multiple parameters (e.g. spatial and recognition
memory), and that they are not confounded by other factors such as
water-induced stress such as associated with the Morris water maze.
• Since CPZ-fed animals are more active (e.g. increased locomotion,
climbing and rearing) and have increased levels of stress hormones
(e.g. corticosterone) and neurotransmitters (e.g. dopamine), these
confound the use of current tests such as forced swim, tail suspen-
sion, sucrose preference, upside down grid and voluntary wheel
running for assessing depression and fatigue-like behaviour.
• A better understanding of the interactions between multiple symp-
toms (e.g. depression, fatigue, pain, visual disturbances, sleep and
epileptic seizure) is needed to determine whether there is a direct
effect of CPZ-feeding on specific systems or whether these condi-
tions are secondary to its broad range of action.
• In order to resolve the contributions of CPZ-induced demyelination
to possible behavioural deficits, quantitative histopathological and/
or biochemical assays of functionally relevant CNS areas and path-
ways are crucial to clarify their individual contributions rather than
just using the corpus callosum as a proxy of dysfunction.
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A B S T R A C T
Feeding cuprizone (CPZ) to mice causes demyelination and reactive gliosis in the central nervous system (CNS),
hallmarks of some neurodegenerative diseases like multiple sclerosis. However, relatively little is known re-
garding the behavioural deficits associated with CPZ-feeding and much of what is known is contradictory. This
study investigated whether 37 days oral feeding of 0.2% CPZ to young adult mice evoked sensorimotor beha-
vioural changes. Behavioural tests included measurements of nociceptive withdrawal reflex responses and lo-
comotor tests. Additionally, these were compared to histological analysis of the relevant CNS regions by analysis
of neuronal and glial cell components. CPZ-fed mice exhibited more foot slips in walking ladder and beam tests
compared to controls. In contrast, no changes in nociceptive thresholds to thermal or mechanical stimuli oc-
curred between groups. Histological analysis showed demyelination throughout the CNS, which was most
prominent in white matter tracts in the cerebrum but was also elevated in areas such as the hippocampus, basal
ganglia and diencephalon. Profound demyelination and gliosis was seen in the deep cerebellar nuclei and brain
stem regions associated with the vestibular system. However, in the spinal cord changes were minimal. No loss of
oligodendrocytes, neurons or motoneurons occurred but a significant increase in astrocyte staining ensued
throughout the white matter of the spinal cord. The results suggest that CPZ differentially affects oligoden-
drocytes throughout the CNS and induces subtle motor changes such as ataxia. This is associated with deficits in
CNS regions associated with motor and balance functions such as the cerebellum and brain stem.
1. Introduction
Feeding cuprizone (CPZ) to mice is commonly used to study de-
myelination (and remyelination) and gliosis in the central nervous
system (CNS) in the absence of an adaptive immune response, because
the blood brain barrier remains intact (Partridge et al., 2015; Sen et al.,
2019a; Sen et al., 2019b). While the precise mechanism of CPZ-induced
toxicity is unclear, it is thought to be because of metal ion imbalance
causing mitochondrial and endoplasmic reticulum stress resulting in
oligodendrocyte (OLG) loss (termed oligodendrocytosis). This causes
demyelination and gliosis (reviewed in Sen et al., 2019b). Despite the
extensive use of CPZ as a tool to study demyelination, there has been
less emphasis on the neuropathological consequences within the CNS.
Almost all studies reported demyelination of the corpus callosum as a
proxy for CPZ efficacy (see Sen et al., 2019b). However, only a few
investigated anatomical changes in the grey and white matter regions of
the cerebrum (Goldberg et al., 2015; Yang et al., 2009), cerebellum
(Groebe et al., 2009; Skripuletz et al., 2010), brain stem or spinal cord
(Herder et al., 2011; Jurevics et al., 2002).
Demyelination and gliosis in the CNS are hallmarks of demyeli-
nating diseases like multiple sclerosis (MS). The CPZ model is an ac-
cepted animal model of MS (Acs and Kalman, 2012; Kipp et al., 2017)
since the histopathology caused closely resembles the oligoden-
dropathology seen in type III and IV MS brain lesions (Lucchinetti et al.,
2000; Lucchinetti et al., 1996). Clinically, the two most common
symptoms of MS patients are motor deficits and pain (see Table 2 of Sen
et al., 2019b). Motor deficits including difficulties in maintaining bal-
ance, reduced walking speed and impaired limb dexterity were reported
in about 80% of MS patients (Benedict et al., 2011; Cattaneo et al.,
2002; Larocca, 2011; Pellegrino et al., 2018). Using the CPZ model,
motor performance was commonly assessed using the rotarod appa-
ratus, with mixed results, due to the limitations of the test (reviewed in
Sen et al., 2019b). That review suggested that increasing the complexity
of the motor task and assessing the accuracy of foot placements when
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traversing an elevated beam or ladder would detect subtle deficits in
CPZ-fed animals, as the two tasks assess different aspects of locomotion
such as foot placement accuracy, limb coordination and balance.
Therefore, this study compared the walking ladder and beam tests to
the rotarod test.
MS patients also show a marked prevalence for pain and para-
esthesia (30–80%; Sen et al., 2019b). However, only a limited number
of CPZ studies have investigated changes in sensory functions such as
nociception (Bolcskei et al., 2018; Tsukahara et al., 2018; Vakilzadeh
et al., 2016), with only one investigating changes in low threshold
tactile and proprioceptive inputs (Bolcskei et al., 2018). None of these
studies correlated behavioural changes with histological investigations
of the relevant ascending or descending somatosensory pathways,
making interpretation of the changes challenging (Sen et al., 2019b).
Therefore, we tested whether CPZ-feeding caused reliable sensorimotor
behavioural deficits using specific sensory and motor behavioural tests
followed by histological examination of specific CNS regions associated
with the relevant somatosensory systems for oligodendrocytosis, de-
myelination, gliosis and neuronal loss.
2. Materials and methods
2.1. Animals, feeding and monitoring
Four-week old male C57BL/6 mice (n = 20) were purchased from
the Animal Resources Centre, Murdoch, WA, Australia (www.arc.wa.-
gov.au). Males were used because it was demonstrated that there was
no gender difference in demyelination and gliosis with CPZ-feeding
(Taylor et al., 2010). At 7 weeks of age, mice were allocated randomly
into two groups: naïve controls (Ctrl, n = 10) or cuprizone-fed (CPZ,
n = 10). Control mice received normal rodent chow whereas the CPZ
group were fed 0.2% w/w CPZ (Sigma-Aldrich, St. Louis, MO, USA)
mixed into standard rodent powder chow (Gordon's Specialty Stock-
feeds, Yanderra, NSW, Australia) for 37 days to induce oligoden-
drocytosis, demyelination and gliosis (Sen et al., 2019a; Sen et al.,
2019b). Mice were weighed every third day to monitor general growth
and health. No obvious changes in posture, gait and body condition
were apparent in either group. Research and animal care procedures
were approved by the Western Sydney University animal ethics com-
mittee (A10394), in accordance with the Australian Code of Practice for
the Care and Use of Animals for Scientific Purposes as laid out by the
National Health and Medical Research Council of Australia.
2.2. Behavioural assessments
These were performed in a blinded manner by the same observer
throughout. All tests occurred between 9 am – 1 pm at room tem-
perature (RT, 21–23 °C), with normal lighting conditions in an isolated
behavioural lab. On test days, animals were habituated to their sur-
roundings for 30 min prior to testing. Baseline behavioural tests oc-
curred four times every third day for 2 weeks prior to group allocation.
The ladder, beam, rotarod and nociceptive tests were performed on
separate days as indicated in Fig. 2.
2.3. Motor tests
Locomotor activity and balance were measured using the accel-
erating rotarod apparatus (Ugo Basile, Gemonio, VA, Italy) as described
previously (Franco-Pons et al., 2007; Traka et al., 2016). Testing was
performed weekly to minimize repeated test-induced tiredness of mice
due to the physical demands of the task. After the habituation period,
each mouse was placed on the rotating drum at an initial speed of 4
revolutions per minute (rpm) that accelerated up to 40 rpm over 300 s.
On each test day, three trials were performed (with a 1-hour rest in-
terval between each trial). The latency to fall off the apparatus, time to
first flip (i.e. the mouse holds onto the rotating rod rather than
walking), and the total number of flips were recorded for each mouse.
Custom-made walking ladder and beam apparatus were used to
assess more complex motor functions. For the walking ladder test,
(Supplementary Fig. 1A) a desk lamp was placed at the starting end to
encourage mice to move toward the safety of the darker home cage. The
cut-off time allowed for crossing the ladder was 1 min. On each test
day, three trials were performed (with 30 min rest between each trial).
All trials were filmed with a Logitech C525 HD Webcam and analysed
offline. The time to cross the ladder was measured. In addition, the
number of foot slips was quantified in two ways: 1) a complete foot slip
when the entire foot missed the rung, which was quantified for both
hind- and fore-limbs; and 2) a partial foot slip, when part of the foot
slips from the rung from both hind- and fore-limbs on days 8, 18 and 32.
During the ladder test, mice often stopped to perform exploratory be-
haviours such as rearing, grooming, defecation, urination and head
dipping. The quantification of the number of exploration activities was
assessed on days 8, 18 and 32.
In the walking beam test (Supplementary Fig. 1B) mice crossed the
beam towards the narrow end connected to the home cage. A desk lamp
was placed behind the starting side of the beam to encourage mice to
walk towards the home cage. The cut-off time allowed for crossing the
beam was 1 min. Each trial (n = 3 trials in total with 30 min rest
between trials) was recorded with a Logitech C525 HD Webcam, and
analysed offline. The time to cross the beam and the total number of
hind limb ‘complete foot slips’ (right and left combined) were quanti-
fied every third day. In both tests, the number of times mice stopped to
perform exploratory behaviours on days 8, 18 and 32 were counted to
investigate whether this behaviour was a contributing factor to the time
taken to cross the beam or ladder.
2.4. Nociceptive tests
Flexion withdrawal responses were measured every third day by
observing the paw withdrawal thresholds to mechanical and thermal
stimuli using the dynamic plantar aesthesiometer and Hargreaves ap-
paratus (Bioseb, Vitrolles, France), respectively, as described previously
(Samour et al., 2017; Shaikh et al., 2016). Briefly, mice were placed
inside a chamber on a wire mesh or glass screen platform for me-
chanical and thermal tests, respectively. The mechanical stimulus was
applied to either the right or the left hind paw at an increasing force
rate of 2 g/second until a flexion withdrawal response was evoked or a
maximal force of 20 g was achieved. The thermal stimulus was applied
using an infrared heat source (power flux: 0.64 mW/cm2) delivered to
the right or left hind paw and the paw withdrawal latency (15 s cut-off)
was recorded. On each trial day, five consecutive paw withdrawal la-
tencies were measured (30 min rest between trials).
2.5. Histology
2.5.1. Tissue processing
Mice were anesthetized with isoflurane (2–3% in 100% oxygen;
Cenvet, Blacktown, NSW, Australia) and perfused with 30 ml of 0.9%
saline using a perfusion pump (Peri-Star, Shanghai, China) followed by
50 ml of ice-cold 4% paraformaldehyde (PFA, Sigma-Aldrich). The
cerebrum, cerebellum, brain stem and spinal cord were removed and
post fixed in 4% PFA at 4 °C for one week. Tissues were then stored in
0.01 M phosphate buffered saline (PBS, Sigma-Aldrich) containing
0.02% sodium azide (Amresco, Solon, OH, USA) to prevent bacterial
growth at 4 °C for up to 1 month. Samples were cryoprotected in dis-
tilled water containing 30% sucrose (Coles, Hawthorn East, VIC,
Australia) solution for 48 h at RT. Samples were embedded in 4% ge-
latine (Chem-Supply, Gillman, SA, Australia) in a cryo-mold (Sakura,
Torrance, CA, USA) and sectioned coronally at 40 µm using a cryostat
(Leica, Wetzlar, HE, Germany). Individual sections were transferred to
either 6-well plates (Sakura) containing 5 ml of cold (5–6 °C) 0.01 M
PBS for free floating staining or mounted onto 0.5% gelatine-coated
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slides (Knittel Glass, Braunschweig, NI, Germany) for silver staining.
2.5.2. Silver myelin staining
This was carried out as previously described (Sen et al., 2019a).
Briefly, 40 µm slide-mounted sections were air dried for 48 h and then
immersed in 10% formalin (Sigma-Aldrich) for 2 weeks at RT to in-
crease staining contrast. Sections from different animals in each group
were stained in parallel to maintain the consistency of staining. Slides
were washed with distilled water and pre-treated with a lipid solvent
pyridine (VWR, Radnor, PA, USA):acetic anhydride (Merck, Darmstadt,
HE, Germany) solution (ratio 2:1) for 30 min at RT. Sections were then
rehydrated using serial ethanol washes of 80, 60, 40 and 20% for 20 s
each, followed by two washes with distilled water. Washed slides were
then immersed in freshly prepared ammonical silver nitrate (Chem-
Supply) containing developing solution (0.2% ammonium nitrate, 0.2%
silver nitrate and 5% sodium carbonate) for 45 min at RT. Unbound
silver was removed by washing with 0.5% acetic acid for 3x3 minutes.
Sections were then dehydrated with 20 s rinses of 20, 40, 60, 80 and
100% ethanol followed by immersion in xylene (VWR) for 5 min at RT.
Finally, slides were sealed with glass cover slips (Knittel Glass) using
1 ml of Entellan® Mounting Medium (Merck), air dried for 72 h, and
stored at RT until viewed under the microscope.
2.5.3. Immunofluorescence staining
Free-floating coronal sections (40 µm) were bathed in warm 0.01 M
PBS for 3x5 minutes to remove residual gelatine. Non-specific antigen
binding was blocked by immersion in 0.01 M PBS containing 10%
normal goat serum (Sigma-Aldrich) at RT for 2 h on an orbital shaker
(Fisher Biotec, Wembley, WA, Australia). For single labelling, sections
were incubated with primary antibodies (Abs) dissolved in 0.1% Triton
X100 (Tx100, Amresco) in 0.01 M PBS (Table 1) for 12 h at RT on an
orbital shaker. Sections were washed thrice in 0.01 M PBS and then
incubated for 2 h at RT with Alexa Fluor conjugated secondary Abs
(Table 1), on an orbital shaker in the dark. Following three more wa-
shes in 0.01 M PBS, sections were mounted onto slides and sealed with
cover-slips (Knittel Glass) using Vectashield™ plus 4′,6-diamidino-2-
phenylindole (DAPI, 1.5 µg/ml, Vector Laboratories, Burlingame, CA,
USA) to counterstain nuclei. For the negative control, the primary an-
tibodies were omitted and all other steps carried out as described
above. Slides were stored at 4 °C in the dark until viewed under the
microscope (within 2 weeks of staining). Double staining using ionized
calcium binding adaptor molecule 1 (IBA 1) and glial fibrillary acidic
protein (GFAP) was performed by mixing the two primary antibodies
(optimized for concentration to avoid bleed through). Blocking,
washing, duration of incubation and mounting protocols were the same
as used in single labelling tissue sections. Fluorescence intensity
quantification was performed on the single stained sections and double-
labelled images were used for illustrative purposes.
2.5.4. Image analysis
2.5.4.1. Silver myelin intensity. All images were captured using a
brightfield microscope (Carl Zeiss, Jena, TH, Germany) using the
same parameter settings for exposure time and illumination intensity.
Images were analysed using ImageJ software (https://imagej.nih.gov/).
The region of interest of an image was contoured and the mean optical
density was quantified as mean grey value (0–256, back-white): sum of
all the pixels in the region of interest divided by the number of pixels
(range black). In silver-stained tissue sections, normal myelin sheaths
appear darkly stained and demyelinated sheaths appear lightly stained,
so the signal intensity increases as myelin stain decreases.
Significant differences were confirmed by comparing the light in-
tensity in control and CPZ-fed animals in each region of interest. In
order to show the extent CPZ-induced demyelination across regions of
high (nuclear) and low (tract regions) light intensity under control
conditions (where myelin staining can vary up to 10-fold) changes were
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value (i.e. CPZ-fed/control, fold change) in each region of interest. In
all histological quantification graphs, nuclear and tract regions were
denoted by the use of black and grey colour coding respectively, on the
x-axes labels. No change between CPZ-fed and control groups was de-
tailed as a 1-fold change whereas a 2-fold change equated to doubling
of the light intensity.
2.5.4.2. Immunofluorescence intensity measurement. All images were
captured using a fluorescence microscope (Carl Zeiss, Germany) using
the same parameters (exposure 100 ms at 20x magnification). Images
were opened in ImageJ and fluorescence intensity was measured from
each region of interest as described above. Data are presented as fold
change relative to control.
2.5.4.3. Stereological quantification of cell numbers. Cells positively
stained for adenomatous polyposis coli (APC) and neuronal nuclei
(NeuN, co-stained with DAPI) were counted using the stereo
investigator optical fractionator workflow software
(www.mbfbioscience.com/stereology) as described previously (Sen
et al., 2019a). At low magnification (10x or 20x objective), the region
of interest was contoured and nucleated cells (DAPI positive) in every
ninth section (360 µm apart) were quantified at high magnification
(63x). To obtain the cell density, the total cell number was divided by
the total measured volume and expressed as 104 cells/mm3. Data are
presented as fold change relative to control. The details of the
parameters for stereology counting can be accessed at the following
link (http:\\galen.uws.edu.au\mmrg\monokesh).
2.5.4.4. Manual counting. Choline acetyltransferase (ChAT) positive
neurons in the spinal cord and calbindin (Calb) positive Purkinje
neurons in the cerebellum were counted manually.
2.6. Anatomical structures
The different CNS regions were identified according to the mouse
brain atlas and spinal cord landmarks (Gyengesi et al., 2014; Harrison
et al., 2013; Paxinos and Franklin, 2012; Sengul et al., 2015).
2.7. Statistical analysis
Behavioural parameters and body weight analysis were performed
using a Repeated Measures Two Way Analysis of Variance (RMANOVA)
with post hoc tests to investigate individual differences between groups.
For histological analysis, 3–5 sections per animal from 3 to 5 animals
per group were quantified. Individual comparisons in histology used an
unpaired two-tailed t-test to determine the consistency and difference
between two groups. The regional (rostral-caudal) distribution of de-
myelination and gliosis in corpus callosum was analysed using two-way
ANOVA. The relationship between gliosis and demyelination was
evaluated in the corpus callosum, cerebellar nuclei, brain stem and
spinal cord. The correlation coefficient R2 was calculated by plotting
the intensity values of GFAP and IBA 1 against the silver staining values
(measuring demyelination) and linear correlation analysis was carried
out at 95% confidence interval. Data were presented as fold change.
Data are presented as means ± standard error of the mean (SEM).
Significant interaction effects are described in the figure legends. The
criterion for statistical significance was set at p < 0.05. Statistical
analyses were performed using GraphPad Prism (version 8.3, GraphPad
Software, San Diego, CA, USA) software. All figures were constructed
using CorelDRAW (version 2018, www.coreldraw.com, Ottawa, ON,
Canada) and Adobe Photoshop CS5 (Adobe, San Jose, CA, USA).
3. Results
3.1. General behaviour
There were no obvious changes in posture, general locomotion or
body fur condition, or obvious neurological deficits apparent in any of
the mice. All mice gained weight over the course of the experiment but
the CPZ group gained weight more slowly than controls (F(11,
99) = 125, p < 0.05), with the divergence beginning after 9 days of
CPZ-feeding and persisting thereafter (p < 0.05, Fig. 1). By the end of
the experiment, control mice had increased their body weight by 21%
compared to 11% for CPZ-fed mice (Fig. 1, p < 0.05).
3.2. Locomotion and motor coordination tests
Using the rotarod apparatus, three different aspects of locomotion
were measured on a weekly basis: latency to fall from the apparatus,
time to first roll around cylinder and number of roll revolutions before
the mouse fell off the apparatus (Fig. 2A–C). No significant differences
were found between control and CPZ-fed mice for any parameter
measured (p > 0.05, two-way ANOVA).
Using the ladder crossing test, it was observed that during the first
two weeks, both control and CPZ-fed mice took significantly longer to
cross the ladder compared to later time points (Fig. 2D, F(9,
90) = 1.48, p < 0.05). This was confirmed by analysis of the ex-
ploratory behaviour at selected time points (days 8, 18 and 32) which
showed that mice in both groups spent more time stopping and ex-
ploring their local environment rather than crossing the ladder at ear-
lier compared to later times (Fig. 2E, p < 0.05, RMANOVA). Between-
group differences in the speed of crossing the ladder were observed only
during the fourth week of CPZ-feeding. Further analysis of the number
of foot slips revealed that after two weeks of CPZ-feeding, treated mice
experienced significantly more forelimb foot slips (Fig. 2 F, G, F(9,
81) = 11.71, p < 0.05) that persisted thereafter. However, no such
deficit was observed for the hind limbs (Fig. 2H, I).
In the walking beam test there was no significant difference be-
tween groups in the time taken to cross the beam (Fig. 2J). However, it
was noted for both groups that it took progressively longer for the mice
to complete the task which began after 3 weeks and was clearly evident
during the 5th week (F(9, 81) = 12.26, p < 0.05). This increase was
primarily due to increased exploratory behaviour (Fig. 2K). However,
in the CPZ group, a significant increase in hindlimb foot faults occurred
during week 5 of feeding whereas control mice rarely made foot faults,
and this did not change over time (Fig. 2L).
3.3. Nociceptive thresholds
No differences in withdrawal latencies or thresholds were found at
any time points within or between groups for either thermal or
Fig. 1. Effects of CPZ on body weight. CPZ-fed mice gained weight more slowly
compared to control mice. Two-way ANOVA was used to determine the effects
of time. Tukey post hoc analysis was used to determine differences between
groups (*p < 0.05) and the duration of feeding compared to baseline
(^p < 0.05). Data is mean ± SEM (n = 10 animals/group). g = gram,
Ctrl = control.
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Fig. 2. Behavioural assessments. Rotarod measurements: (A) latency to fall off the apparatus, (B) time to first flip, and (C) number of flips before falling off. Walking
ladder test measurements: time to cross ladder (D) number of stops for exploratory behaviour during ladder crossing (E) partial or complete forelimb (F, G) or
hindlimb (H, I) foot slips. Walking beam test measurements: time to cross beam (J), number of complete hind limb foot slips (K) and number of stops for
exploratory behaviour whilst crossing (L). Measurements of thermal (M) and mechanical (N) nociceptive paw withdrawal thresholds. Abbreviations: sec,
seconds; n, number and g, grams force. Two-way ANOVA & Tukey post hoc analysis were used to determine between group differences and RMANOVA was used to
determine individual group differences over time *p < 0.05. Data are expressed as mean ± SEM (n = 10 animals/group). *p < 0.05 (difference between groups)
and ^p < 0.05 (difference across time points compared to the first day of testing). Ctrl = control.
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mechanical sensitivity (p > 0.05, 2-way ANOVA, Fig. 2M, N).
3.4. Histology
3.4.1. Cerebrum
The cerebrum comprises the cerebral cortices, the underlying hip-
pocampi and basal ganglia and associated white matter tracts. To
confirm the effectiveness of CPZ, the amount of demyelination and loss
of mature OLG cells were quantified using silver- and APC-staining,
respectively, in the corpus callosum (Fig. 3; Supplementary Fig. 2).
CPZ-fed mice showed a significant reduction (p < 0.05) in myelin
staining and OLG numbers compared to control in the midline corpus
callosum (Fig. 3). Further analysis revealed a regional difference in the
rostro-caudal plane with regard to demyelination in the corpus cal-
losum, with significantly more demyelination in caudal sections
(Supplementary Fig. 3D). In addition, a differential demyelination be-
tween the corpus callosum and the underlying dorsal fornix as well as
the adjacent cingulum was evident (Fig. 3). This prompted a more
careful look at other white matter tracts in the forebrain. Demyelination
occurred in the external capsule as well as the anterior commissure, but
not in the optic nerve/tract (Fig. 3). In the cortical grey matter of
control mice, silver staining was differentially distributed with strong
staining in the deeper layers that became less intense toward the cor-
tical surface (Fig. 3). Following CPZ-feeding, extensive demyelination
was observed in areas such as the auditory, visual, primary motor,
secondary motor, primary motor forelimb and hindlimb and secondary
Fig. 3. Effects of CPZ on demyelination in the cerebrum. A). Representative examples of silver stained images of the grey and white matter regions of the forebrain
and diencephalon. B). Quantification, (n = 5 animals/group and 3–5 sections/animal). Data are presented as the mean (± SEM). An unpaired two-tailed t-test was
used to determine differences between groups. Significant differences amongst groups are indicated by *p < 0.05. Dashed lines show the regions either quantified or
discussed in the text. Abbreviations: AC, anterior commissure; AI, primary auditory cortex; CC, corpus callosum; CG, cingulum; CPU, caudate putamen; Ctrl, control;
DFX, dorsal fornix; DG, dentate gyrus; EC, external capsule; F, fornix; FI, fimbria; GPe, external globus pallidus; GPi, internal globus pallidus; HP, hippocampus; HTH,
hypothalamus; IC, internal capsule; LST, lateral striatum; MST, middle striatum; MSN, middle septal nucleus; MI, primary motor cortex; MII, secondary motor cortex;
MTT, mammillothalamic tract; OPT, optic tract; SIFL, primary somatosensory forelimb cortex; SIHL, primary somatosensory hindlimb cortex; SII, secondary so-
matosensory cortex; TH, thalamus; VI, primary visual cortex and VP, ventral pallidum.
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Fig. 4. Effects of CPZ on gliosis in the cerebrum. Representative images A (rostral, top and caudal, bottom) of GFAP, IBA 1 and merged staining and quantification of
GFAP (B) and IBA 1 (C), respectively (n = 5 animals/group and 3–5 sections/animal) in the grey and white matter regions of the cerebrum. Data are presented as the
mean (± SEM). An unpaired two-tailed t-test was used to determine differences between groups. Significant differences amongst groups are indicated by *p < 0.05.
Dashed lines show the regions either quantified or discussed in the text. Abbreviations: AC, anterior commissure; AI, primary auditory cortex; CC, corpus callosum;
CG, cingulum; Ctrl, control; DFX, dorsal fornix; DG, dentate gyrus; EC, external capsule; F, fornix; FI, fimbria; GPe, external globus pallidus; GPi, internal globus
pallidus; HP, hippocampus; HTH, hypothalamus; IC, internal capsule; LST, lateral striatum; MST, medial striatum; MSN, medial septal nucleus; MI, primary motor
cortex; MII, secondary motor cortex; MTT, mammillothalamic tract; SIFL, primary somatosensory forelimb cortex; SIHL, primary somatosensory hindlimb cortex; SII,
secondary somatosensory cortex; TH, thalamus; VI, primary visual cortex and VP, ventral pallidum.
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somatosensory cortical regions (Fig. 3). Gliosis was also a hallmark of
CPZ-induced pathology in the demyelinated areas. In the cerebrum of
CPZ-fed mice, there was a significant increase in IBA 1 and GFAP
staining in all regions where silver staining was decreased (Fig. 4;
Supplementary Fig. 3B, C, E, F). Correlation analysis in the corpus
callosum demonstrated that the intensity of gliosis was proportional to
the amount of demyelination (Fig. 5).
Given that the cingulum and fornix showed demyelination, an in-
vestigation of the hippocampus was performed. A generalised decrease
in silver staining was observed with a concurrent decrease in APC
number in the hippocampus (Fig. 3; Supplementary Fig. 2). GFAP
staining increased in the fimbria of the fornix. In the hippocampal grey
matter, increased staining occurred particularly in the dentate gyrus
(granular region), the molecular layer of CA1-3, and the outer peri-
meter of the hippocampal complex (alveus and stratum oriens) com-
pared to control mice (Fig. 4). Similarly, an increase in IBA 1 staining
within the hippocampus was observed but with some differences e.g. no
obvious increase in the dentate gyrus area (Fig. 4).
Analysis of the basal ganglia revealed demyelination in the lateral
and medial striatal regions, globus pallidus external and internal seg-
ments, medial septal nucleus, ventral pallidum and substantia nigra
(Fig. 3) regions. In the striatum, demyelination was more evident in the
lateral region compared to the medial region, especially the ven-
trolateral area. Increased GFAP staining was more generalised
throughout the striatum, whereas increased IBA 1 staining was seen
particularly associated with the striosomes (fibres of passage) in the
striatum of CPZ-fed mice compared to control (Fig. 4). Strong gliosis
was seen in the globus pallidal regions (Fig. 4). Likewise, marked IBA 1
staining occurred in the medial septal nucleus, ventral pallidum and
substantia nigra regions (Figs. 4 and 7).
3.4.2. Diencephalon
Demyelination was observed in the internal and external capsules,
and thalamic regions (both sensory and motor), with a concomitant
elevated glial response (Figs. 3 and 4). However, in the hypothalamus,
although there was a significant decrease in silver staining (Fig. 3),
there was only a very limited gliotic response with elevated microglial
staining restricted to the lateral hypothalamic regions through which
the medial forebrain and nigrostriatal pathways run. The astroglial
response was essentially unchanged from controls (Fig. 4). Demyeli-
nation and gliosis were also observed in the mammillary body nuclei
(Figs. 4, 6, 7).
3.4.3. Midbrain
Inspection of silver-stained midbrain sections in CPZ mice showed
that only certain regions were affected. Decreased silver staining oc-
curred in the commissural axons connecting the superior and inferior
colliculi, inferior colliculi, substantia nigra, tegmental region (including
the trigeminal mesencephalic and motor nuclei) and the periaqueductal
grey compared to control (Fig. 6). No decrease in silver staining was
seen in areas such as the superior colliculus, the mesencephalic or red
nuclei (Fig. 6B). In contrast, some gliosis occurred in the red nucleus,
tegmental and ventral periaqueductal grey regions but not in the su-
perior colliculus or mesencephalic nucleus as confirmed by GFAP and
IBA 1 staining (Fig. 7).
3.4.4. Hindbrain
Visual inspection of silver-stained slides showed that specific re-
gions of the hindbrain were affected. Significant demyelination was
seen in the deep cerebellar nuclei (Fig. 6). This result was consistent
with the significantly decreased number of APCs and the increased
GFAP and IBA 1 staining in the deep cerebellar nuclei regions
(Supplementary Fig. 2; Fig. 7). Correlation analysis of this region (deep
cerebellar nuclei) revealed that the intensity of gliosis was proportional
to the amount of demyelination (Fig. 5). However, other white matter
regions of the cerebellum such as the arbor vitae within the different
lobes appeared unchanged with respect to silver staining even though
quantification of APC numbers and glial cell responses showed sig-
nificant changes (Supplementary Fig. 2; Fig. 6). Quantification of Pur-
kinje cell numbers using calbindin staining from the cerebellar vermis
of lobules 6, 9, 10 did not detect any changes compared to control
(p > 0.05, Supplementary Fig. 4). No obvious change in silver staining
was seen in the middle and inferior cerebellar peduncles (Fig. 6A, B)
whereas significant decreased staining (p < 0.05) occurred in the
superior cerebellar peduncles of CPZ-fed mice compared to controls
(Fig. 6). Quantitative analysis of OLG numbers in the hindbrain showed
a clear reduction of APC positive OLG in the cerebellar nuclei regions
(p < 0.05, Supplementary Fig. 2). In contrast, no significant APC cell
loss was found in the middle cerebellar peduncle (Supplementary
Fig. 2A-C). Additionally, a significant increase in GFAP and IBA 1 in-
tensity (p < 0.05) was found in superior cerebellar peduncle (Fig. 7).
In contrast, only increased GFAP, but not IBA 1, intensity was found in
the inferior cerebellar peduncle (Fig. 7).
Silver staining in the pons revealed significant demyelination, OLG
cell loss and gliosis in all the vestibular nuclei as well as the prepositus
nuclei and medial longitudinal fascicular tract (Supplementary Fig. 1;
Figs. 6 and 7). However, little demyelination or gliosis was seen in the
Fig. 5. Relationship of demyelination to gliosis in different regions of the CNS. Pearson’s correlation coefficients for astro- and micro-gliosis as function of de-
myelination in the corpus callosum A), cerebellum B), brain stem C) and spinal cord D). Ctrl = control.
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vestibulocochlear nerve. Additionally, silver staining in the pons and
medulla suggested a generalised decrease in intensity, making nuclei
such as the facial and trigeminal nuclei more prominent (Fig. 6).
However, very little gliosis was seen within the pons and medulla of
CPZ-fed mice and when detected the affected areas did not always
coincide (Fig. 7). For example, elevated GFAP staining occurred in the
trigeminal tract, facial and vestibulocochlear nerves and in the closed
medulla around the central canal near the vagal and hypoglossal nuclei
(data not shown) whereas IBA 1 levels appeared unchanged. Con-
versely, increased IBA 1 staining was seen in areas corresponding to the
(caption on next page)
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pyramidal tract whereas GFAP was not (Fig. 7). Correlation analysis in
the brain stem demonstrated that the intensity of gliosis was not pro-
portional to the amount of demyelination (Fig. 5).
3.4.5. Spinal cord
Analysis of silver staining in the spinal cord revealed intense
staining in the white and grey matter regions at all levels (Fig. 8A, C),
with no significant difference in intensity between CPZ-fed and control
mice. Importantly, quantification of APC-positive OLG staining in dif-
ferent spinal cord regions revealed no differences at any level in control
vs CPZ-fed mice (Fig. 8B, D, p > 0.05). Surprisingly, GFAP staining
was significantly increased in the white matter tracts of CPZ-fed mice in
cervical, thoracic and lumbar regions whereas grey matter levels were
similar between groups (Fig. 8E, F). When the microglial response was
analysed with IBA 1, significant changes were observed mainly in the
cervical spinal cord in both white and grey matter regions (Fig. 8E, G).
Thus, gliosis in the spinal cord did not correlate with the demyelination
(Fig. 5).
Given that the behavioural motor deficits could indicate loss of
motor output, the number of motor neurons in cervical and lumbar
regions was quantified using ChAT as a marker. No significant differ-
ence between control and CPZ-fed mice was found (Fig. 9A, B). NeuN
staining was used to identify Clarke’s nucleus (the ascending proprio-
ceptive neurons of the spinocerebellar tract) in the medial deep dorsal
horn of the thoracic and cervical cord. No significant difference in
NeuN numbers between groups was found (Fig. 9C, D).
4. Discussion
Feeding mice with 0.2% CPZ for 37 days produced subtle deficits
associated with motor coordination. Nociceptive withdrawal thresholds
were unaffected. Histological analysis of the CNS confirmed the de-
myelination and gliosis in the corpus callosum, hippocampus, basal
ganglia and deep cerebellar nuclei. However, this study extends the
histopathological knowledge by detailing and quantifying demyelina-
tion and gliosis in other regions such as the limbic circuits, deep cere-
bral cortical regions, thalamic nuclei and brain stem nuclei associated
with balance and audio-visual reflex responses. Within the spinal cord,
demyelination of white matter tracts was not obvious but increased
astrocyte staining occurred at all spinal levels whereas the microglial
response was much more limited. The profound histological changes in
hindbrain motor pathways suggest that degeneration of vestibulocer-
ebellar connections may play an important role in the abnormal be-
haviour. Most importantly, quantitative analysis clearly showed that
OLG cells were lost within the brain but that this did not occur in the
spinal cord.
4.1. Motor behaviour in relation to histological changes
Initiation and coordination of voluntary movements involves four
hierarchical systems: upper motoneurons of the pyramidal and extra-
pyramidal (brain stem) systems (to initiate voluntary movements), the
basal ganglia (motor program storage), the cerebellum (motor co-
ordination) and the spinal cord lower motoneurons (movement
execution). Histological analysis revealed profound demyelination in all
these regions, except the spinal cord. For example, reduced silver
staining occurred in the primary motor (MI), secondary motor and so-
matosensory cortex cortical grey areas, with a corresponding increase
in GFAP and IBA 1 staining. These regions are associated with the origin
of the pyramidal tract whose axons run through the internal capsule
and ventral parts of the brain stem, areas that also showed demyeli-
nation and gliosis. Studies using transient optogenetic inactivation of
the forelimb motor cortex areas in mice produced a reduction of choice
and executive functions (Morandell and Huber, 2017) and lesions of the
MI cortex affect the learning and execution of motor tasks (Heindorf
et al., 2018). Injury in the corticospinal tract has been associated with
motor impairment in rats (Bieler et al., 2018). The marked degenera-
tion and gliosis in the commissural tracts (corpus callosum and anterior
commissure) may also have contributed to the incoordination, as other
studies have shown impairment of complex motor tasks such as bi-
manual finger movements (Bonzano et al., 2008; Gean-Marton et al.,
1991; Huitinga et al., 2001).
It was hypothesised that increasing the complexity of the motor task
would produce subtle behavioural deficits (Sen et al., 2019b). The ro-
tarod apparatus did not to detect any motor deficits in CPZ-fed animals,
consistent with prior studies (reviewed in Sen et al., 2019b). In this
study, motor deficits were manifest as errors in paw placement on the
ladder rungs or foot slips (i.e. dysmetria), and were present from the
second to fifth weeks of CPZ-feeding.
Dysmetria is a symptom of ataxia often associated with damage to
the posterior lobe of the cerebellum (Ha et al., 2016; Soblosky et al.,
1997). These results are consistent with other studies using the complex
wheel apparatus which detected ataxia within 2–3 weeks of CPZ-
feeding (Hibbits et al., 2009; Liebetanz and Merkler, 2006; Manrique-
Hoyos et al., 2012; Mierzwa et al., 2013). The ladder test detected early
motor deficits while the beam test detected deficits at later time points,
which may be related to the different visuospatial aspects of each test.
Both the walking ladder and walking beam are thus sensitive tests to
detect and quantify deficits of motor coordination in mice.
The most profound histological changes occurred in the cerebellum.
At 5 weeks, only the deep cerebellar nuclei showed intense gliosis and
demyelination, as previously documented (Skripuletz et al., 2010).
Purkinje cells and the cerebellar cortex were unaffected, consistent with
the fact that cerebellar demyelination gets progressively worse so that
both grey and white matter were maximally affected by 12 weeks of
CPZ-feeding (Skripuletz et al., 2010). The cerebellar nuclei receive in-
puts from the somatosensory, pontine and vestibular systems, with the
latter having reciprocal connections. No demyelination was seen in the
inferior and middle cerebellar (input) penduncles but demyelination
occurred only in the superior cerebellar (output) peduncles suggesting
that the ataxia was more likely due to cerebellar output, rather than
input. The superior cerebellar peduncles project to the hypothalamus,
motor thalamus, basal ganglia nuclei and brain stem, all of which also
showed demyelination. Interestingly, demyelination in the medial cer-
ebellar nucleus may be associated with the reduced weight gain seen in
CPZ-fed mice compared to controls since this nucleus has direct con-
nections with the hypothalamic satiety centres (Li et al., 2017), regions
which showed demyelination and gliosis in this study.
Fig. 6. Effects of CPZ on demyelination in the mid- and hind-brain. Representative images A) and quantification B) of silver-stained images (n = 5 animals/group
and 3–5 sections/animal) in the grey and white matter regions of the mid and hind brain. Data are presented as the mean (± SEM). An unpaired two-tailed t-test was
used to determine differences between groups. Significant differences among the groups are indicated by *p < 0.05. Dashed lines show the regions either quantified
or discussed in the text. Abbreviations: 5T, trigeminal tract; 7N, facial nucleus; 8N, vestibulocochlear nerve; CB, cerebellar vermis; CCX, cerebellum cortex; CSC,
commissure superior colliculus; Ctrl, control; CVN, cerebellar vestibular nucleus; DN, dentate nucleus; HP, hippocampus; ICN, inferior colliculus nucleus; ICP,
inferior cerebellar peduncle; IPN, interposed nucleus; LL, lateral lemniscus; LVN, lateral vestibular nucleus; ML, medial lemniscus; MCP, middle cerebellar peduncle;
MGN, medial geniculate nucleus; MLF, medial longitudinal fasciculus; MN, mammillary nucleus; MVN, middle vestibular nucleus; PAG, periaqueductal grey; Pr5,
principal trigeminal nucleus; PN, prepositor nucleus; PT, pyramidal tract; RN, red nucleus; SCN, superior colliculus nucleus; SCP, superior cerebellar peduncle; SN,
substantia nigra; Sp5, spinal trigeminal nucleus; SPVN, spinal vestibular nucleus; SUVN, superior vestibular nucleus; TN, tegmental nucleus; Vmo, trigeminal motor
nucleus and Vmes, trigeminal mesencephalic nucleus. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of
this article.)
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Fig. 7. Effects of CPZ on gliosis in the midbrain and hindbrain. Representative images of GFAP, IBA 1 and merged staining A, B) and quantification C, D) of GFAP and
IBA 1-stained images (n = 5 animals/group and 3–5 sections/animal) in the grey and white matter regions of the mid- and hindbrains. Data are presented as the
mean (± SEM). An unpaired two-tailed t-test was used to determine differences between groups. Significant differences among the groups are indicated by
*p < 0.05. Dashed lines show the regions either quantified or discussed in the text. Abbreviations: 5 T, trigeminal tract; 7 N, facial nucleus; 8 N, vestibulocochlear
nerve; CB, cerebellar vermis; CCX, cerebellum cortex; Ctrl, control; CVN, cerebellar vestibular nucleus; DN, dentate nucleus; ICN, inferior colliculus nucleus; ICP,
inferior cerebellar peduncle; IPN, interposed nucleus; LL, lateral lemniscus; LVN, lateral vestibular nucleus; ML, medial lemniscus; MCP, middle cerebellar peduncle;
MGN, medial geniculate nucleus; MLF, medial longitudinal fasciculus; MN, medial mammillary nucleus; MVN, middle vestibular nucleus; PAG, periaqueductal grey;
Pr5, principal trigeminal nucleus; PN, prepositus nucleus; PT, pyramidal tract; RN, red nucleus; SCN, superior colliculus nucleus; SCP, superior cerebellar peduncle;
SN, substantia nigra; Sp5, spinal trigeminal nucleus; SPVN, spinal vestibular nucleus; SUVN, superior vestibular nucleus; TN, tegmental nucleus and Vmes, trigeminal
mesencephalic nucleus. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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This is the first comprehensive study to investigate the effects of CPZ
on brain stem structures. Within the midbrain, intense gliosis occurred
in the inferior colliculi but not in the superior colliculi whereas the
effects were more localised to nuclear areas in the pons and medulla.
Demyelination and gliosis were observed in all the vestibular nuclei
(superior, spinal, lateral, middle and cerebellar) and the adjacent pre-
positus nucleus. These nuclei are important not only for balance but
also for oculomotor reflexes. For example, the prepositus nucleus is part
of the horizontal gaze circuits and has strong connections with the
medial vestibular nuclei, inferior olive, pontine paramedian reticular
formation, cerebellum and anterior thalamus (Butler and Taube, 2015;
Seo et al., 2004; Watson, 2012). Damage to this region can result in
postural ataxia and nystagmus (Seo et al., 2004) and damage to the
medial and lateral vestibular tracts that are important in maintaining
balance while walking in the beam (Horak, 2010; Murray et al., 2018)
may have contributed to the motor deficits seen in the CPZ-fed mice.
This damage also indicates that there may be other deficits associated
with the visual tracking system, which may have contributed to the foot
slips. Whether or not CPZ induces visual disturbances or hearing loss
awaits further study but damage to the inferior colliculus can induce
hearing deficits or impaired blink responses (Freeman et al., 2007;
McFadden and Willott, 1994).
The cerebellum plays not only an important role in motor co-
ordination but also in cognitive functions (Buckner, 2013; Parmar et al.,
2018; Shipman and Green, 2019). For example, patients with MS
showing cerebellar dysfunction perform worse in cognitive perfor-
mance assessed by using information processing speed, working
memory tests (Weier et al., 2014). Moreover, the hippocampus-tha-
lamus-cerebellum network facilitates the learning and execution of
motor function (Babayan et al., 2017; Goldberg et al., 2015; Kern et al.,
2015; Shipman and Green, 2019). This study confirmed those histolo-
gical changes as well as demyelination and gliosis in the substantia
nigra of the basal ganglia, and in limbic structures such as the medial
septal nucleus, ventral pallidum and dorsolateral prefrontal cortex.
Lesions to these areas result in cognitive decline in MS, Alzheimer’s,
Parkinson’s and Huntington’s diseases (Delano-Wood et al., 2012; Keser
et al., 2018; Koenig et al., 2015). Some studies have argued that ex-
ploratory behaviour can be used as a measure of anxiety, and CPZ in-
duces anxiety-like behaviour (Sen et al., 2019b), although it is hard to
separate the cognitive and emotional aspects of a test from the motor
Fig. 7. (continued)
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Fig. 8. Effects of CPZ on demyelination, OLG loss and gliosis in the in the spinal cord. Representative images of silver A), APC B) and GFAP, IBA 1 and merged
staining E) and quantification C, D, F, G) of silver, APC, GFAP and IBA 1-staining (n = 5 animals/group and 3–5 sections/animal) in the grey and white matter
regions of the spinal cord. Data are presented as the mean (± SEM). An unpaired two-tailed t-test was used to determine differences between groups. Significant
differences among the groups are indicated by *p < 0.05. Dashed lines in A, B, E indicate the regions quantified and the dashed lines in C, D, F, G separate the
different levels of spinal cord. An unpaired two-tailed t-test was used to determine differences between groups. Significant differences among the groups are indicated
by *p < 0.05. Abbreviations: Ctrl, control; DF, dorsal funiculus; DH, dorsal horn; DLF, dorsal lateral funiculus; VF, ventral funiculus; VH, ventral horn and VLF,
ventral lateral funiculus.
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performance. Although this study did not assess cognitive ability di-
rectly, the fact that the scores for crossing the beam/ladder in terms of
time spent exploring were similar between CPZ and control mice argues
against cognitive decline as the primary cause of motor changes.
4.2. Nociceptive behaviour
No differences in mechanical or thermal nociceptive withdrawal
reflexes occurred between control and CPZ-fed groups at any time
point, consistent with previous findings using similar mechanical or
different thermal nociceptive tests (Bolcskei et al., 2018; Vakilzadeh
et al., 2016). Herder et al (Herder et al., 2011) previously reported no
demyelination in cervical and thoracic spinal cord in CPZ-fed mice,
consistent with our results. We extend these findings by confirming
similar observations in the lumbar spinal cord, the area associated with
the reflex response circuitry. Moreover, histological analysis of lower
motor neuron and Clarke’s nucleus numbers revealed no changes sug-
gesting that the motor incoordination is unlikely to originate in the
spinal cord. This supposition is supported by the observation of pro-
found demyelination and gliosis in the thalamus and somatosensory
cortices.
In contrast to the lack of myelin loss, increased GFAP staining oc-
curred in the spinal cord white matter. Interestingly, the magnitude of
gliosis showed a proximo-distal gradient in that gliosis was highest in
the cervical spinal cord, then the thoracic cord and then lumbar cord. A
similar segmental gradient pattern occurred for IBA 1 staining.
However, unlike GFAP staining, increased IBA 1 staining was more
prominent in the grey matter. Taken together these results suggest that
CPZ-feeding does not induce demyelination in the spinal cord at this
time point and that demyelination is not the trigger for a glial response.
The fact that CPZ does induce a glial response that is more severe at
proximal than distal levels suggests that degenerative events may only
be beginning and thus that analysis at later time points may reveal more
extensive pathology, which may or may not be associated with altered
nociceptive thresholds. This awaits further study.
4.3. Regional differences in demyelination.
This study confirmed earlier reports of a differential demyelination
of CNS regions. For example, cerebellar demyelination peaks by
12 weeks of CPZ-feeding (Skripuletz et al., 2010), whereas in the corpus
callosum, cerebral cortex and hippocampus this occurred at 5–6 weeks
(Berghoff et al., 2017; Gudi et al., 2009). Likewise, myelination of the
optic nerve and tract were unaffected at 5 weeks of CPZ-feeding but
were demyelinated by 12 (Namekata et al., 2014). It has been suggested
that this differential susceptibility to CPZ is due to the differential
Fig. 9. Effects of CPZ on specific subpopulations of spinal cord neurons. Representative images of ChAT-stained motoneurons (A) and NeuN positive neurons (C) of
Clarke’s nucleus in the spinal cord and their quantification (B, D). Dashed lines indicate the regions quantified (n = 3–5 animals/group, 5 sections/animal).
Ctrl = control.
M.K. Sen, et al. Brain, Behavior, and Immunity xxx (xxxx) xxx–xxx
14
maturation of white matter tracts; the later they mature, the more
susceptible they are (Yang et al., 2009), whilst others have suggested
that the effects are due to regional differences in microglia (Skripuletz
et al., 2010). However, even within a tract, a gradient of demyelination
was observed. For example, in the corpus callosum a rostrocaudal
gradient of demyelination and gliosis was found such that greater de-
myelination occurred in the caudal regions such as the splenium. Si-
milarly, the gliotic response in the spinal cord was greater at cervical
levels compared to thoracic and lumbar levels. Another possibility for
these effects could be that different regions of the CNS have different
subtypes of OLGs based on biochemical profile and axon myelination
(Butt et al., 1995). Most recently, RNAscope analysis has revealed 12
different subtypes of mature OLGs with a differential distribution in
brain and spinal cord. Moreover, they respond differently to trauma
(Floriddia et al., 2019).
5. Conclusions
Standard feeding of 0.2% CPZ to mice for 5 weeks induced motor
(but not nociceptive) deficits that were only discernible when complex
behavioural tasks were used. Errors, particularly in coordination, ap-
peared closely related to demyelination of cerebellar systems and its
CNS connections. Moreover, OLG cell loss occurred in the brain but not
the spinal cord, indicating a regional sensitivity of oligodendrocytosis,
demyelination and gliosis. An important, and yet, unanswered question
is what happens when CPZ-feeding ceases and remyelination is allowed
to occur. Do the motor deficits reverse or persist? This should be the
focus of future work.
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SF1: Custom made locomotor apparatus. 
(A) Walking ladder apparatus: dimensions: 60cm long, 47 rungs, 3mm in diameter, spaced 
12mm apart, bordered by a transparent plastic sheet (3mm thick, 15cm high) placed 13cm 
above the bench surface. (B) Walking beam apparatus: 70cm long wooden beam, 11mm 
width at one end tapering to 8mm at the other, 12 mm high was placed horizontally 50cm 
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SF2: Effects of CPZ-feeding on OLG cell numbers in different regions of the CNS.  
Representative images A, and quantification B, of APC-positive OLGs from grey and white 
matter regions of the cerebrum, cerebellum, and brainstem. Significant differences among the 
groups are indicated by *p<0.05, (n=3-5 animals/group and 3-5 sections/animal). Dashed 
lines indicate the regions quantified.  Abbreviations: CC, corpus callosum; CCX, cerebellum 
cortex; Ctrl, control; CVN, cerebellar vestibular nucleus; DN, dentate nucleus; HP, 
hippocampus; ICN, inferior colliculus nucleus; IPN, interposed nucleus; LVN, lateral 
vestibular nucleus; MCP, middle cerebellar peduncle; MVN, middle vestibular nucleus; PN, 








SF3: Differential effects of CPZ on demyelination and gliosis in the corpus callosum 
(CC) in the rostro-caudal plane. 
Representative images of silver A, GFAP B, and IBA 1 C, staining of the CC. Numbers 1-8 
represent the rostrocaudal sequence of sections in the CC and dashed lines indicate the 
regions quantified or discussed in the text. A significant rostral-caudal gradient of CPZ-
induced demyelination D, (p<0.05, fold change) and GFAP intensity E, and IBA 1 intensity 
F, was observed in the CC (1-2 rostral, 3-5 middle and 6-8 caudal). An unpaired two-tailed t-
test was used to determine differences between the control and CPZ groups (*p<0.05). 
Multiple comparison test using two way ANOVA and Tukey post hoc analysis were used to 
determine differences among section positions compared to control (^p<0.05); n=8 
sections/animal, n=5 animals/group. Abbreviations:  CC, corpus callosum; Ctrl, control and 
DFX, dorsal fornix. 
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SF4: Analysis of Purkinje cells in the cerebellum cortex 
Representative images A, and quantification B, of calbindin-positive Purkinje cells in lobules 
6, 9 and 10 of the cerebellar vermis (CB). No differences between groups were observed (n=5 
animals/group, 3 sections/animal, unpaired two-tailed t-test). Dashed lines show the regions 
quantified. Abbreviation: Ctrl, control. 
Myelin basic protein: Myelin basic protein staining in the spinal cord revealed significant 
difference in staining at the lumbar spinal cord region only (Figure 1A,B). 
 
Figure 9: Regional suppression of MBP in the spinal cord  
Quantification A) and representative images (B) of staining intensity of MBP for myelin from 
spinal cord (n=5 animals/group and 5 sections/animal) in the gray and white matter regions. 
An unpaired two-tailed t-test was used to determine differences between groups. Significant 
differences among the groups are indicated by *p<0.05. Dashed lines in B separate the 
different regions of spinal cord used for quantification in A. Abbreviations: DF, dorsal 






















6.1 Peripheral immune system suppression limits the recruitment of T-cells into the CNS  
Studies I and II have been conducted to investigate whether blood brain barrier (BBB) 
disruption in CPZ-fed mice facilitates T-cells infiltration into the central nervous system 
(CNS). CPZ was fed for 5 and 12 weeks using the standard (0.2%) or a half of standard dose 
(0.1%) to induce oligodendrocytes (OLG) degeneration, demyelination and glial activation 
[22, 29, 82, 113]. The BBB was disrupted using pertussis toxin (PT) injection [236-238] 
during weeks 1-2 of CPZ-feeding. Histological analysis showed that CPZ evoked a robust 
concurrent OLG degeneration, demyelination and glial response in the cerebrum and 
cerebellum, consistent with many other studies [7, 22, 24, 82, 132, 161, 282]. The detection 
of T-cells (CD4+ and CD8+) was carried out using immunofluorescence and a high sensitive 
WB protocol [283], as well as using commercially available recombinant proteins in 
‘spiking’ samples. Yet, no detectable T-cell signal was found in the brain using these 
methodologies. The absence of T-cells in the brain despite breaching the BBB has been 
associated with the suppression of T-cells signal and atrophy of spleen. Using WB and 
immunofluorescence, it was found that the signal intensity of T-cells (CD4+ and CD8+) was 
significantly reduced in the spleens of CPZ-fed animals, following short and prolonged 
feeding. This study also supported by the previous observations where it has been showed 
that CPZ-feeding can reduce the size of the adaptive immune organs such as spleen and 
thymus [11-13]-organs responsible for T-cells function [284, 285]. Moreover, in the present 
work (Chapter-3) using 2D proteomics decreased abundance of at least two proteins which 
are known to suppress T-cell function were found: Calcium/calmodulin-dependent protein 
kinase type II subunit alpha, a protein known to play a role in CD8 T-cell proliferation and 
the transition to a cytotoxic phenotype [286, 287]. Likewise, leukocyte elastase inhibitor A, a 
protein that normally supresses the action of proteases including those released by T-cells 
[288], was supressed. The decreased spots abundance of these proteins in CPZ-fed animal 
indicated the suppression of immune function. The suppressive effect on T-cell function is 
also supported by the previous observations showing an absence of protein disulphide 
isomerase in CPZ-fed mice [29] which is key protein in assembly of the major 
histocompatibility (MHC) class I molecules [29, 289]. Secondly, studies with experimental 
autoimmune encephalomyelitis (EAE), as well as Theiler's murine encephalomyelitis virus, 
animal models, both of which are based on T-cell mediated autoimmune response, showed 
that the severity of disease delayed when CPZ was fed in animals [290, 291].  
It has been described from several papers that CPZ causes alteration of essential ions such as 
Fe2+, Cu2+, Mn2+ and Zn2+ in different organs such as brain and liver [3, 15, 58, 59]. However, 
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it is speculated that the ion imbalance properties of CPZ is associated with peripheral immune 
system dysregulation [12, 13, 291]. For example, T-cells require metal ions such as copper 
(Cu2+) for its proper functioning. Cu2+ syntheses IL-2 (a pleiotropic cytokine) that is involved 
in the growth and maturation of T-cells; as a result of Cu2+ chelation using 2,3,2-tetraamine 
(a high affinity Cu2+ chelator) the IL-2 mRNA expression decreased [292, 293]. Since CPZ 
causes ion imbalance including the chelation of Cu2+, it can be expected that CPZ can reduce 
the normal maturation and function of T-cells. In addition, dysregulation of metabolism and 
dysfunction of mitochondria associated with CPZ-feeding has been identified in this study 
(Chapter-3) may be associated with the dysregulation of immune system. Studies have 
revealed that T-cells relay on mitochondria during all stages of adaptive immune responses 
and considered as the ‘master metabolic regulator of T-cells’ [294] and dysregulation of 
mitochondria may lead to the compromisation of immune system [295]. 
 
6.2 CPZ induced metabolic dysfunction associated with OLG degeneration  
Using a ‘top-down’ proteomics approach 33 unique protein spots were identified based on the 
changes in the relative abundance (≥1.5 fold increase or decrease) across different groups 
from studies I and II. The strength of the present study (Chapter-3) was to use a sensitive 
approach over the ‘shot-gun’ (i.e. bottom-up) approach. The top-down approach can resolve a 
large number of proteins including low abundance and post-translationally modified protein 
species with high degree of consistency across technical and biological replicates [29, 260, 
296, 297]. In addition, in the present study (Chapter-3), to maximize the reproducibility in 
protein identification, sufficient technical (n=3 gels/fraction) and biological (n=5 
animals/group) replicates were used in contrast to earlier work where either ‘bottom up’ 
approach or limited replicates were used [11, 23, 29, 298, 299].  
 
Protein by protein literature search and bioinformatics analysis showed that the majority of 
the 33 proteins were involved in metabolic functions. When identified proteins were 
compared with the previously published literature on CPZ, EAE and multiple sclerosis (MS), 
it was found that 8 proteoforms (creatine kinase U-type, glutamate dehydrogenase 1, vesicle-
fusing ATPase, propionyl co-enzyme A carboxylase-β, tyrosine-tRNA ligase, actin-related 
protein 2/3 complex subunit 5, charged multi-vesicular body protein and adipocyte plasma 
membrane-associated protein) had not previously been reported in relation to CPZ, EAE or 
MS studies whereas the other 25 proteins were. Further literature mining showed that the 
identified proteins were found to associate with the metabolic pathways such as glycolysis, 
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oxidative phosphorylation and Krebs cycle. In addition, a strong cluster of interacting 
metabolic proteoforms (ATP synthase subunit-α, NADH dehydrogenase iron-sulfur protein 2, 
aconitate hydratase, creatine kinase U-type, glutamate dehydrogenase 1, aspartate 
aminotransferase, oxoglutarate dehydrogenase like-protein, succinate dehydrogenase 
flavoprotein subunit, malate dehydrogenase, tyrosine-tRNA ligase, hexokinase 1, fructose-
bisphosphate aldolase C, propionyl co-enzyme A carboxylase-β, isovaleryl-CoA 
dehydrogenase and voltage-dependent anion-selective channel protein) further support the 
metabolic disturbances and mitochondrial dysfunction in CPZ model.  
 
OLG primarily depend upon mitochondria for their energy supply and disruption of 
mitochondrial function has been associated with the OLG loss [76, 300]. OLG require an 
extensive amount of energy to produce and maintain their myelin sheaths [85] by extending 
its surface area [39, 76, 77] and covering an area of ~5-50×103 μm2 [53, 84]. The high 
metabolic rates associated with maintaining such expansive structures is associated with the 
increased production of toxic substances such as reactive oxygen (and nitrogen) species 
which pre-disposes OLG to oxidative injury, which becomes particularly problematic when 
OLG are exposed to toxins such as CPZ [76]. Moreover, OLG have only a  limited storage of 
antioxidative substances such as glutathione [90, 91], metallothionein [94] and manganese 
superoxide dismutase [95] which increases the susceptibility of OLG against oxidative 
damage. In addition, such condition triggers the endoplasmic reticulum stress and induction 
of unfolded protein response which may enhance the OLG degeneration alone with 
mitochondria [301]. In the proteomic analysis (study I), endoplasmic reticulum stress related 
protein calreticulin may be associated with the unfolded protein response [302-304]. 
Moreover, the hypertrophy of astrocytes and microglia may increase the local energy demand 
in the demyelinating areas which further enhance OLG stress. Therefore, CPZ-mediated 








6.3 Increasing the complexity of motor task detects subtle motor deficits  
In this thesis motor function was assessed using rotarod, inverted screen, walking ladder and 
walking beam tests. In studies I and II rotarod and inverted screen showed no detectable 
motor deficits in CPZ-fed mice. One explanation for this is the lack of sensitivity of the 
instruments. In rotarod, mice do not fall off the rod prior to the emergence of severe motor 
decline because of their capacity to maintain their centre of gravity over the rotating drum or 
complete a revolution without falling. Likewise, in the inverted screen test, mice retained 
sufficient strength (and motor coordination) to hold onto the wire mesh using all four limbs. 
However, in the literature conflicting results were reported where no deficits were shown 
[305-308]; although in some studies motor deficits were reported using rotarod [73, 125, 241, 
309-317] in CPZ model. On the basis of observations from our own study (Chapter-3) and 
the literature review, it was hypothesised that by increasing the complexity of the tasks for 
motor assessment, subtle deficits can be detected. In study III, the walking beam and ladder 
were used to measure the motor function and compared with rotarod. In walking beam, 
mouse had to walk along a progressively narrowing (11 mm to 8 mm) beam whereas in the 
walking ladder, a narrow walking corridor was used by the mouse to cross the ladder rungs. 
The advantage of these instruments is that animals need to give more concentration to keep 
balance and walk in a confined narrow way which appeared to be more challenging compared 
to rotarod or inverted screen. A significant difference in the number of foot slips were found 
as early as week 2 using ladder and walking beam showed significant change from week 4.5. 
These results showed that more complex locomotor tasks can reveal subtle motor deficits.  
 
In the CPZ literature, the demyelination and gliosis in the corpus callosum have been used as 
a proxy in most of the motor behavioural studies to describe the causes of behavioural 
deficits which is inappropriate and inaccurate [19, 73, 241, 305-307, 309, 311-316, 318-321]. 
It suggests that the functionally relevant pathways associated with the deficits are yet to be 
identified. I hypothesised that the CPZ-induced OLG loss, demyelination and gliosis in the 
motor pathways are involved in motor behavioural changes. From the present study (study 
III) the OLG degeneration, demyelination and gliosis were found in the descending motor 
pathways such as cerebellar balance systems [322, 323]. In CPZ-fed mice, changes in the 
vestibular tract were found suggesting motor incoordination in the CPZ-fed mice may be 
associated with the vestibular tract injury. In contrast, no major difference was found in 
rubrospinal and reticulospinal tracts which are associated with locomotion, reaching and 
posture deficits [324-326]. Moreover, following CPZ-feeding we found a marked 
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demyelination and glial activation in all parts (rostral and caudal) of the corpus callosum. A 
considerable amount of literature has been argued that the demyelination and gliosis in the 
corpus callosum was associated with the impaired interhemispheric communication resulting 
motor incoordination in the CPZ-fed mice [19, 109, 110, 241, 318, 320].  
 
6.4 Nociceptive behaviour is unaltered following CPZ-feeding 
The thermal and mechanical nociceptive threshold was measured only in study III using 
dynamic plantar aesthesiometer and Hargreaves instruments. Similar to motor tests, relevant 
sensory pathways were not investigated rather studied only in the corpus callosum [305, 327, 
328]. In the present study, no significant difference in mechano-nociceptive and thermo-
nociceptive responses was found in any time point during CPZ-feeding using dynamic plantar 
aesthesiometer and Hargreaves instruments, respectively. Our observation was consistent 
with the previous studies where no nociceptive response was detected in CPZ-fed animal 
[305, 327]. A possible explanation for the absence of nociceptive response may be the lack of 
changes in the sensory pathway. Some authors have speculated that the changes of 
nociceptive response may arise from OLG degeneration and autoimmune response [329, 330] 
and injury [331] in spinal cord. However, no demyelination or OLG degeneration was found 
in the spinal cord different afferent pathways components such as the spinothalamic [332, 
333] or spinocerebellar [334] tracts, although astrogliosis was evident. In addition, the lack of 
degeneration of sensory neurons (Clark’s nucleus in cervical and thoracic spinal cord) 
suggests that spinal cord ascending pathways are likely to be unaffected.  
 
6.5 Spinal and cerebellar neuronal subpopulations are unaffected by CPZ-feeding 
Given the motor deficits it is reasonable to ask whether demyelination and gliosis affect 
particular motor neuronal subpopulations in the cerebellum and spinal cord.  In study III, 
Purkinje neurons are the dominant cortical output from the cerebellum to the deep cerebellar 
nuclei. These can be identified using calbindin (Calb) antibody. Quantification of the 
cerebellum vermal regions of lobules 6, 9 and 10 showed no difference in number of Calb-
positive Purkinje neurons between CPZ-fed and Ctrl mice. Alpha motor neurons from spinal 
cord were identified using choline acetyltransferase (ChAT) antibody and were quantified in 
the cervical, and lumbar ventral horns of spinal cord; again no difference was found between 
groups. Quantification of neuronal nuclei (NeuN) positive neurons associated with Clarke’s 
nucleus in the thoracic spinal cord or the interbasilar nucleus (in cervical spinal cord) also 
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showed no group differences. Other studies have also shown that NeuN staining from optic 
nerve [109], cerebral cortex [320] and hippocampus [110] of cerebrum also showed no 
changes. Collectively, these data suggest that CPZ-feeding is not associated with the loss of 
neurons, consistent with previous in vitro [28, 111] and in vivo [109, 110, 320] studies.  
 
6.6 CNS histopathology following CPZ-feeding 
Many studies have focused on the histological investigation in the corpus callosum but no 
study has systematically investigated all other regions of CNS demyelination induced by 
CPZ-feeding. In study III, a detailed investigation was conducted. A concurrent marked loss 
of OLG, demyelination and gliosis was found in most of the investigated areas of the 
cerebrum, cerebellum and brain stem whereas only gliosis was observed in spinal cord. The 
differential susceptibility of the different regions to CPZ may occur from several reasons. The 
distinct anatomical structure and variation in the density of OLG in different parts of the CNS 
structures may play role in regional variability. For example, in normal conditions the 
number of neurite outgrowth inhibitor A (NOGO A) positive OLG is greater in the corpus 
callosum than in cerebral cortex [22]. Similarly, the density of NOGO A positive OLG is 
lower in the cortex than in the white matter lobes of cerebellum [24]. Similarly, GFAP 
positive astrocytes and IBA 1 positive microglia are found in greater amount in corpus 
callosum than cerebral cortex [22]. In addition, differences in ‘intrinsic capacity’ have been 
hypothesised to account for OLG susceptibility to injury [38, 146]. More specifically, the loss 
of the non-receptor tyrosine kinase Fyn (a signalling molecule of the Src kinase family) 
causes more hypo-myelination [147] in brain than in the spinal cord [148]. Likewise, unequal 
distribution of type III neuregulin-1 (cell adhesion signalling molecule, plays role in OLG 
proliferation and development) may increase the susceptibility to OLG injury in corpus 




This thesis has generated many research questions for further investigation including: 
 
Preservation of adaptive immune system 
The present thesis has shown that despite breaching the BBB during CPZ-induced 
oligodendrocytosis and gliosis, no detectable T-cell signal was found in the brain. Studies I 
and II provide evidence that this lack of T-cell involvement may be due to a direct 
suppressive effect on the peripheral adaptive immune system. Further investigation and 
experimentation is strongly recommended to identify the mechanism of CPZ-induced 
immune system suppression. In addition, in order to investigate whether oligodendrocytosis 
can lead to a secondary immune response (‘inside-out’ theory of MS) in the CPZ animal 
model, strategies that preserves the peripheral immune system should be investigated. One 
such strategy was published during the candidature in which feeding CPZ only was limited to 
2 weeks and combined with immune booster (complete Fraud adjuvant) and disruption of the 
BBB [31]. Prior to the release of this paper, the findings reported here formed the basis 
agreed divergence of work undertaken by two doctoral candidates:  
 
The first, as described in the Chapters-4 and -5 of this thesis, focused on the behavioural 
consequences and the regional neuro-anatomical impact of CPZ-feeding.  
 
and,  
The second, focused on new strategies to overcome the suppression of the peripheral 
immune system mediated by CPZ, whereby castration was used to reverse the normal the 
androgen-dependent involution of the thymus and spleen in order to test whether the CPZ-
mediated oligodendrocytosis can evoke an immune response.  The results of this study 
will form the basis of co-authored papers and the final chapters of Mohammed 
Almuslehi’s doctoral thesis.  
 
In addition, the present work has shown that using the half standard dose (0.1% CPZ) of 
CPZ-feeding for short and long period of time induces a comparable oligodendrocytosis with 
relatively less suppression of the adaptive immune system. Future research should therefore 






Validation of proteoform(s) for the identification of biomarker(s) 
The present study identified 33 unique proteoforms using ‘top-down’ proteomics approach. 
Literature mining and bioinformatics analysis revealed the association of these proteins 
mainly with the mitochondrial and metabolic functions. Due to the extensive dependency of 
OLG on mitochondrial function, internal biochemical perturbations elicit degeneration of 
OLG resulting demyelination. Further work needs to be done to establish whether these 
proteins are indeed involved in regulating OLG function as the pathoaetiology of 
oligodendrocytosis in CPZ and/or MS is ill defined. Moreover, it would be informative to 
validate the role of the 33 proteins using multidisciplinary approaches such as western blot 
and transcriptomics. While this study used whole brain samples to identify proteome changes, 
detailed proteomic analysis of tissue from defined regions of the CNS including cerebellum, 
brain stem and spinal cord may explain the temporaleffects of CPZ. Moreover, it is 
recommended to carry out further research in human MS samples to understand the role of 
the identified proteoforms to generate potential biomarker(s).  
 
Inflammatory markers identification 
The present study concentrated on the OLG degeneration, demyelination, gliosis and 
neuronal loss. However, whether the glial response triggers the secretion of inflammatory 
mediators (e.g. IL-6, TNF-α and IFN-γ) was not investigated in the present work but 
techniques such as Luminex [335, 336] or enzyme-linked immunosorbent assay [337, 338] 
can be used to quantify the secretory mediators. The excessive secretion of pro-inflammatory 
mediators may increase disease states such as oligodendrocytosis and changes in the BBB 
that underpin the subsequent access of T-cell into the CNS.  
 
Behavioural tests need more investigation  
For the assessment of motor functions, rotarod, inverted screen, walking ladder and walking 
beam tests were used. Using rotarod and inverted screen no detectable deficits were found 
whereas walking ladder and beam, tasks with increased complexity, detected early subtle 
deficits. This result suggested that due to the insensitivity of rotarod and inverted screen for 
detecting motor deficits, measuring motor function using these instruments in CPZ model 
should be excluded. In walking beam investigations, multiple cameras should be used to 
visualize fore- and hind- limb foot slips. In the walking ladder test, random withdrawal of the 
rungs from the ladder to make the test into complex to further test the motor learning deficits. 
In addition, in this thesis only the thermal and mechanical nociceptive responses were 
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assessed. Proprioception, which is important to normal spatial awareness and balance, 
functions which appear compromised in the CPZ model should be investigated in future 
studies. Whether CPZ causes other behavioural deficits such as depression, fatigue and 
sleeping disturbances remains ill-defined and frequently confounded by the test used. A 

































This thesis concludes that:  
 
 A standard (0.2%) or half standard (0.1%) dose of CPZ evokes a comparable 
oligodendrocytosis in 5 weeks feeding. Interestingly, prolonged exposure (12 weeks) with 
0.1% CPZ-induced a similar histological (e.g. oligodendrocytosis, demyelination and gliosis) 
change as seen with 0.2% CPZ.  
 Peripheral immune system suppression was the major impediment of investigation of the 
‘inside-out’ hypothesis of MS using CPZ model even when the BBB was compromised. 
 CPZ-induced mitochondrial stress has been associated with the oligodendrocytosis.  
 Increasing the complexity of the tasks for motor assessment can detect early (≥2 weeks) 
subtle motor behavioural deficits consistent with ataxia. 
 Demyelination and gliosis in the cerebellar systems, vestibular structures and white matter 
tracts contribute to motor deficits. 
 Although gliosis was observed in the sensory pathway (e.g. dorsal column, spinothalamic 
tract and lemniscus system); no changes were observed in nociceptive reflex withdrawal 
responses to thermal and mechanical stimuli.  
 CPZ-causes a regional specific oligodendrocytosis, demyelination and gliosis, which is 
higher in the cerebrum and cerebellum, lower in the brain stem and very limited in the spinal 
cord. 
 Specific neuronal subpopulations of the cerebellum and spinal cord are unaffected by CPZ-
ingestion. 
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